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Abstract 
 
Renal transplantation is the treatment of choice for patients with end stage renal 
disease. Despite the significant advances made over the last fifty years, one 
predicament that still perplexes the transplant community is late allograft loss. The two 
major contributing factors include the limitations with the clinical utility of various 
markers for early diagnosis and lack of appropriate therapy. This thesis deals with the 
issue of early diagnosis and tries to establish a link between the clinical, histological 
and immunological phenotype with a view to identify prognostic markers. Firstly, low-
grade proteinuria is clinically analysed for its utility to predict graft outcomes. Secondly, 
a disjunction between the clinical and histological phenotype and more importantly the 
limited utility of the clinical phenotype to determine the prognosis for a troubled allograft 
in light of clinical dysfunction is considered. Thirdly, a novel definition of human B 
regulatory cells is proposed with a view to address the discrepancy in the current 
literature with regards to their identification. Fourthly, a link between the histological 
phenotype of late allograft dysfunction is correlated with the frequency and function of 
regulatory B cells. Here, the functional diversity of the B cells, specifically within a small 
sub-group of B regulatory cells in relation to histological abnormalities is considered. 
Finally, the phenotype and functionality of the Bregs are explored for their use as 
potential markers for allograft outcomes and the utility of a simple phenotype tested in 
a prospective sample of patients from a randomized controlled trial.   
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Preface 
 
I have always dreamt of becoming a physician. My interest in renal transplantation 
developed initially whilst working at a renal transplant centre in India before my arrival 
in the UK in 2001. My interest and enthusiasm to learn more in the field of renal 
transplantation grew further since my introduction to Richard Baker, a great inspiring 
mentor. At one of the earlier interactions, we deliberated to look into clinical markers 
that predict long-term graft outcomes in renal transplantation. In Leeds, at St. James’s 
University Hospital renal unit we had the privilege of being able to analyse proteinuria 
in depth as a clinical marker as every patient at every clinic visit gets their urine 
checked for random protein excretion by urinary protein creatinine ratio. We planned to 
use two very basic and cheap clinical markers, namely proteinuria and serum 
creatinine to identify troubled grafts and understand any potential immunological 
alterations that account for their plight. 
My interest to look into B lymphocytes and their function developed out of a mere 
coincidence when I stumbled on two patients who were given alemtuzumab for 
induction treatment and who had given me blood samples for assessment of their 
overall lymphocyte reconstitution.  These patients had a significantly higher proportion 
of B lymphocytes in their blood when compared to healthy volunteers. This has indeed 
kick started my work on the B cell phenotype and its significance in renal 
transplantation. In this thesis, I have tried to link the clinical phenotype of renal 
transplant recipients to a histological phenotype and finally correlate this to the 
immunological phenotype mainly centred on the functionality of B lymphocyte subsets. 
The scope of a thesis entitled ‘the diverse roles of human B lymphocytes in renal 
transplantation’ is very broad. Renal transplantation provides the best form of renal 
replacement therapy by not only improving the quality of life of patients with end stage 
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renal disease but also increasing their overall survival (Port, Wolfe et al. 1993, Wolfe, 
Ashby et al. 1999). However renal transplant do not last for ever and one of the major 
problems we face at present is lack of improvement of long-term outcomes despite 
significant advancements made in the management of early complications after 
transplantation. 
In the introduction, I have attempted to provide an overview and also insight into the 
need to understand the spectrum of immunopathology that besieges chronic allograft 
loss, with particular emphasis on the role of B lymphocytes. B lymphocytes have 
traditionally been studied in relation to the production of antibodies. Doubt over the role 
of antibodies in the rejection of renal allografts emerged from early rodent models of 
transplantation.  Moreover microscopic examination of failing renal allografts failed to 
demonstrate the signature of antibody mediated damage, namely the deposition of 
immunoglobulins.  However two major advances in the last decade have changed this 
situation.  The discovery by Feucht that the human complement component C4d is 
covalently bonded at sites of antibody-mediated complement activation has revealed 
hitherto unseen evidence of antibody mediated damage in renal allografts (Feucht, 
Felber et al. 1991, Feucht and Mihatsch 2005).  Secondly new technologies have been 
developed to detect human anti-HLA antibodies in patient’s serum with previously 
unimaginable sensitivities. I have provided a detailed overview of the emergence and 
significance of antibody detection methodology and the role of post-transplant HLA 
specific antibody detection in the current day transplant clinical practice.  
More diverse roles of B lymphocytes have emerged over the last decade and now it is 
established that certain B cell subsets are capable of regulating immune response.  A 
brief history of the discovery of the B regulatory cells follows, as the study of these cells 
has become pivotal to our better understanding of immunopathology. An overview of 
the role of B cells as regulators of immune response and their significance in the 
context of human renal transplantation follows.  
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The introduction concludes with concise statements of the objectives and aims of the 
clinical studies and experimental work to be described in this thesis. 
Chapter-3 describes the clinical studies performed to understand the utility of low-grade 
proteinuria as a marker of premature graft loss. Previous studies from other groups 
have suggested that proteinuria, as early as three months after transplantation can 
predict long term graft loss. Here, the impact of changes in this dynamic variable over 
time on clinical outcomes is presented. More importantly, a link between the clinical 
and histological phenotype of troubled grafts is explored which sets a background for 
the experimental work on human B cell subsets that continues in the following 
chapters. 
Chapter-4 attempts to identify regulatory B cells by pro or anti-inflammatory cytokine 
polarization. The inherent heterogeneity even within a small subset of the putative B 
regulatory cells in humans is also described. Next, these cells are studied in the 
context of renal allograft dysfunction with a particular emphasis on chronic antibody 
mediated rejection.   The utility of these cells as potential markers of clinical outcomes 
in troubled renal allografts is then explored. The following chapter is a descriptive 
summary of a randomized controlled trial performed in Leeds, comparing two steroid 
free immunosuppression regimes using either alemtuzumab or basiliximab. Here I 
come back to the point that kindled my interest in the role of B cells in transplantation- 
What is the nature and role of the repopulated B cells in maintaining allograft function 
when patients receive induction therapy with alemtuzumab?  
The findings of this thesis and their implications are discussed in the final chapter.  
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Chapter-1: Introduction 
 
The incidence of End Stage Renal Disease (ESRD) requiring renal replacement 
therapy in the UK is estimated at 107 per million population in 2010 and this represents 
a considerable increase over the last decade. Patients with ESRD requiring dialysis 
have a significantly higher mortality rate when compared to general population. It is 
estimated that the 5 year survival of men and women starting dialysis is worse than 
those suffering from colon and breast cancer respectively (Parfrey and Foley 1999). 
This high rate of mortality emanates from a substantially higher incidence of 
cardiovascular disease in these patients. As shown in Figure 1, it is alarming to note 
that the effect of ESRD on cardiovascular mortality is notably worse in relatively 
younger patients. In the UK, it is reckoned that the mortality of young patients on 
dialysis is 25 times higher than general population 
 
 
 
 
 
 
 
 
 
 
Figure 1: Cardiovascular disease mortality by age, ethnicity and gender in general 
population and in dialysis patients 
(Parfrey and Foley 1999) 
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1.1 Renal Transplantation-clinical outcomes 
Renal transplantation offers a long-term survival benefit for patients with end stage 
renal disease when compared to dialysis (Wolfe, Ashby et al. 1999), as well as a 
significant cost saving.  Moreover, renal transplantation has been shown to attenuate 
the progression of cardiovascular disease in patients with ESRD (Meier-Kriesche, 
Schold et al. 2004) making it the best form of renal replacement therapy available. 
J.E. Murray’s  first account on the usage of immunosuppressive drug therapy in human 
kidney transplantation reported a 70% graft loss within the first year (Murray, Merrill et 
al. 1963). However renal allograft survival has increased enormously over the past few 
decades mainly due to improvements in first year survival and a significant 
improvement in the level of graft function achieved at one year post-transplantation 
(Hariharan, McBride et al. 2002, Lamb, Lodhi et al. 2011) (Figure 2).  There is however 
a discordance between acute rejection rates and long term graft survival after 1996 
since graft outcomes have remained relatively unchanged despite further 
improvements in the rates of acute rejection (Hariharan, Johnson et al. 2000). This 
phenomenon is partly attributed to the lack of improvement in the long-term outcomes 
of low-risk renal transplants including living donor transplants (Lamb, Lodhi et al. 2011) 
and to a trend towards fewer late acute rejections showing a complete response to 
therapy. (Meier-Kriesche, Schold et al. 2004). Further major improvements in the rate 
of acute rejection and its treatment are unlikely. 
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Figure 2: (A) Cumulative half-lives of the grafts between 1989 and 2005. (B)Significant 
improvement in the 0-1 year graft attrition rate during the period 1989-2009. 
(Lamb, Lodhi et al. 2011) 
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1.2 Allograft loss 
1.2.1 Chronic allograft dysfunction 
It is essential to understand the pathology of allograft loss in order to address the 
problems underlying the goal of long-term graft maintenance. Approximately half of all 
the allografts are lost when patients die with a functioning graft. The other half are lost 
due to graft failure. Several investigators have attempted to clarify the causes of graft 
failure but the process is complicated by the finding that late failing grafts display 
similar histological findings characterized by interstitial fibrosis and tubular atrophy, 
also called chronic allograft nephropathy (CAN) (Solez, Axelsen et al. 1993). The term 
CAN has been rejected since it encourages diagnostic nihilism and obscures the 
probable heterogeneous nature of progressive graft damage. Hereafter the process will 
be called chronic allograft dysfunction (CAD). It has become increasingly clear that the 
underlying pathophysiology of CAD is multifactorial. There are immunological 
contributions to this process leading to graft rejection and non-immunological factors 
including viral infections and the nephrotoxicity of immunosuppressive drugs.  
Over the past decade there was a significant shift in the understanding of the pathology 
of CAD. There was an initial emphasis on the importance of calcineurin inhibitor (CNI) 
drug toxicity in the pathogenesis of CAD. Two distinctive phases of allograft injury were 
proposed- an initial phase of early tubulo-interstitial damage from ischaemic injury and 
rejection and a later phase of progressive histological changes (arteriolar hyalinosis 
with luminal narrowing, increasing glomerular sclerosis and additional tubulo-interstitial 
damage) accompanied by the use of CNIs. This latter phase was shown to be universal 
at 10 years post-transplantation (Nankivell, Borrows et al. 2003). Interestingly Nankivell 
et al. have reported that rejection was uncommon in the latter phase. Based on this 
paradigm, several authors have reported some success with minimization of CNI in 
patients with CAD (Stoves, Newstead et al. 2004, Garcia, Pinheiro-Machado et al. 
2006). However it should be noted that patients had excellent graft function with a 
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mean isotopic glomerular filtration rate (GFR) of 50.2ml/min even at 6 to 10 years of 
follow-up in the study reported by Nankivell et al despite the histological findings. Also, 
arteriolar hyalinosis and fibrointimal thickening were not necessarily specific to the 
diagnosis of CNI toxicity.  
In contrast to the diagnostic scepticism provided by the usage of interstitial fibrosis and 
tubular atrophy (IFTA) or CAN as an aetiology for chronic allograft loss, and 
challenging the existing dogma that most chronic allograft damage is relate to CNI 
induced damage, F.G Cosio’s group from Mayo Clinic have shown that most cases of 
kidney allograft failure can be attributed to a specific cause if sufficient histological and 
clinical information is available. Interestingly glomerular pathology which includes 
transplant glomerulopathy, recurrent disease and de novo glomerular disease has 
been shown to be the single most common cause of allograft loss and more importantly 
CNI toxicity as a cause of IFTA has only been reported in 2.1% of patients (El-Zoghby, 
Stegall et al. 2009).  In a prospective histological and clinical analysis of “for cause 
biopsies” Halloran’s group  from Canada have shown that the commonest cause of late 
allograft failure is antibody mediated graft damage and in keeping with the observations 
from Cosio’s group, they have also shown that drug toxicity and non-specific scarring 
are relatively uncommon (Sis, Campbell et al. 2007, Einecke, Sis et al. 2009). The 
significance of antibody mediated rejection as a cause of long-term graft loss has thus 
been underscored.  
 
1.2.2 Allograft rejection 
As it is now established that chronic antibody mediated rejection (CAMR) plays a 
significant role in the demise of an allograft, I shall elucidate the evolution of our 
understanding of the pathology of allograft rejection and the role of various 
immunological processes underpinning the pathological outcomes with a particular 
emphasis on CAMR. 
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Rejection of skin allografts has been one of the most potent and convenient 
experimental models for the study of immunologically mediated tissue destruction. 
Impelled by the exigencies of war, skin allograft rejection was first studied by Medawar 
in humans and then in animals (Gibson and Medawar 1943, Medawar 1944, Medawar 
1945). In 1943, Gibson and Medawar working at the Glasgow Royal Infirmary provided 
a detailed description of the outcome of treating a young woman with a combination of 
both skin pinch autografts and homografts from her brother. This patient with thermal 
burns was treated with 52 pinch autografts from her thigh and 50 homografts from her 
brother. A second set of 28 pinch homografts from the same donor were transplanted 
to a different part of the raw area 15 days after the application of the first. Biopsy 
specimens from these grafts were collected at each change of dressings and examined 
histologically.  Whilst the autografts grew and coalesced to form a continuous sheet of 
skin tissue, the growth and development of homografts was rather different. The first 
sets of homografts were similar to the autografts initially but started to degenerate by 
day 15 and were lost by day 23. The second set homografts showed a far rapid 
dissolution by day-8. Based on the histological observations, a process of active 
immunization has been postulated that would account for the destruction of foreign 
epidermis. This was clearly one of the earliest demonstrations of acute and secondary 
accelerated acute rejection in the context of human transplantation. Even prior to 
Medawar, it was Peter Gorer working at Guy’s Hospital in London at the time, who 
showed that rejection of murine tumours was due to the antigens present on the donor 
tissue and that these grafts induced alloantibodies that could agglutinate donor 
erythrocytes (Amos, Gorer et al. 1954). 
1.2.2.1 Kidney transplant as an immunogenic stimulus 
The central problem in transplantation is the immune response of the host against the 
transplanted antigens of the donor. The successful outcome of any transplant depends 
on the modulation of this response through medical intervention. Both innate and 
adaptive immune responses are activated by transplantation and play a crucial role in 
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the process of allograft rejection. Unlike the adaptive system, the innate immune 
system comprises inflammatory cells (dendritic cells, monocytes, macrophages, 
neutrophils and other cells) that do not express rearranging receptors, have limited 
clonal expansion, and, in the most part, do not generate memory. Cells of the innate 
immune system instead express germ-line encoded pattern recognition receptors 
(PRR) that detect conserved pathogen associated molecular patterns (PAMP) present 
in microbes but not shared by mammalian cells (Palm and Medzhitov 2009, 
Oberbarnscheidt, Zecher et al. 2011). The innate immune system also encompasses 
non-cellular mediators capable of microbial recognition—for example, complement 
proteins. Activation of the innate immune system by microbial ligands causes 
inflammation, the first line of defence against infection, but more importantly induces 
the maturation and migration of antigen presenting cells (APC) to secondary lymphoid 
tissues where they trigger primary T cell and B cell responses. Recognition of PAMP by 
PRR forms the cornerstone of the Janeway theory and provides a robust explanation 
for how the adaptive immune response to a large variety of pathogens is initiated by 
the innate immune system.  These cells are being increasingly appreciated as 
significant players in the process of allograft rejection (LaRosa, Rahman et al. 2007, 
Liu and Li 2010). In part this is based on clinical findings that depletion of T cells with 
alemtuzumab is not effective in preventing rejection and that rejection occurs in 
association with monocytic and eosinophilic inflammation (Kirk, Hale et al. 2003, Wu, 
Bond et al. 2006). There is also an emerging understanding that the innate immune 
system has a role in the induction of transplant tolerance (Morelli and Thomson 2007). 
The adaptive immune response begins with recognition of self from non-self by both T 
and B lymphocytes through their respective receptors.  
1.2.2.2 Major Histocompatibility Complex (MHC) 
Immune system is a remarkable defence mechanism against myriad potentially 
pathogenic microorganisms that inhabit the world we live in and is  often compared to 
the Red Queen in Alice’s Adventures in Wonderland, (Danilova 2006) who must keep 
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moving just to avoid falling behind. Because of the perpetual conflict with pathogens, 
the immune system is in constant flux. This is exemplified by differences in the immune 
systems of animals within the same phylogenetic group.  
The question remained as to the nature of the inciting antigens on the foreign tissue 
that were spurring the immune response. George Snell, working in Maine, had 
described the genes responsible for the genetic behaviour of tumour transplants in 
mice and named them the histocompatibility genes. The prefix ‘histo’ was used 
because he felt that the same genes which determine the susceptibility or resistance to 
tumour transplants probably also determine susceptibility or resistance to tissue 
transplants and these genes were symbolized as group by letter-‘H’ (Snell 1948). Jean 
Dausset and his group in Paris discovered antibodies to a leukocyte antigen called 
MAC in the sera of French patients who received multiple blood transfusions. This 
antigen is now known as HLA-A*0201 (Dausset 1958). There were numerous other 
groups interested in these leukocyte antigens which were designated as Human 
Leukocyte Antigens (HLA).  The genes of the MHC in humans (HLA) are located on the 
short arm of chromosome six and they encode distinct classes of cell surface 
molecules- HLA-class-1 and HLA-class-2.  Humans have three main highly 
polymorphic MHC class I genes, known as HLA-A, HLA-B and HLA-C. These genes 
transcribe proteins which, along with 2-microglobulin form the class-1 molecules. 
There are six MHC class II genes in humans, namely HLA-DPA1, HLA-DPB1, HLA-
DQA1, HLA-DQB1, HLA-DRA and HLA-DRB1. These genes encode the class II 
molecules which are dimers of an alpha and beta chain (Halloran, Wadgymar et al. 
1986).  
The structure of MHC molecules has been elucidated at the molecular level. Initially the 
structure of HLA-A*0201 was determined and it revealed the presence of a nona-
peptide in the grove formed by the -pleated sheet in between the two -helices that 
form the recognition site for the T cell receptor. The identification of this peptide has 
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finally shed light on our understanding of MHC restriction and antigen processing. The 
description of the structure of HLA class-2 molecule, HLA-DR1 followed next (Brown, 
Jardetzky et al. 1993, Stern, Brown et al. 1994). Figure 3 compares the molecular 
structures of HLA-A2 and DR-1 as described by Brown et al. According to the data 
available from the IMGT/HLA database (http://www.ebi.ac.uk/imgt/hla/stats.html), a 
total of 3296 HLA-A, B and C a chain alleles have been identified. For renal transplant 
recipients, tissue type is routinely reported for HLA-A, B and DR for the purpose of the 
identification of the best possible match. 
 
  
Figure 3: HLA DR1 (class-2) superimposed on HLA-A2 (class-1) 
(a). One DR-1  heterodimer and one HLA-A2 molecule. (b). Top view showing the overall 
similarity of the peptide binding groves. (c). Side view of the 1 domain helical regions showing 
differences at both ends. (d). Side view of the  helical regions of the DR1-1 and  HLA-A2-2 
domains (Brown, Jardetzky et al. 1993). 
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Given both their polymorphism and ability to elicit strong immune responses, the 
presence of allogeneic HLA antigens on the allograft is the most important determinant 
of the alloresponse and therefore the most influential factor in determining the intensity 
of graft rejection. This was shown for the first time in the mouse models of allogeneic 
skin grafting where grafts that differed at MHC loci were promptly rejected (Billingham, 
Brent et al. 1954). In fact the collaborative transplant study in 1985 has highlighted the 
importance of appropriate HLA matching to promote better graft survival as shown in 
Figure 4 (Opelz 1985, Cecka 1997).   
 
Figure 4: HLA-A, B and DR mismatches and graft survival (1982-1984) 
(Cecka 1997) 
 
1.2.2.3 Minor histocompatibility antigens  
However it should also be noted that there are numerous genetic loci, outside of the 
MHC region, coding for minor histocompatibility antigens that were capable of inducing 
allograft rejection (Eichwald and Silmser 1955, Graff and Bailey 1973). In 1990 
Rammensee and his colleagues separated distinct peptides from MHC molecules 
thereby providing evidence for minor histocompatibility antigens to be peptides 
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(Rotzschke, Falk et al. 1990, Wallny and Rammensee 1990). These antigens are 
encoded by polymorphic genes that belong to non-HLA related genes (Dzierzak-Mietla, 
Markiewicz et al. 2012). In the context of transplantation, the fact that genetic 
polymorphisms are present in endogenous proteins expressed by the donor and not 
the recipient suggests that these proteins are recognised as non-self and therefore 
they can elicit a donor specific response (Robertson, Chai et al. 2007, Bleakley, 
Otterud et al. 2010). 
1.2.2.4 Allorecognition-direct, indirect and semi direct pathways 
One of the most striking features of the T cell response provoked by the MHC 
incompatible cells is its vigour as reflected by the rejection of the solid organ 
transplants and graft vs. host disease in bone marrow transplant recipients. The 
strength of this response is accounted for by the uniquely high precursor frequency of T 
cells with allospecificity. This feature of the alloresponse was first detected by for class-
I reactive T cells (Skinner and Marbrook 1976, Lindahl and Wilson 1977). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Pathways of Allorecognition 
(Processed or intact) 
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Direct allorecognition (Figure 5a) is defined as the recognition by the recipient T cells of 
the intact MHC alloantigens displayed on the surface of the donor antigen presenting 
cells (APC) carried within the allograft. Two facts are central to the characterization of 
the direct pathway.  
1. The high precursor frequency of the alloreactive T cells that recognize allogeneic 
MHC molecules. 
2. The rules of self MHC restriction are apparently disregarded in the direct binding of 
the TCR to the allogeneic MHC molecules.  
The recognition of the nominal antigen in the context of self MHC molecules and 
recognition of the alloantigen is brought about by overlapping populations of T cells 
(Lombardi, Sidhu et al. 1989). Approximately half of the cells involved in the 
alloresponse have been shown to be primed previously to a nominal antigen 
(Lombardi, Sidhu et al. 1990). The precise nature of the ligand recognised by the 
alloreactive T cells still remains unclear. There are two different hypotheses that make 
very different assumptions about the nature of the ligand bound by the alloreactive T 
cells and provide explanations for the wide repertoire of the alloreactive T cells.  
The multiple binary complex hypothesis (Figure 6), proposed by Matzinger and 
Bevan in 1977 proposes that the antigen binding grooves of MHC molecules expressed 
on normal cells are occupied by an extremely diverse repertoire of peptides derived 
from the processing of  proteins presented with class I or class II MHC molecules. 
Alloreactive T cells are specific for individual complexes of MHC and the peptide. As a 
consequence, a single allogeneic MHC molecule is able to stimulate a large number of 
distinct T cell clones (for distinct peptides) (Matzinger and Bevan 1977). 
The high determinant-density hypothesis (Figure 6) proposed by Bevan explains 
that the attention of the TCR is focussed on the exposed residues of the non-self MHC 
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molecule irrespective of the occupancy of its antigen binding site.  Therefore, at least in 
theory, all non-self MHC molecules of any given isotype (for example HLA-DR), 
presented by the APC could act as the ligand for the alloreactive T cell. Harding and 
Unanue have shown that only a small fraction of class II molecules presented by the 
APC will be occupied by a particular allospecific peptide. There may be 100 fold higher 
available number of ligands, or determinant density, per cell for the alloreactive T cells 
than is available for a conventional self-restricted antigen specific T cell response. 
Therefore, cells of lower affinity for an antigen specific response may be called into 
alloreactive repertoire; such that cells of low, intermediate and high affinity for the allo-
MHC molecule  could lead to the generation of a high precursor frequency (Harding 
and Unanue 1990). 
 
 
 Figure 6: Ligand bound by alloreactive T cells 
 
The interaction of the donor APC and the recipient T cells has been shown to occur 
predominantly in secondary lymphoid organs (Larsen, Morris et al. 1990). Once the 
donor APC induces the activation of the alloreactive T cells, these effector cells migrate 
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back to the graft and destroy the allograft. This pathway is primarily responsible for 
process of acute cellular rejection of the allograft (Warrens, Lombardi et al. 1994). 
Evidence for the existence of an alternative route for allorecognition was provided by 
Lechler and Batchelor through experiments in a rat model of transplantation (Lechler 
and Batchelor 1982). They observed that MHC incompatible kidney allografts depleted 
of indigenous passenger leucocytes were permanently accepted without 
immunosuppression in certain donor/recipient combinations but were lost to rejection in 
others. This second route for allorecognition is called the indirect pathway (Figure 5B). 
Here allogeneic MHC and other donor antigens are processed and presented by the 
recipient APC. In contrast to the direct pathway, this is the normal mechanism of T cell 
stimulation by nominal antigens (i.e. processed peptides restricted by self MHC 
molecules). The first direct demonstration of the indirect pathway was by Sherwood, 
Brent and Rayfield, who showed that host APCs could present both class I and class II 
antigens to syngeneic lymphocytes and bring about skin allograft rejection (Sherwood, 
Brent et al. 1986). Alloantigens shed from the graft are naturally processed as 
exogenous antigens by self-APCs, promoting alloreactive helper T cells that recognise 
allopeptides bound to autologous MHC class II molecules. This suggests that the 
indirect pathway might contribute to long term allograft damage as the graft has lost its 
dendritic cells and the direct pathway becomes hyporesponsive.  
B lymphocytes require the presence of CD4+ T cells to induce class switching and to 
differentiate into antibody secreting plasma cells. These T cells must have been 
activated by MHC class II molecules either on dendritic cells or alternatively autologous 
class II positive B cells. B cells may represent important APCs in the context of the 
alloresponse since although numerically inferior they do possess B cell receptors with 
high affinity for alloantigens and they retain the ability to proliferate in response to 
antigen (c.f. dendritic cells).  The presence of class switched IgG alloantibodies is 
therefore indirect proof for T cell help provided through indirect pathway (Lanzavecchia 
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1985, Steele, Laufer et al. 1996).  In experimental animals, it has also been shown that 
cardiac allograft survival was significantly prolonged in mice with defective B cell 
antigen presentation (Nozaki, Rosenblum et al. 2008).  
In the murine system, Benichou et al. showed that T cells collected from mice that had 
been sensitized by allogeneic splenocyte infusion or skin grafts proliferate to synthetic 
peptides derived from the polymorphic regions of the  and chains of the allogeneic 
class II MHC molecule presented by self APCs (Benichou, Takizawa et al. 1992). A 
number of other investigators have demonstrated T cell responses to synthetic 
peptides derived from allogeneic donor MHC molecules. In these experiments it has 
been established that the priming of CD4+ T cells by the indirect route can bring about 
a full range of effector responses including DTH (Waaga, Chandraker et al. 1998), 
priming of CD8+ CTLs (Lee, Grusby et al. 1994, Popov, Fedoseyeva et al. 1995), 
production of alloantibodies (Steele, Laufer et al. 1996) and regulatory cytokine 
secretion (Vella, Magee et al. 1999). Taken together, these experiments show that T 
cell activation by the indirect pathway occurs and can orchestrate the whole gamut of 
alloreactive effector responses. One of the more impressive examples is the work by 
Fabre and colleagues who initially showed that peptides from allogeneic MHC 
molecules could stimulate both the production of alloantibodies and alloreactive CD4+ 
T cells (Parker, Dalchau et al. 1992). They then went on to show that immunization with 
isolated denatured chains of class I and class II rat MHC molecules could accelerate 
the rejection of allogeneic skin grafts (Dalchau, Fangmann et al. 1992). This feat was 
then repeated by the immunization of graft recipients with peptide fragments of donor 
MHC antigens, bringing about accelerated graft rejection even when the allografts had 
been depleted of APCs (Fangmann, Dalchau et al. 1992, Benham, Sawyer et al. 1996). 
By using peptide fragments, only indirect pathway presentation is possible in this 
system. 
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In humans, the frequency of T cells engaged in indirect recognition of synthetic DR1 
peptides in an in vitro culture system was found to be about 100 fold lower than that of 
T cells participating in direct recognition of native HLA DR antigen (Liu, Sun et al. 
1993). 
In humans both direct and indirect pathways of allorecognition were studied 
simultaneously in long standing renal transplant recipients for the first time by Baker 
and colleagues. Using limiting dilution analysis (LDA), they have demonstrated donor 
specific direct pathway hyporesponsiveness defined either by cell proliferation or 
cytokine secretion. This phenomenon was not dependent on the diagnosis of IFTA with 
allograft dysfunction. Using a mixture of donor membrane proteins, they went on to 
demonstrate that indirect pathway activated alloreactive T cells are significantly higher 
in number in patients with deteriorating graft function, thereby establishing the 
significance of indirect pathway activation in the context of late allograft dysfunction 
(Baker, Hernandez-Fuentes et al. 2001).  Following this, several groups have 
confirmed the significance of indirect allorecognition in the context of chronic allograft 
dysfunction using less cumbersome techniques such as ELISPOT by showing that 
patients with CAD have a higher frequency of circulating indirect pathway activated 
alloreactive CD4+ T cells (Najafian, Salama et al. 2002, Poggio, Clemente et al. 2004); 
patients with CAD demonstrate direct pathway hyporesponsiveness whilst those with 
proteinuria show indirect anti-donor alloreactivity (Bestard, Nickel et al. 2008).   
The third mechanism of allorecognition is through the semi direct pathway or “linked 
allorecognition” (Figure 5C). Here, the recipient T cells interact with self-APC that have 
acquired intact donor MHC-peptide complexes from the donor cells through membrane 
transfer (Herrera, Golshayan et al. 2004). In the immune system, cells are capable of 
exchanging surface molecules and this is especially true of dendritic cells which can 
acquire MHC-peptide complexes from other dendritic cells and endothelial cells 
(Bedford, Garner et al. 1999). Therefore self APC not only have acquired intact donor 
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MHC but also processed these molecules and able to present these peptides thereby 
possessing the ability to simultaneously stimulate alloreactive CD4+ T cells by the 
indirect pathway and CD8+ T cells by the direct pathway (Herrera, Golshayan et al. 
2004). 
 
1.2.2.5 Clinical consequences of the allorecognition 
1.2.2.5a Hyperacute rejection 
Hyperacute rejection refers to rapid rejection of either allografts or xenografts which is 
due to preformed donor specific antibodies. These antibodies are of two principal 
lineages.  
1. Low affinity IgM and IgG antibodies that are specific for ABO blood group antigens 
and mandate ABO blood group matching in solid organ transplantation. Similar 
antibodies exist in humans against galactose--1-3-galactose epitope present in all 
other mammals and this constitutes one of the major impediments to successful 
xenotransplantation (Parker, Bruno et al. 1994).  
2. High affinity IgG antibodies directed against HLA class I antigens expressed on 
vascular endothelium. These antibodies commonly develop as a consequence of prior 
immunization either by blood transfusions, pregnancies or previous allografts.  In 1966, 
Kissmeyer Neilson described the pathology of hyperacute rejection in two cases of 
multiparous women who received renal transplants (Kissmeyer-Nielsen, Olsen et al. 
1966). These patients had demonstrable complement fixing antibodies in their serum. It 
was the binding of these antibodies that triggered activation of clotting and complement 
cascades leading to intravascular thrombosis, ischemia and subsequent necrosis 
(Figure 7). 
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Figure 7: Microscopic and gross histology of hyperacute rejection 
(glomerular micro thrombi, intravascular thrombus and graft necrosis) 
(Cornell, Smith et al. 2008) 
 
 
1.2.2.5b. Acute cellular rejection 
Renal allografts can be rejected quite rapidly even in the absence of preformed 
alloantibodies. In routine clinical practice with the use of immunosuppression, this 
usually occurs between 5 days and 3 months after transplantation. With current therapy 
directed largely against T cells, the incidence of acute cellular rejection is 
approximately 5-10% in the first post-transplant year. Pathologically, acute cellular 
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rejection is manifested by the accumulation of mononuclear cells in the interstitium, 
accompanied by the inflammation of tubules (tubulitis) and sometimes of small and 
medium sized arteries (intimal arteritis) (Colvin 2006). Glomerulitis is rarely a 
conspicuous feature of acute cellular rejection with a predominance of CD3+ T and 
CD68+ macrophages. However, why the glomerulus becomes a target in a minority of 
cases still remains a mystery (Tinckam, Djurdjev et al. 2005). 
Tubulitis:  Tubulitis is an important lesion in the diagnosis of ACR and is believed to 
contribute to the abrupt rise in serum creatinine. This lesion is T cell dependent and 
occurs even in the absence of B cells and alloantibody (Jabs, Sedlmeyer et al. 2003). T 
cells are attracted to the cortical tubules probably via chemokines (CCL2, CCL5, 
CX3CL1) from tubular cells, made in response to cytokines from inflammatory cells. T 
cells, especially cytotoxic T cells enter between the tubular cells and may cause 
apoptosis by releasing cytolytic granules containing granzyme B and perforin or by 
exposure to FasL on the T cell surface. The integrin component (CD103) is postulated 
to help retain T cells in the epithelial layer by binding to E-cadherin expressed strongly 
in the distal nephron. FOXP3+ Tregs also accumulate but their function is unknown. In 
response tubules secrete IL15 and protease inhibitor-9 which in turn inhibit granzyme-B 
and perforin respectively. Infiltrating macrophages secrete TGF- and upon chronic 
exposure, tubules undergo epithelial-mesenchymal transformation with the loss of E-
cadherin. These cells may infiltrate the interstitium and promote fibrosis (Figure 8) 
(Cornell, Smith et al. 2008). Although multiple cytokines and chemokines are 
selectively expressed in ACR, the genes that are differentially expressed in clinical vs. 
subclinical ACR in protocol biopsies are T-bet, FasL and CD152 (Hoffmann, Hale et al. 
2005).  
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Figure 8: Postulated events in tubulitis (acute cellular rejection) 
(Cornell, Smith et al. 2008) 
 
Intimal arteritis: Endarteritis affects large and small arteries focally both within and 
outside the parenchyma and can occur even without the participation of alloantibody as 
shown in murine models (Russell, Chase et al. 1997, Wieczorek, Bigaud et al. 2006). 
Apoptosis of the vascular endothelial cells is present in the sites of arteritis but this 
lesion is not always associated with an interstitial inflammation, thereby suggesting that 
a T cell pathway distinct from that of tubulitis is involved (Cailhier, Laplante et al. 2006).   
In this lesion, the inflammatory cells infiltrating the endothelial cell are mostly T cells 
and macrophages with an effector phenotype. Inflammatory cellular adhesion and 
trans-endothelial migration begins when abluminal chemokines (CCL4, CCL5, CXCL8) 
are transcytosed to the luminal surface and bound by luminal glycosaminoglycans thus 
creating a chemotactic gradient for inflammatory cell migration (Middleton, Patterson et 
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al. 2002, Choy, Kerjner et al. 2004). Endarteritis is detected in approximately 25-40% of 
ACR but rarely seen in stable grafts (Mengel, Gwinner et al. 2007). This lesion 
responds poorly to steroids but is reversible with anti T cell therapy (OKT3/ATG) again 
stressing the importance of T cells (Colvin 2006). 
In summary, ACR is a complex process involving many effector cells including T cells 
and macrophages. Despite the well documented pre-eminence of the cellular 
components there is some evidence for the involvement of alloantibody. In renal 
transplantation, about 10% of the biopsies for ACR show evidence of intravascular 
fibrinoid necrosis with occasional evidence of antibody and complement deposition by 
immunofluorescence. 
 
1.2.2.5c Antibody mediated rejection 
Seminal work by Gorer and others has shown that mouse skin allografts can induce 
antibody that can agglutinate donor erythrocytes (Amos, Gorer et al. 1954, Gorer 
1955). However passive transfer of the antibody at the time of engraftment failed to 
cause accelerated rejection in contrast to the adoptive transfer of the sensitised 
lymphocytes which promptly caused rejection. Moreover, T cells were considered to be 
the central regulators and effectors of the process of allograft rejection as lack of T 
cells in animal models led to the non-rejection phenotype (Manning, Reed et al. 1973). 
The apparent lack of response to the early transfer of the antibody was later shown to 
be secondary to the lack of perfusion of the skin grafts during the first few days 
(Gerlag, Koene et al. 1975). Evidence accumulated for the implication of antibody in 
chronic rejection and in 1970, Russell and colleagues identified a strong link between 
the presence of HLA specific antibody and chronic transplant arteriopathy (stenotic 
arterial lesions of the graft) (Jeannet, Pinn et al. 1970). Furthermore experimental 
studies in murine models have confirmed the ability of the passively transferred 
antibody to cause transplant arteriopathy even in immunologically deficient mice but 
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not in the absence of B cells  (Russell, Chase et al. 1997). A further breakthrough 
occurred with the demonstration of the connection between the antibody and graft 
damage by the identification of C4d deposition as a marker of complement fixation in 
the tissues (Feucht, Felber et al. 1991, Collins, Schneeberger et al. 1999). Chronic 
antibody mediated rejection as a significant cause of chronic allograft loss is now 
widely recognised. 
Acute antibody mediated rejection (AAMR):  At present AAMR is diagnosed based 
on four criteria (Colvin and Smith 2005). 
1. Clinical evidence of graft dysfunction 
2. Histological evidence of tissue injury (e.g. Acute tubular injury, inflammatory 
infiltrate, capillary microthrombi, fibrinoid necrosis) 
3. Immunopathological evidence for the action of antibodies (eg. C4d deposition) 
4. Serologic evidence for the presence of donor specific antibody at the time of the 
biopsy 
On an average this occurs in about 7% of allografts and is seen in around 30% of 
allografts with acute rejection (Herzenberg, Gill et al. 2002, Mauiyyedi, Crespo et al. 
2002, Racusen, Colvin et al. 2003). Demonstration of C4d deposition in the capillaries, 
a technique pioneered by Feucht has become crucial in the diagnosis of AAMR with 
varying specificity (50-95%) and sensitivity (78-96%) (Bohmig, Exner et al. 2002, 
Mauiyyedi, Crespo et al. 2002, Feucht and Mihatsch 2005). C4d is an inactive fragment 
derived from C4b in the classical complement pathway. C4d per se does not have a 
functional role but remains bound to the tissue for several days after the 
immunoglobulin and C1 have been released. C4d is deposited in the majority of the 
peritubular capillaries as an intense ring pattern, detected by immunofluorescence 
microscopy (Figure 9) (Regele, Bohmig et al. 2002). Electron microscopy demonstrates 
C4d on the surface and within the intracytoplasmic vesicles of the endothelial cells 
(Regele, Bohmig et al. 2002). Although anti-HLA DSA are detected in about 90% of 
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patients who have C4d deposition, AAMR can occur even in the absence of 
demonstrable circulating DSA probably due to the adsorption of the antibody onto the 
graft (Martin, Guignier et al. 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: Immunofluorescence microscopy for C4d 
(A). Control case with CNI nephrotoxicity (B) AMR 
(Mauiyyedi, Crespo et al. 2002) 
 
Complement and AAMR: In animal studies and in humans, complement fixation is 
essential for the pathogenesis of AAMR. Passive transfer of complement fixing 
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isotypes of alloantibodies can mediate AAMR in animal models of kidney and heart 
transplants independent of Fc receptors or NK cells (Wasowska, Qian et al. 2001, 
Rahimi, Qian et al. 2004). In humans, activation of C1 (composed of C1q, C1r, and 
C1s) is initiated by the interaction of globular domains of C1q with IgG or IgM bound to 
the antigen epitopes of the graft endothelium. The C1q binding potential of human IgG 
subclasses is as follows- IgG3>IgG1>IgG2>IgG4. Conformational changes within C1q 
then allow the cleavage and activation of C1r which in turn activates C1s.  C1s is the 
enzyme that activates C2 and C4. C4 is cleaved by C1s into C4a and C4b, exposing 
the sulfhydryl group. The reactive sulfhydryl group forms a rapid ester or amide bond 
with the nearby molecules that contain hydroxyl or amino groups.   C4b is inactivated 
by factor 1 into C4d which remains covalently bound to the surface of the capillary 
endothelium. Eventually C4d is cleared from the tissue after the antibody response has 
ended (can take place within as early as 8 days) (Collins, Schneeberger et al. 1999). 
Further steps leading to the formation of the membrane attack complex are 
demonstrated in Figure 10 (Colvin and Smith 2005).  
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Figure 10: Classical pathway of complement activation 
(Colvin and Smith 2005) 
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The acute effects of complement activation are well described- 
1. Chemoattraction of neutrophils and macrophages (C3a and C5a) 
2. Vasospasm (PGE2 from macrophages) 
3. Edema (histamine from the activated mast cells) 
4. Lysis of endothelial cells (MAC) 
5. Vascular microthrombi (Von Willibrand factor released by the activated 
endothelial cells and platelet aggregation) 
 
Complement independent pathway and chronic antibody mediated rejection 
(CAMR): Antibody can also damage target cells through complement independent 
pathways which also contribute to the pathogenesis of antibody mediated rejection.  
Current evidence suggests that complement independent pathways contribute to the 
pathogenesis of CAMR (Colvin and Smith 2005). In the absence of complement or 
inflammatory cells, alloantibody (for example HLA class I DSA) can induce endothelial 
cell activation (to synthesize cytokines and chemokines), and also promote their 
proliferation through NF-(Smith, Lawson et al. 2000, Zhang and Reed 2009).  The 
activation of the endothelial cells may be relevant to the arterial intimal proliferation, a 
lesion characteristic of CAMR. Antibody can also lyse target cells through low affinity 
FCIII receptors on the surface of NK cells and macrophages (antibody dependent 
cell mediated cytotoxicity). Figure 11 demonstrates both complement independent and 
dependent pathways for endothelial cell damage (Colvin and Smith 2005). 
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Figure 11: Complement dependent and independent effects on endothelium 
(Cornell, Smith et al. 2008) 
 
In humans, the role of complement independent endothelial injury in the pathogenesis 
of CAMR has been studied indirectly through gene expression studies. These studies 
are pioneered by Halloran’s group who have demonstrated that endothelial transcripts 
(ENDATS) are preferentially expressed in patients with CAMR, and that they correlate 
with histological lesions and predict graft outcomes irrespective of peritubular C4d 
deposition thereby raising an important question on the utility of C4d staining in the 
diagnosis of CAMR (Sis, Jhangri et al. 2009). Furthermore, in an analysis of patients 
with DSA, they have shown that DSA selective transcripts demonstrated a selective 
high expression in the NK cells and correlated with a diagnosis of CAMR. Interestingly 
immunostaining of the cells in the peritubular capillaries of these patients revealed that 
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most of these cells are CD16+ CD56+ NK cells and not T cells. This study highlights 
the importance of NK cells in the context of CAMR (Hidalgo, Sis et al. 2010).  
The classical histological lesions of CAMR are (Colvin 2011) (Figure 12) 
1. Transplant glomerulopathy 
a. Duplication of glomerular basement membrane (GBM) 
b. Absence of evidence of immune complex glomerulonephritis/chronic 
thrombotic microangiopathy 
c. Glomerulitis (majority of the cellular infiltrate-CD68+, minority CD3+) 
2. Transplant arteriopathy 
a. Fibrointimal thickening of the arteries 
b. Inflammatory cells present within the thickened intima 
3. Peritubular capillaropathy 
a. Peritubular capillary basement membrane multilayering 
b. Loss of peritubular capillaries over time 
c. Mononuclear cells in the peritubular capillaries  
d. C4d deposition in some cases 
4. Interstitial fibrosis and Tubular atrophy 
a. Non-specific feature 
b. If present, C4d deposition may offer a diagnostic clue 
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Figure 12: Histological lesions of CAMR 
(A). Mononuclear infiltrate within the glomerulus and basement membrane multilayering. (B). 
Patchy C4d deposition in the peritubular capillaries by immunofluorescence.  (C). EM showing 
duplication of GBM and activated endothelial cell. (D). Peritubular capillaries with prominent 
inflammatory infiltrate (Cornell, Smith et al. 2008). 
 
When the damaged endothelium repairs itself, it also forms a new basement 
membrane layer. The pathologic finding of basement membrane multilamination is 
thought to occur by repeated episodes of injury to the endothelium by the antibody. 
Ivanyi and colleagues have proposed that peritubular capillaropathy can be defined as 
one peritubular capillary with seven or more circumferential layers or three or more 
peritubular capillaries with 5-6 layers (Ivanyi, Kemeny et al. 2001). What leads to the 
episodic antibody mediated injury is not clearly known but one potential explanation is 
summarized in Figure 13 (Cornell, Smith et al. 2008). 
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Figure 13: Hypothetical relationship between DSA, C4d and basement membrane 
multilayering (Cornell, Smith et al. 2008) 
 
 
According to this scheme circulating DSA may be below the level of detection at a 
given time point but typical lesions persist in the graft. 
Four theoretical stages for the evolution of CAMR have been described at a NIH 
consensus conference (Takemoto, Zeevi et al. 2004). As shown in Figure 14, this 
staging process proposes that appearance of DSA in the circulation marks the first 
stage which progresses eventually to allograft loss. Although this provides a clear view 
of the progression of the disease process, it is in fact an over-simplification of a rather 
complex immuno-pathological process. For example the time frame from the origin of 
DSA to the development of histological lesions can vary and same is true of the lapse 
between the onset of histological lesions to that of allograft dysfunction. Moreover, C4d 
31 | P a g e  
 
detection which heralds the start of stage-2 may not occur in some cases of 
histologically proven CAMR. 
 
 
 
 Figure 14: Proposed sequence of stages of CAMR 
(Takemoto, Zeevi et al. 2004) 
 
1.2.2.5d Accommodation 
Accommodation is defined as the resistance of a graft to the acute pathological effects 
of allospecific antibodies and complement fixation (Koch, Khalpey et al. 2004). 
Alexandre and colleagues initially observed this phenomenon in the recipients of ABO 
incompatible renal transplants (Alexandre, Squifflet et al. 1987). They described how 
transient depletion of blood group specific antibodies allowed immediate graft survival. 
However there was rebound of the antibody concentration within the first 10 days that 
led to graft rejection in about 90% of the patients. Importantly, for the remaining grafts 
after 21 days, there was no correlation between the titre of the antibody and the 
occurrence of rejection.  
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In animal experiments, the absence of T cell help and the emergence of B cell 
tolerance through exposure to incompatible carbohydrate antigens leading to the 
development of non-complement fixing antibodies have been cited as possible 
mechanisms for accommodation (Ogawa, Mohiuddin et al. 2004). Also the emergence 
of anti-apoptotic proteins, such as B cell lymphoma-2 (Bcl-2), Bcl-XL and haem-
oxygenase-1 (HO-1), has been demonstrated in rodent studies in the context of 
allograft accommodation (Tabata, de Perrot et al. 2003). In humans, antibody induced 
increase in the endothelial expression of Bcl-XL has been demonstrated as a molecular 
mechanism for the phenomenon of accommodation in HLA mismatched renal allografts 
by Salama et al. (Salama, Delikouras et al. 2001). Finally complement regulation has 
also been shown to be involved in the development of accommodation. Four cell 
surface inhibitors of complement activation have thus far been identified (Collins, 
Schneeberger et al. 1999). 
1. CR1  
2. Decay Accelerating Factor (DAF, CD55) 
3. Membrane Cofactor Protein (MCP, CD46) 
4. Protectin (CD59)- inhibits MAC 
It is easy to assume that accommodation is an ‘all or none’ process. But some authors 
propose that there are gradations and indeed that CAMR is partially accommodated 
AAMR (Colvin and Smith 2005).  
 
1.2.2.5e Tolerance 
The opposite phenomenon to CAD is characterized by excellent graft function with no 
evidence of morphological graft damage which, if it occurs in the absence of 
immunosuppression, is termed tolerance. Nearly seventy years ago, Owen 
documented the coexistence of two types of erythrocytes in the blood of dizygotic cattle 
twins (freemartins). He concluded that the twins must have exchanged the erythrocytes 
 
Inhibit both classical and 
alternate pathways at the level 
of C3 and C5 convertase 
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or their precursors in utero and that the cells survived as the calves grew into adults. 
This naturally acquired non-reactivity to foreign red cells with their antigens was a clear 
example of immunological tolerance in action (Owen 1945). The phenomenon of 
actively acquired tolerance was further described by Medawar and colleagues in 
experiments demonstrating the inability of individuals to react immunologically against 
foreign tissue, to which they had been previously exposed in foetal life (Billingham, 
Brent et al. 1953). 
Instead of a strict definition of tolerance, an operationally tolerant state has been 
defined as long-term graft survival in a patient who is no longer taking any maintenance 
immunosuppression (Calne 2004). Such a state of operational tolerance is very rare in 
routine clinical practice and is exemplified either by non-adherence or by patients with 
malignancy or severe infections who discontinue immunosuppression but maintain 
stable graft function. There has been much interest in the identification of immune 
signature for operational tolerance since the identification of a similar phenotype in 
other transplant recipients may facilitate the safe withdrawal of immunosuppression. 
 
1.2.3 Markers of allograft loss or tolerance 
There is an unmet need for specific markers that can identify patients across the 
spectrum of immunological risk of renal transplantation (i.e. CAD vs. operational 
tolerance). Such risk stratification would inform the choice of immunosuppressive 
strategy with potentially progressive minimization of immunosuppression in patients 
with low-immunological risk or intensification if there is evidence of on-going immune 
activation.  Such individualized immunosuppressive strategy may eventually help 
realize the ultimate goal of prolonging long term graft life. 
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1.2.3.1 Chronic allograft loss-Clinical markers 
Late renal allograft loss is one of the biggest challenges in the field of transplantation 
and early diagnosis is thwarted by the inability to detect early graft injury. Two of the 
commonest clinical variables measured routinely in practice are serum creatinine and 
urine protein excretion. 
Serum creatinine measured at one year was identified as an important determinant of 
long term allograft survival in a large registry analysis by Hariharan (Hariharan, 
McBride et al. 2002). In this study they demonstrated that subsets of patients with 
markedly reduced graft life can be identified by using renal function measured by 
serum creatinine at one year or the change in creatinine between 6 months and one 
year after transplantation (Δ creatinine). For this they have used a cut-off for serum 
creatinine of 1.5mg/dl and 0.3 for Δ creatinine. Patients who had renal function worse 
than these cut-off values demonstrated a step wise reduction in the overall graft 
survival and the graft half-life even after adjusting for potential confounding factors, 
thereby suggesting that serum creatinine can be used as a surrogate end point for 
eventual graft loss. However there is one significant shortcoming of this analysis which 
is the measurement itself. Serum creatinine is not a reliable method for estimating renal 
function; as it dependent on age, gender, ethnicity and body weight. 
While there is no disputing the strong correlation of renal function and renal transplant 
outcomes, caution is advised in extrapolating this. In establishing highly associated 
diagnostics as predictive entities, further steps of validation are required (Armitage 
2002). In another study Kaplan and colleagues further analysed the utility of serum 
creatinine as a predictive marker (Kaplan, Schold et al. 2003). In their analysis, serum 
creatinine was found to generate an odds ratio of around 2 for graft loss which 
suggests doubling of the risk for allograft loss. But when the utility of the variable was 
assessed by Receiver Operational Characteristic (ROC) curve, the area under curve 
value was a mere 0.67. In other words, the ability of serum creatinine to discriminate 
observations between the actual failure cases and the cases that do not fail is a 
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minimal gain from random allocation alone (analogous to an area of 0.500). More 
importantly, no particular range of the creatinine values had any predictive character or 
a discrete cut-off that could be utilized. Overall, this study highlighted the limited value 
of serum creatinine as a predictive marker for allograft loss although it concurred with 
previous finding that creatinine is a strong risk factor.  
 
Ever since the seminal description of Bright’s disease, proteinuria has been used as a 
marker of renal parenchymal damage, and in most renal diseases, proteinuria is an 
important early prognostic marker of poor outcome (Cattran, Pei et al. 1992, Burton 
and Harris 1996, Harris, Burton et al. 1996, Iseki, Ikemiya et al. 2003, Reich, Troyanov 
et al. 2007). Furthermore, in patients without overt renal disease, low-grade proteinuria 
is a marker of poor cardiovascular outcome (Grimm, Svendsen et al. 1997). The origin 
of protein in the urine may simply be a reflection of established renal damage, but there 
is some evidence that it may be indicative of earlier processes in the chain of injurious 
events that ultimately lead to renal fibrosis and glomerulosclerosis. For example, 
protein may be acting as a mediator of renal injury, initiating multiple inflammatory 
pathways that lead to renal fibrosis and scarring (Abbate, Zoja et al. 2006). Recent 
evidence also suggests that low-grade proteinuria may be indicative of on-going 
endothelial injury (Stam, van Guldener et al. 2006). Perhaps, more importantly, there is 
some evidence that proteinuria is a modifiable risk factor and that reduction of protein 
excretion may be a worthwhile therapeutic goal leading to improved clinical outcomes 
(Bakris 2008). 
Allograft glomerular diseases that lead to high grade proteinuria are shown to be 
associated with reduced kidney allograft survival (First, Vaidya et al. 1984) . More 
recent studies show this relationship extends to lower levels of proteinuria that may or 
may not be associated with glomerular pathology (Halimi, Laouad et al. 2005, Amer, 
Fidler et al. 2007, Halimi 2013). Investigating the cause of early post-transplant 
proteinuria is complex because after transplantation protein may originate from the 
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allograft or from native kidneys, may be due to various allograft pathologies, and/or 
may be a side effect of immunosuppressive medications. Thus, stating that proteinuria 
relates to graft survival is an oversimplification because among other variables, the 
cause of proteinuria likely has an effect on that relationship. For example low levels of 
proteinuria have been attributed to several mechanisms including glomerular 
hyperfiltration, endothelial activation, tubular defects in the absorption of albumin, and 
proteinuria originating from the native kidneys, all of which may be modulated by the 
hemodynamic effects of calcineurin inhibitors and all of which may have a significant 
effect on graft outcomes (First, Vaidya et al. 1984, D'Cunha, Parasuraman et al. 2005, 
Myslak, Amer et al. 2006, Straathof-Galema, Wetzels et al. 2006, Amer, Fidler et al. 
2007, Russo, Sandoval et al. 2007). Still, these observations emphasize the 
importance of monitoring urine protein excretion post-transplant, investigating the 
cause of even low levels of proteinuria, and considering therapy.  
 
1.2.3.2 Chronic allograft loss-Immunological markers- T cells 
Lymphocytes, despite their monotonous morphological appearance, have kindled the 
curiosity and challenged the experimental skills of investigators across the breadth of 
medicine. We have come to know them as either T (Thymus derived) or B (bursa of 
fabricius or bone marrow derived) lymphocytes and the diverse roles played by the 
latter in the context of human renal transplantation will be the focus of this thesis. 
T cells have been regarded to have central regulatory and effector roles in graft 
rejection since experimental animals without T cells permanently accept foreign skin 
grafts from other animals with increasing phylogenic disparity (Manning, Reed et al. 
1973). In the context of chronic antibody mediated rejection (CAMR), T cells also 
provide help for the alloresponsive B cell by both non-cognate and cognate interactions 
(Steele, Laufer et al. 1996). Given the potential role of the T cells in the pathogenesis 
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of CAMR, the measurement and characterization of T cell function may provide a 
marker for clinical use (see below). 
During the past decade, the Th1/Th2 paradigm of the helper T cell activation has 
evolved to include two distinct subsets called regulatory T cells and Th17 cells. 
Regulatory T cells are identified by the expression of FoxP3 (Forkhead box P3), which 
is a member of the Forkhead/winged-helix family of transcription factors. These cells 
have been shown to suppress immune responses either through their interactions with 
dendritic cells or via cytokine mediated inactivation of responder T cells (Sakaguchi, 
Yamaguchi et al. 2008). Th17 cells were identified by the production of the IL-17 family 
of cytokines (IL17 A-F) along with IL-21 and IL-22 upon stimulation (Bettelli, Korn et al. 
2007). Even though these cells have been shown to play an important role in 
autoimmunity and infection, their specific role in the context of CAD/tolerance is less 
well understood. 
ELISPOT is one of the most sensitive assays to detect and quantify antigen specific 
responses of activated T cells and the technique has paved the way for a more 
objective and reproducible functional analysis of T cells (Czerkinsky, Nilsson et al. 
1983). Analysis of interferon-(IFN-) production by T cells using the ELISPOT 
technique in response to stimulation by peptides corresponding to the polymorphic 
hypervariable regions of the  chains of HLA-DR molecules has been shown to predict 
rejection and correlate with graft function in patients undergoing renal transplantation 
(Najafian, Salama et al. 2002, Bestard, Nickel et al. 2008). Interestingly, patients with 
stable function and low IFN- CD4+ T cell responses demonstrated regulation of the 
indirect pathway alloresponse by regulatory T cells (Salama, Najafian et al. 2003). 
Lower frequencies of direct pathway anti-donor IFN- secreting CD4+ T cell responses 
were also seen in operationally tolerant patients (Sagoo, Perucha et al. 2010).   
 
38 | P a g e  
 
1.2.3.3 B lymphocytes  
A simple definition of B lymphocytes is a population of cells that express clonally 
diverse cell surface immunoglobulin (Ig) receptors recognizing specific antigenic 
epitopes. Their origin can be traced to the evolution of adaptive immunity in jawed 
vertebrates beginning more than 500 million years ago (Cooper and Alder 2006). 
Mammalian B-cell development encompasses a continuum of stages that begin in 
primary lymphoid tissue (e.g., human foetal liver and foetal/adult marrow), with 
subsequent functional maturation in secondary lymphoid tissue (e.g., human lymph 
nodes and spleen). The functional/protective end point is antibody production by 
terminally differentiated plasma cells. However, these B-cell development stages and 
their functional identities were essentially discovered in reverse chronologic order. 
Before presenting various B cell markers in the context of transplantation, I shall briefly 
discuss the development and maturation of B cells. 
 
1.2.3.3a Development of B cells 
B cells along with the other cells of lymphoid lineage are all derived from common 
lymphoid progenitors which in turn arise from the pluripotent stem cells (Figure 15) 
(LeBien and Tedder 2008). The bone marrow stromal cells provide the external signals 
for this maturation process. Pluripotent stem cells next differentiate into multipotent 
progenitor cells which express a surface tyrosine kinase called FLT3 which is needed 
for differentiation into the next stage, i.e. common lymphoid progenitor. Lymphocyte 
development is accompanied by the expression of the receptor for IL7. IL7 which is 
dominantly produced by the stromal cells is essential for the growth and the survival of 
the developing B cells. The common lymphoid progenitor gives rise to the earliest B 
lineage cell, i.e. the pro-B cell in which immunoglobulin gene re-arrangement begins. A 
definitive B cell fate is determined by the induction of B lineage specific transcription 
factor, E2A. From here, further development of B cell ensues, with the re-arrangement 
of the heavy chain locus followed by the L chain loci. The consecutive stages of B cell 
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development include-early pro B cell, late pro B cell, large pre B cell, small pre B cell, 
immature B cell and mature B cell.  The rearrangement of Ig gene occurs via an error-
prone process involving the combinatorial rearrangement of the V, D, and J gene 
segments in the H chain locus and the V and J gene segments in the L chain loci. Pre-
B cells arise from progenitor (pro-B) cells that express neither the pre-BCR nor surface 
Ig. Subsequently, BCR expression is a pre-requisite for the development and survival 
of these cells in the periphery (Lam, Kuhn et al. 1997). Once the re-arranged light chain 
pairs with a  chain, IgM can be expressed on the cell surface and the pre- B cell 
becomes an immature B cell. At this stage, the antigen receptor is first tested for 
tolerance to self-antigens (central tolerance). The fate of the immature cell depends on 
interactions of surface IgM (IgM). IgM interacts with Ig and Ig to form a functional B 
cell Receptor (BCR). Ig signalling is key to the emigration of the immature B cell. 
Immature B cells that have no strong reactivity to self-antigens undergo maturation and 
carried by venous blood to the lymphoid organs (Spleen). A self-reactive immature B 
cell has 4 potential fates (Murphy 2008): 
 
1. Clonal deletion: Removal of cells of particular antigen specificity  
2. Receptor editing: Further gene re-arrangements that replace the autoreactive 
BCR with a non-self-reactive BCR 
3. Anergy: a state of permanent unresponsiveness upon weak cross-linking of the 
antigen 
4. Immunological ignorance: to self-antigen such that these cells behave as if they 
are not self-reactive at all. 
 
The immature B cell that leaves the marrow on its way to the spleen is called a 
transitional B cell. There are three types of the mature B cell as shown in Figure 16. 
Antigen-induced B-cell activation and differentiation in secondary lymphoid tissues is 
mediated by dynamic changes in gene expression that give rise to the germinal centre 
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(GC) reaction. The GC reaction is characterized by clonal expansion, class switching 
recombination (CSR) at the Ig locus, somatic hyper mutation (SHM) of VH genes, and 
selection for increased affinity of a BCR for its unique antigenic epitope through affinity 
maturation. CSR, also known as isotype-switching, was first demonstrated in the 
chicken (Kincade, Lawton et al. 1970). CSR and SHM are mediated by an enzyme 
designated activation-induced cytidine deaminase (AID) which is induced in B cells in 
GCs where CSR and SHM occur (Muramatsu, Kinoshita et al. 2000, LeBien and 
Tedder 2008) . 
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Figure 15: Maturation of human B cells 
(LeBien and Tedder 2008) 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Mature naïve B cells 
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1.2.3.3b B cells as antibody producing cells 
The discovery of B cells did not originate in the identification of a cell, but rather the 
identification of an effector protein (i.e., Ig or antibody). Identification of serum 
gammaglobulin as the source of antibodies was a launching point for the eventual 
discovery of antibody producing cells (Tiselius and Kabat 1938). Plasma cells were 
suggested as a source of antibody production as early as 1948 (Fagraeus 1948). All 
antibodies are constructed in the same way from paired heavy and light chains that are 
composed of constant (C) and variable regions (V). Each light chain has a variable and 
constant region while the heavy chain is composed of one variable and three constant 
regions (CH1, CH2, and CH3). Five different classes of the antibody can be 
distinguished by their C region whilst differences within the V regions confer antigen 
specificity. Proteolytic enzymes like papain cleave the antibody molecule at its hinge 
yielding two identical fragments that contain antigen binding activity. These are called 
Fab fragments. Each Fab fragment is composed of a light chain paired with the 
variable region and CH1 domain of the heavy chain. The other fragment contains no 
antigen binding activity but was originally observed to crystallize readily and therefore 
called the Fc fragment. Antibodies of various classes operate in distinct places and 
have distinct effector functions. They are briefly summarized in Figure 17. IgG antibody 
further consists of 4 subclasses-IgG1, IgG2, IgG3, IgG4. Of these IgG3 has the 
strongest ability to fix complement, whilst IgG4 does not fix complement. 
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Figure 17: Brief summary of Immunoglobulin classes 
 
 Monomer Dimer/monomer Pentamer Monomer monomer 
Antigen binding 
sites 
2 4/2 10 2 2 
Molecular weight  150,000 170,000-385,000 900,000 180,000 200,000 
% of total Ig in the 
serum 
80% 13% 6% 1% 0.002% 
Half life 23 days 6 days 5 days 3 days 2.5 days 
Fixes complement? Yes No Yes No no 
Crosses placenta? Yes No No No No 
Fc binds to… Phagocytes    Mast 
cells/basophils 
Biological function Neutralization, 
opsonisation, 
memory antibodies 
Secretory antibody 
Neutralization 
Complement 
activation, first 
response 
Receptor on B 
cells 
Antibody of 
allergy 
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Antibody and Transplantation: The production of alloantibody (Non-IgM) usually 
requires T-cell help. MHC molecules are presented to recipient T cells by either the 
direct or indirect pathways of allorecognition. The activated T cells can then provide 
help for B-cell activation, antibody class switching and affinity maturation, through 
various T-cell-derived cytokines and co-stimulatory factors (such as ICOS (inducible T-
cell co-stimulator), CD40 ligand, and CD80 and CD86). Experiments in mice indicate 
that, for B-cell help, the antigen that is recognized by the T cell needs to be presented 
by self-APCs (indirect pathway), perhaps because the T cell needs to react with and 
signal through self-MHC class II molecules on the surface of the B cell (i.e. B cell is 
acting as APC) (Mitchison 2004). By contrast, the production of IgM alloantibodies that 
are specific for MHC molecules and carbohydrate antigens (ABO) might not require T-
cell help (Steele, Laufer et al. 1996).. The B-cell response leads to the production of 
long-lived plasma cells, which migrate to the bone marrow and continue to produce 
antibody indefinitely, without requiring T-cell help (Shapiro-Shelef and Calame 2005). 
 
The landmark report that hyperacute rejection was related to the presence of 
preformed donor-specific antibodies provided unequivocal evidence for the role of B 
cells and antibody in graft rejection (Kissmeyer-Nielsen, Olsen et al. 1966). The 
detection and the association of such antibodies with fibrointimal proliferation in the 
renal allografts (chronic allograft arteriopathy) (Jeannet, Pinn et al. 1970) emphasized 
the role played by the antibody in the pathogenesis of CAD.  
The advent of Luminex xMAP technology (Figure 18) has provided solid phase 
antibody assays that can detect the presence of HLA specific antibodies with high 
sensitivity. 
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Figure 18: Luminex technology for antibody detection 
Luminex is based on flow cytometry. 5.6 micron polystyrene microspheres are internally dyed 
with varying amounts of red and infrared fluorophores to obtain 100 distinct sets. The surface 
chemistry on these microspheres allows simple chemical coupling of capture reagents such as 
HLA molecules. High-tech fluidics based on flow cytometry allows profiling and analysis of these 
microspheres by detection lasers. Because each microsphere carries a unique signature, the 
Luminex system can identify which set it belongs to.  
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Several studies have reported an association between the development of donor 
specific (DSA) and non-donor specific (NDSA) HLA specific antibodies and poor graft 
survival (Worthington, Martin et al. 2003, Terasaki and Ozawa 2004, Hourmant, 
Cesbron-Gautier et al. 2005, Lachmann, Terasaki et al. 2009). In these studies, the 
overall prevalence of these antibodies after transplantation ranged from 12 to 60%. 
Such a wide variation in the prevalence rates could be the result of different monitoring 
techniques. In almost all these studies HLA specific antibodies were analysed at either 
one or two time points, with no serial evaluation to determine when they develop and if 
they persist at the time of graft failure. Also, clinical status at the time of DSA 
development may vary from normal function to acute dysfunction with rapid graft loss. 
A humoral theory of transplantation has been proposed implicating these antibodies in 
the causation of graft rejection and loss (Terasaki P I. 2003).  However some 
unanswered questions remain. The presence of post-transplant HLA specific 
antibodies in patients with no apparent graft dysfunction in part contradicts the humoral 
theory (Bartel, Regele et al. 2008). Also in sequential screening protocols these 
antibodies do not always predict acute rejection since their appearance does not 
precede rejection episodes (Gill, Landsberg et al. 2010). The relevance of DSA in 
clinical practice was examined by Nickerson’s group in Canada in 2012. In this 
longitudinal study, they have shown that DSAs develop in 15% of low-risk renal 
transplant recipients and that graft survival is significantly reduced in such patients. 
Interestingly, patients with DSA were more likely to have had preceding clinical and 
subclinical cellular rejections in the 0–6 month post-transplant period. Moreover, in 
those who develop graft dysfunction, DSAs typically emerge before the onset of 
proteinuria or a rise in creatinine. In non-adherent patients who present with DSA and 
dysfunction, the histology was often a mixed picture of cellular and antibody-mediated 
rejection. Finally, they have shown that histological antibody-mediated injury could 
occur in patients with DSAs in the absence of graft dysfunction and that the degree of 
injury could progress in these patients despite augmented immunosuppression (Wiebe, 
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Gibson et al. 2012). This is the most comprehensive assessment of the clinical 
relevance of HLA specific DSAs to date.  
 
Complement activation by antibodies has been shown to be an important mediator of 
graft injury. Hence, assessment of the ability of antibodies to fix complement has 
gained increasing interest. C4d binding by antibodies has been shown to correlate with 
graft survival in small cohorts of transplant recipients (Smith, Hamour et al. 2007).  
Since the “signal” for C4d binding by antibodies is relatively low, the ability of 
antibodies to bind C1q is a current focus (Tyan 2012). Recent small series have shown 
that the presence of C1q-binding antibodies correlates with worse graft survival of 
kidney and heart transplants (Sutherland, Chen et al. 2012, Freitas, Rebellato et al. 
2013, Zeevi, Lunz et al. 2013). In a recent study designed to determine the ability of 
C1q binding by post-transplant donor-specific antibodies to risk stratify renal transplant 
recipients, Loupy and colleagues have demonstrated that C1q binding by antibodies 
was strongly correlated with antibody-mediated rejection in the first year after 
transplantation, with more microvascular inflammation and injury, more C4d deposition 
in the peritubular capillaries of the graft, and a lower estimated glomerular filtration rate 
(GFR) at 1 year (Loupy, Lefaucheur et al. 2013). C1q-binding antibodies also 
correlated with worse 5-year graft survival, whether they were detected at the time of 
rejection during the first year or at 1 year, and with a higher risk of graft loss in each of 
three categories of estimated GFR at 1 year. However, there remains one significant 
caveat to this analysis. In this study, C1q binding was strongly correlated with the 
strength of the DSA with C1q binding being recorded predominantly in a cohort of 
patients with a median fluorescence intensity of >6000. This will be a potential 
argument against the use of such an expensive assay when the outcome is simply 
related to the strength of the DSA. Even though this study shows that C1q binding risk 
stratifies renal transplant patients, it indirectly suggests that the strength of the DSA is 
as strong a clinical marker. 
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Apart from the anti-HLA DSA, non HLA antibodies have also been studied as markers 
of graft outcomes in solid organ transplantation in small cohorts. Antibodies of interest 
include, anti-angiotensin-1 receptor antibody (AT1R-Ab), anti-endothelin type A 
receptor antibody (ETAR-Ab), anti-K-1 tubulin antibody and anti-collagen-V antibody. 
Their clinical applicability needs testing in larger cohorts (Dragun, Catar et al. 2013). 
 
1.2.3.3c Cytokine producing B cells 
Studies of B lymphocytes and their roles in the normal immune response have 
traditionally focused on their potential to differentiate into Ab-producing cells, thereby 
contributing to cognate humoral immunity. However, in recent years, animal studies 
have generated a growing interest in the contribution of Ab-independent functions of B 
cells to immune responses (Lund, Garvy et al. 2005, Lund and Randall 2010). Multiple 
reports from animal models of infection and autoimmune disease have implicated 
activated B cells as effective APCs (Serreze, Fleming et al. 1998, Shlomchik, Craft et 
al. 2001, O'Neill, Shlomchik et al. 2005). B cells may also contribute to immune 
responses through the secretion of effector cytokines (Harris, Haynes et al. 2000, Lund 
and Randall 2010), and emerging animal and human studies have shown that the 
selective manipulation of B cell cytokines can impact on the expression of autoimmune 
disease models (Fillatreau, Sweenie et al. 2002, Mizoguchi, Mizoguchi et al. 2002, 
Duddy, Niino et al. 2007, Bar-Or, Fawaz et al. 2010). 
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1.2.3.3d B regulatory cells 
The existence of B cells with suppressive capacity was first reported in the mid-1970s 
by Katz and colleagues in guinea pigs (Katz, Parker et al. 1974). In this seminal piece 
of work, they demonstrated that B cells suppress DTH type reactions in a series of 
immunization experiments. They postulated that these suppressor cells in DTH form a 
separate sub-population of easily identifiable Ig-coated cells that are distinct from those 
which become antibody producing cells. This was the first report of the ability of B cells 
to regulate T cell function. Following this original observation, suppressive B cells 
generated in mice were shown to be  associated with the induction of antigen specific 
suppressor T cells (Shimamura, Hashimoto et al. 1982). Briefly, various milestones in 
the history of B regulatory cells are summarized in Table 1. As shown in this table, 
different approaches led to the identification of IL-10 as a key player in this suppressive 
function. It was in 2002, that Mizoguchi and colleagues demonstrated that IL-10 
producing B cells are enriched in the CD1dhi B cell subset and that they control 
autoimmune colitis and for the first time named these cells regulatory B cells 
(Mizoguchi, Mizoguchi et al. 2002). In humans, CD19+CD24hiCD38hi transitional B cells 
have been shown to correlate with the CD1dhi population in mice and they express IL-
10 when studied in vitro. Interestingly, these cells, which exhibit regulatory properties in 
healthy volunteers, lose their ability to regulate inflammatory Th1 immune responses in 
patients with SLE (Blair, Norena et al. 2010). In contrast, Tedder’s group from Durham, 
NC, have shown that IL-10 positive B cells are enriched within the memory sub-
population, thereby suggesting a degree of plasticity within the regulatory B populations 
(Iwata, Matsushita et al. 2011). 
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Table 1: History of Breg research
Year Mouse Human 
1974 B cells suppress DTH (Neta and Salvin 1974)  
1996 B cell–deficient mice develop chronic EAE (Wolf, Dittel et al. 1996)  
2002 IL-10-producing B cells regulate autoimmunity (Fillatreau, Sweenie et al. 2002). 
CD19
+
CD1d
hi
 B cells producing IL-10 control Th2-driven colitis (Mizoguchi, Mizoguchi 
et al. 2002) 
 
2003 CD40 and antigen-activated B cells prevent CIA (Mauri, Gray et al. 2003)  
2004 Helminth-induced IL-10-producing B cells protect mice from  anaphylaxis 
(Mangan, Fallon et al. 2004) 
 
2007 CD19
+
CD21
hi
CD23
hi
IL-10
+
 B cells protect mice from developing  CIA (Evans, 
Chavez-Rueda et al. 2007). Apoptotic cells induce regulatory B cells (Gray, Miles et 
al. 2007). B cell–mediated  suppression of EAE requires B7 costimulatory molecules 
to induce Tregs (Mann, Maresz et al. 2007). 
Impaired IL-10-production by B cells in MS patients (Duddy, Niino et al. 2007) 
B cell depletion therapy may give rise to functionally competent Breg pool upon B 
cell repopulation in SLE patients(Anolik, Barnard et al. 2007) 
2008 TLR-activated B cells suppress EAE by inhibiting Th1/Th17 responses 
(Lampropoulou, Hoehlig et al. 2008) 
Helminth-induced CD1dhi IL-10-producing B cells partially 
ameliorate MS (Correale, Farez et al. 2008). 
2009 GIFT15-induced Bregs suppress EAE (Rafei, Hsieh et al. 2009)  
2010 Bregs prevent AIA via induction of Tregs (Amu, Saunders et al. 2010) CD19
+
CD24
hi
CD38
hi
 IL-10-producing Bregs suppress Th1 differentiation (Blair, Norena 
et al. 2010). B10 cells suppress monocyte cytokine production (Iwata, Matsushita et al. 
2011). Increased CD19+CD24hiCD38hiIL-10+ B cells associated with positive outcome in 
renal transplant recipients (Newell, Asare et al. 2010). 
2011 Breg IL-10 production is regulated by STIM1 and STIM2 calcium sensors 
(Matsumoto, Fujii et al. 2011). IL-10-producing B cells induce Tregs and inhibit 
Th1/Th17 cells during acute inflammation (Carter, Vasconcellos et al. 2011). B cells 
inhibit antitumor responses via the release of TNF-a (Schioppa, Moore et al. 2011). 
TIM1 is a new inclusive marker for Bregs (Ding, Yeung et al. 2011) 
 
2013  CD19
+
CD24
hi
CD38
hi
 IL-10-producing Bregs maintain Treg while limiting Th1 and Th17 
differentiation (Flores-Borja, Bosma et al. 2013) 
51 | P a g e  
 
Phenotypic and functional markers of Bregs: Various phenotypic markers that have 
been used to define Bregs in mice and human beings and their respective functions are 
summarized in Table 2.  Since the discovery of the Bregs, IL-10 secretion has been 
considered a key trait of this population. 
IL-10: Interleukin-10 (IL-10) was first described as cytokine synthesis inhibitory factor 
(CSIF), produced by mouse Th2 cells that inhibited the activation of and cytokine 
production by Th1 cells (Fiorentino, Bond et al. 1989).  Biochemical  and X-ray 
crystallographic analyses of human IL-10 (Walter and Nagabhushan 1995) 
demonstrated that it is an acid-sensitive, non-covalent homodimer of two 
interpenetrating polypeptide chains, similar to interferon. The functions of IL-10 are 
mediated through its receptor which is composed of at least two subunits that are 
members of the interferon receptor family - a high affinity IL-10R1 and low affinity IL-
10R2. IL-10 R1 is expressed by most hemopoietic cells, although generally at 
measured levels of only a few hundred per cell. IL-10 R1 expression on T cells is down 
regulated by activation and in contrast, activation of monocytes is associated with up 
regulation, consistent with IL-10’s role as an inhibitory factor for these cells (Tan, 
Indelicato et al. 1993, Liu, Wei et al. 1994). IL-10R2 is an accessory subunit for 
signalling and contributes little to IL-10-binding affinity. Its principal function appears to 
be recruitment of a Jak kinase (Tyk2) into the signalling complex (Kotenko, Krause et 
al. 1997). The best characterized IL-10 signalling pathway is the Jak/stat (Janus 
kinase/Signal Transducer and Activator of Transcription) system. The IL-10/IL-10R 
interaction engages the Jak family tyrosine kinases Jak1 and Tyk2 (Finbloom and 
Winestock 1995), which are constitutively associated with IL-10R1 and IL-10R2 
respectively. IL-10 induces tyrosine phosphorylation and activation of the latent 
transcription factors stat3, stat1, and in non-macrophage cells, stat5. 
IL-10 potently inhibits production of IL-1, TNF and various other inflammatory cytokines 
and the CC/CX group of chemokines that are implicated in the recruitment of 
inflammatory cells by activated monocytes/macrophages (de Waal Malefyt, Abrams et 
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al. 1991, Moore, de Waal Malefyt et al. 2001). The inhibitory effects of IL-10 on IL-1 
and TNF production are crucial to its anti-inflammatory activities, because these 
cytokines often have synergistic actions on inflammatory pathways and processes, and 
amplify these responses by inducing secondary mediators such as chemokines, 
prostaglandins, and PAF. Moreover, IL-10 thereby has the ability to affect both Th1 and 
Th2 responses. Both transcriptional and posttranscriptional mechanisms have been 
implicated in the inhibitory effects of IL-10 on cytokine and chemokine production. IL-10 
down regulates the expression of MHC on APCs which significantly affects the T cell–
activating capacity of a monocytic APC. Thus, IL-10 inhibits cytokine, chemokine, 
PGE2 production, and antigen presentation (Niiro, Otsuka et al. 1995, Koppelman, 
Neefjes et al. 1997). IL-10 also has a significant effect on the maturation and function 
of B cells wherein it enhances B cell survival, proliferation, Ig production and class 
switch (Rousset, Garcia et al. 1992). Apart from the indirect effect of this cytokine of T 
cells through the APCs, IL-10 is also capable of directly inhibiting pro-inflammatory 
cytokines by T cells (de Waal Malefyt, Yssel et al. 1993). Interestingly, activation of T 
cells in the presence of IL-10 can induce non-responsiveness/ anergy, which cannot be 
reversed by IL-2 or stimulation by anti-CD3 and anti-CD28 (Groux, Bigler et al. 1996). 
In the context of transplantation, IL-10 has been extensively studied in animal models 
of both solid organ and bone marrow transplantation with variable results. The effects 
of IL-10 on allograft outcomes in these models represent a complex product of multiple 
factors including timing, kinetics, and amounts of cytokine (Moore, de Waal Malefyt et 
al. 2001). 
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Table 2: Phenotypic markers for Bregs 
  
Marker Expression 
level 
Function Limitations for their use Mouse Humans 
CD1d High Expressed on APC, presents lipid antigen Constitutively expressed on all B 
subsets 
Yes yes 
CD5 Positive Major ligand of CD72, found on thymocytes, T cells, thymic 
NKT cells and a subset of B cells 
Upregulated upon activation Yes Yes 
CD10 Variable Zinc mettaloprotease that degrades small secreted peptides. 
Marker for follicular lymphoma 
  Yes 
CD19 Positive BCR activation  Yes Yes 
CD21 Positive BCR activation  Yes Yes 
CD23 Variable Low affinity IgE receptor, negative regulator of IgE production Down regulated upon activation Yes  
CD24 High Heat stable antigen, Expressed on B cell progenitors. Provides 
T cell costimulation 
Upregulated upon activation with 
LPS 
Yes Yes 
CD27 Variable Marker for memory B cells, binds to CD70. Induces T 
costimulation and B activation 
Upregulated upon activation  Yes 
CD38 Variable Marker for activation, monitors intracellular Ca   Yes 
CD62L Negative Cell adhesion molecule involved in homing of lymphocytes to 
lymph nodes 
Downregulated upon migration Yes  
CD138 Variable Plasma cell marker, mediates B cell-matrix interactions   Yes 
CD93 Variable B cells at early stage of maturation. Intracellular adhesion and 
clear apoptotic cells 
 Yes  
IgD Variable Provides activation signal for B cells  Yes  
IgM High Role in complement activation  Yes Yes 
IL-10 Positive Anti-inflammatory cytokine  Yes Yes 
FasL variable Induces apoptosis  Yes  
TIM-1 positive   Yes ? 
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Origin and function of Bregs: The diversity in the phenotype of reported Bregs has 
led to controversy regarding their origin and development. Lampropoulou and 
colleagues have proposed that Bregs develop from the naïve follicular B cells and gain 
suppressive function through integrated signals provided through TLRs, engagement of 
CD40 and BCR (Lampropoulou, Hoehlig et al. 2008). However, in human beings and in 
animal models, naïve B cells represent a population that are the least common 
secretors of IL-10 (Evans, Chavez-Rueda et al. 2007, Blair, Chavez-Rueda et al. 2009, 
Blair, Norena et al. 2010). Moreover, mice that have follicular B cells and lack marginal 
zone B cells indeed develop spontaneous colitis. This brings us to the second model 
for the origin of the Bregs. According to this model, proposed by Mauri’s group, Bregs 
arise from a common progenitor, namely T2-marginal zone precursor B cells.  The T2-
MZP stage of B cell development is immature and such cells are programmed to 
respond quickly to environmental triggers. This model of the development which is 
summarized in Figure 19 (Mauri and Bosma 2012) shows that T2MZP B cells are 
initially activated through a TLR in response to a pathogen leading to the secretion of 
IL-10. Persistent inflammation causes activation of the T cells which provide further 
help for the activation of the Bregs which in turn leads to feedback signals to the T cells 
thereby modulating their responses.  
Although various mechanisms have been studied in the context of B regulatory activity, 
TLR and CD40 mediated pathways are considered to be crucial (Mauri and Bosma 
2012). Toll like Receptors (TLR) are pattern recognition receptors that recognise 
conserved microbial products and alert host cells of the presence of these danger 
signals. Although TLRs are critical for host defence, signalling through some TLRs can 
elicit a protective effect from inflammation. 
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Figure 19: Breg differentiation and regulatory mechanisms (Mauri and Bosma 2012) 
Two-step pathway for the development of Bregs. Step 1: a common progenitor, namely 
autoreactive T2-MZP Bregs, produces IL-10 after TLR stimulation. Step 2: Bregs are further 
activated and release an optimal amount of IL-10 in response to CD154+CD4+ T cells. This 
step also requires antigen recognition. The chief mechanism of suppression is via the release of 
IL-10, leading to the suppression of Th1, Th17 responses, and TNF-αfrom monocytes. 
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TLR9 has been studied extensively in this context. For example, TLR-9 deficient mice 
develop an exacerbated lupus-like syndrome and polymorphisms in the tlr9 gene which 
reduce the expression of TLR9  have been shown to increase predisposition to SLE in 
humans(Christensen, Shupe et al. 2006, Tao, Fujii et al. 2007). Administration of TLR9 
and TLR4 agonists has been shown to suppress the course of diabetes, EAE and 
arthritis in mice (Quintana, Rotem et al. 2000, Buenafe and Bourdette 2007, Wu, 
Sawaya et al. 2007). Interestingly, stimulation of B subsets by TLRs promotes 
differential cytokine expression. For example, stimulation of MZP T2 cells with TLR2 
and TLR4 promotes IL-10 secretion which is enhanced by the addition of CD40. In 
contrast under similar conditions follicular B cells predominantly secrete Interferon-. In 
a similar fashion, CpG, a TLR9 ligand, has also been shown to up-regulate the 
production of IL-10 in neonates (Sun, Deriaud et al. 2005, Barr, Brown et al. 2007, 
Gray, Gray et al. 2007, Lampropoulou, Hoehlig et al. 2008).  
CD40 is a membrane associated protein and a member of TNF receptor super family. 
Prolonged and strong signalling via CD40 has been shown to have an inhibitory effect 
on the secretion of antibodies by B cells (Miyashita, McIlraith et al. 1997). CD40-CD40L 
interaction has been shown to be a critical pathway for the activation of Bregs (Mauri, 
Mars et al. 2000, Fillatreau, Sweenie et al. 2002, Mauri, Gray et al. 2003, Evans, 
Chavez-Rueda et al. 2007). In animal models of transplant tolerance using anti-
CD45RB antibodies, CD40 has again been shown to be a requirement for the induction 
of tolerance thereby suggesting that tolerance induction is dependent on direct T and B 
cell contact. Interestingly this effect was independent of IL-10 (Deng, Moore et al. 
2007). 
Bregs and Transplantation: An increasing interest in Bregs has recently emerged 
within the field of clinical renal transplantation. Studies in renal transplant recipients 
who are not maintained on immunosuppression (operationally tolerant) have shown 
that there is a higher expression of genes related to B cells in their peripheral blood 
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and urine. More importantly, these patients have higher numbers of CD24hiCD38hi 
transitional B cells and cells with elevated expression of CD5 and CD1d. When 
compared to patients on maintenance immunosuppression, tolerant patients also 
demonstrated higher levels of IL-10 secretion by transitional B cells upon non-specific 
stimulation with PMA and ionomycin (Newell, Asare et al. 2010, Pallier, Hillion et al. 
2010, Sagoo, Perucha et al. 2010). Despite the potential for clinical applicability one 
major question remains - Is this signature a mere representation of the lack of 
immunosuppression? Further prospective studies are required to understand the 
clinical significance of Bregs in human transplantation. 
Finally, despite multiple candidate phenotypes presented in this section, the identity of 
an inclusive marker for Bregs remains a holy grail in the field of Bregs. To this end, 
Rothstein’s group from Pittsburgh have identified T cell Ig domain and Mucin domain-1 
(TIM-1) as an inclusive marker for murine Bregs.  TIM-1 was expressed in the majority 
of IL-10+ B cells and TIM-1 specific antibody promoted tolerance in mice which is B cell 
dependent (Ding, Yeung et al. 2011). This marker has not been validated in humans 
and a search for an inclusive marker for human B regs continues. This is especially 
important because there is an increasing interest in the role of B cells as immune 
regulators in transplantation. The development of consensus regarding the Breg 
phenotype will take us a step forward towards not only identifying a potential biomarker 
but also cell-based immunotherapy.  
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1.3 Objectives of the thesis 
The main objectives of this thesis are set out as below: 
1. To study the clinical utility of proteinuria as a marker for graft outcomes in renal 
transplant recipients (Chapter-3) 
 
2. To investigate the link between the clinical phenotype (defined by deteriorating 
creatinine and proteinuria), histological phenotype and outcomes in patients 
with troubled renal allografts (Chapter-3) 
 
3.  To define human B regulatory cells based on the secretion and synthesis of 
both IL-10 and a prototype pro-inflammatory cytokine TNF-(Chapter-4) 
 
4. To establish the link between the histological phenotype and Bregs in renal 
transplantation (Chapter-4) 
 
5. To validate the utility of the phenotype of human B regs in a random sample of 
patients from a RCT of two steroid avoidance regimes (Chapter-5)
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Chapter-2: Methods 
2.1 Identification of allografts at risk-Utility of proteinuria 
Electronic clinical records of all consecutive renal transplants performed and followed 
up at St. James’s University Hospital, Leeds between 1988 and 2008 were searched to 
identify potential subjects for this part of the analysis. For the assessment of the clinical 
utility of proteinuria, the epidemiological study is divided into two parts. 
1. The analysis of the significance of early low-grade proteinuria after 
transplantation (3 months post-transplantation) and its impact on graft 
outcomes.  
2. Longitudinal analysis of low grade proteinuria and its impact on graft outcomes. 
 
2.1.1 Measurement of proteinuria 
Proteinuria was assessed using the urine protein creatinine ratio (uPCR). All transplant 
clinics were held during the morning, so that PCR determination represents a 
midmorning sample. Urinary protein was measured by an automated turbidometric 
method (O'Malley and Penney 1984)  using the quaternary ammonium salt 
benzethonium chloride, and creatinine by an in-house modification of the Jaffe method, 
incorporating a pre-dilutional circuit (Mallinson 1985). The protein creatinine ratio was 
calculated as protein (g/l) × 1000 divided by creatinine (mmol/l), with units of g/mol. 
The factor of 1000 is required to produce values with the same units as those in 
previously reported studies, as protein concentration was originally measured in mg/dl. 
The median of urine PCR values obtained in the 3rd post-transplant month was used 
for this analysis, and patients were divided into subgroups depending on the degree of 
proteinuria. Proteinuria was assessed for every transplant recipient at every clinic visit 
using a random urine protein/creatinine ratio (uPCR). uPCR was validated for 
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quantifying proteinuria against 24hr protein excretion at our centre (Dyson, Will et al. 
1992) and had been shown to correlate very well with 24hr urine protein excretion. For 
example a uPCR value of 1000 equates to 1g proteinuria/24hrs. Significant proteinuria 
was defined as a urinary PCR value above 150 (0.15 g/24 hrs equivalent). 
 
2.1.2 Immunosuppression 
All patients received 1g of intravenous methylprednisolone at induction followed by 
maintenance immunosuppression which consisted of ciclosporin, azathioprine and 
prednisolone between 1988 and 1998. Patients who were diabetic or who had a two 
DR mismatch received two does of intravenous basiliximab 20 mg at day 0 and day 4 
between 1998 and 2004. Since 2004, all patients received Basiliximab along with 
methylprednisolone at induction and patients were maintained on a steroid free 
maintenance immunosuppression comprising tacrolimus and mycophenolate. 
Maintenance prednisolone was used in moderate to high risk renal transplant recipients 
as described above. 
 
2.1.3 Longitudinal analysis of low grade proteinuria- Impact on graft outcomes 
Proteinuria was calculated for every patient based on their uPCR for years 1, 2 and 3 
after transplantation. Any patient with a proteinuria estimate of more than 1g/day was 
excluded from this analysis as the main goal was to assess the dynamics of low-grade 
proteinuria. Based on the annual mean uPCR estimates, patients were divided into two 
groups - Proteinuria absent (A) with a mean uPCR of <150 and low-grade proteinuria 
(P) with a mean uPCR between 150 and 990. Between years 1 to 2, patients were 
divided into 4 groups namely; A/A, P/A, A/P, P/P based on the evolution of low-grade 
proteinuria. Patients were grouped in a similar fashion between years 2 and 3 as well. 
Like proteinuria, mean systolic blood pressure was recorded for years 1 to 3. In 
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accordance to the WHO standard and the previously published Collaborative transplant 
study a cut off value of 140mm of Hg was used to define systolic hypertension(Opelz, 
Dohler et al. 2005). The primary outcome measure was graft loss up to 10 years which 
was determined by return to dialysis or death. Change in renal function was estimated 
by eGFR calculations for the first 5 years of follow-up. Patients who were lost to follow-
up and those who were transferred out to a different centre were excluded from the 
analysis. 
 
2.1.4 Analysis of the significance of early low-grade proteinuria 
For this part of the study all consecutive patients transplanted between 1988 and 2003 
were included. Patients and grafts that survived less than 3 months were excluded 
from the analysis. Variables affecting long-term graft and patient outcomes after 
transplantation were identified for inclusion in multivariate analysis. These included 
recipient age, sex ethnicity, cause of end-stage renal disease (glomerular disease 
including diabetic nephropathy, infection/obstruction, and others), donor age, sex and 
cause of death (cerebrovascular accident, trauma, others), type of donation (cadaveric 
and living), graft number, total human leukocyte antigen and HLA-DR mismatches, 
systolic and diastolic blood pressures at 3 months, delayed graft function, biopsy-
proven acute rejection, cytomegalovirus disease, diabetes mellitus at the time of 
transplantation, median serum creatinine and proteinuria measured during the 3rd 
month after transplantation, and the era of transplantation (1988 –1992, 1993–1997, 
and 1998–2003).  
The median of all the urine PCR values obtained in the 3rd post-transplant month was 
used for this analysis, and patients were divided into four subgroups depending on the 
degree of proteinuria. Significant proteinuria was defined as a urinary PCR value above 
150 (0.15 g/24 hrs equivalent). Patients with PCR less than 150 constituted group 1, 
whereas group 2 had a PCR between 150 and 500 (0.15 g– 0.5 g/24 hrs equivalent), 
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group 3 between 500 and 1000 (0.5 g–1.0 g/24 hrs equivalent), and group 4 had a 
PCR more than 1000 (1.0 g/24 hrs equivalent). Patient demographics were compared 
across the different proteinuria groups. The primary outcome measures were death-
censored graft loss, death with a functioning graft, and vascular events during the 
lifetime of the graft. A composite vascular endpoint consisted of fatal and nonfatal 
myocardial infarction, unstable angina, congestive cardiac failure, cardiac arrhythmia, 
cerebrovascular accident (thrombotic, embolic, and haemorrhagic), transient ischemic 
attack, limb revascularization, and limb amputation during the lifetime of the graft. 
Estimated glomerular filtration rate (eGFR) achieved at 5 years after transplantation 
was a secondary outcome measure. GFR was estimated using the four-variable 
abbreviated Modification of Diet in Renal Disease formula. 
 
2.1.5 Histological assessment of troubled allografts  
For this study, all renal transplant recipients followed up at the renal transplant unit at 
the St. James’s University Hospital were assessed for proteinuria by uPCR along with 
the review of their serum creatinine. Patients who presented with proteinuria of more 
than 500mg (uPCR>500) on three consecutive occasions were offered a renal 
transplant biopsy, irrespective of their serum creatinine. Additionally patients who 
presented with a gradual decline of renal function determined by deterioration of their 
serum creatinine over a period of 2 years were also included. Deteriorating grafts or 
‘troubled grafts were defined based on the calculations made in the creeping creatinine 
study (Dudley, Pohanka et al. 2005). An example of a patient with creeping creatinine 
compared to the one with stable creatinine is shown below (Figure 20). 
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Figure 20: 1/creatinine plots for representative patients with creeping creatinine or stable 
creatinine 
 
Based on the development of persistent proteinuria and creeping creatinine, patients 
were divided into three groups (creeping creatinine (CC), proteinuria only (IP), creeping 
creatinine+proteinuria (PC). The biopsies of all the three groups of patients were 
examined by an independent blinded histopathologist. A serum sample was collected 
from all the patients for the determination of donor specific antibody within 6 weeks of 
the biopsy.  
 
2.1.5.1 Serum analysis for HLA-specific antibodies: 
For serum separation, venous blood samples were collected in 6ml plain vacutainer 
tubes with no additive. The samples were left to stand at room temperature for about 
30 minutes and centrifuged at 2000 rpm for 10 minutes at room temperature. The 
serum was then aliquoted and stored at -20˚ C. 
Serum samples were thawed at room temperature away from direct sunlight. Lab 
screen wash buffer was diluted (×10) in distilled water. A 96 well PVDF filter plate was 
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used for the assay and the rows of wells not to be used were covered with a plate 
sealer. The wells were pre-wet by adding 300l of diluted wash buffer after which the 
plate was placed on a plate shaker at speed-3 for 10 minutes. The wash buffer was 
drained on a vacuum manifold. 10l of serum was added to the appropriate well and 
this was mixed with 2.5l of labscreen mixed antigen assay beads. The plate was 
incubated at room temperature away from light on the plate shaker for 30 minutes. 
Following the incubation, nonspecific binding was removed by three washes adding 
200l of the diluted wash buffer followed by aspiration on the vacuum manifold. After 
the final wash, 50l of diluted (1:100) PE conjugated anti-human IgG was added to 
each respective well. The plate was again incubated for 30 min as above. After 
incubation, three further wash steps were carried out and after the final wash step, 80l  
of PBS was added to each well and the plate was analysed on the Luminex platform.  
Serum reactivity was calculated by the fluorescent signal for each HLA coated bead 
after correction for non-specific binding to the negative control bead. All data was 
normalized to the lab screen negative control serum. The strength of the HLA reactivity 
was assigned by the normalized background ratio which was calculated by using the 
formula. 
Normalized background ratio=(S#N /SNC bead) / (BG#N/BGNC bead) 
S#N= Sample specific fluorescent value for bead #N 
SNC bead= Sample specific fluorescent value for negative control bead 
BG#N= Background negative control serum fluorescent value for bead #N 
BGNC bead= Background negative control serum fluorescent value for negative control 
bead. (Analysis of the data from this assay was performed by using the fusion 
software.) 
An NBG ratio>1.5 was considered positive for HLA antibody screen. 
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Samples which were positive in the screening assay were reanalysed using the single 
antigen Labscreen assay in a similar fashion to the screening assay apart from addition 
of Class I or Class II HLA beads in the place of the mixed screen beads to the 
respective serum samples. Allele specificity for HLA reactivity was assessed by the 
beads which were positive in the single antigen assay. A normalized mean fluorescent 
value>1000 was considered positive. 
Normalized mean fluorescent value= S#N- BG#N 
 
2.1.5.2 Histopathology 
All biopsies are examined and scored by PP as per the 2011 Banff classification 
(Mengel, Sis et al. 2012). Microcirculatory damage which characterizes the histological 
phenotype of chronic antibody mediated rejection (CAMR) is defined by the presence 
of glomerulitis, peritubular capillaritis and transplant glomerulopathy with or without 
linear diffuse deposition of C4d in the peritubular capillaries. Glomerulitis (g score 0-3) 
lesions describe the percentage of glomeruli with occlusion of endocapillary space by 
mononuclear cells and endothelial swelling. Peritubular capillaritis score (ptc score 0-3) 
examines the number of infiltrating monocytes or neutrophils in the most affected 
capillary and is considered positive with a score of 1 when more than 10% of the 
capillaries are affected. Transplant glomerulopathy (cg score 0-3) is defined by the 
presence of double contours on light microscopy; with no or minimal deposition of 
immune complexes on immunofluorescence in the absence of hepatitis C infection or 
thrombotic microangiopathy. Electron microscopy was only performed in a selected 
number of specimens, where the lesions were equivocal on light microscopy.  
Microcirculatory inflammation defined by g+ptc scores (range 0-6), is also analysed to 
compute graft survival (de Kort, Willicombe et al. 2013).  
Broad histological classes included microcirculatory damage (MCD), glomerulonephritis 
(GN), T cell mediated rejection (including borderline for TCMR), interstitial fibrosis and 
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tubular atrophy (IFTA, scarring in the absence of obvious aetiology) and others (BK 
virus nephropathy, ascending infection, hypertensive arteriosclerosis and amyloidosis).  
 
2.1.6 Statistical Analysis 
Statistical analysis was performed by SPSS for Windows version 20 (SPSS, Chicago, 
IL) and Graph pad version-6. All continuous variables were expressed as mean ± 
standard deviation unless stated otherwise. All categorical variables were expressed as 
the percentage of the population. All continuous variables were compared across the 
groups using either univariate analysis of variance (ANOVA) or student t-test. All 
categorical variables were compared by the chi-square test. Graft failure was defined 
as return to dialysis. The Kaplan–Meier method was used to estimate graft survival and 
patient groups were compared using the Log Rank test. Univariate Cox regression 
analysis was used to study the impact of variables on the primary outcomes. For every 
primary outcome, proteinuria was analysed using a multivariate Cox-proportional 
hazards model, adjusting for the effect of other factors that were significant (P<0.05) in 
the univariate analysis to establish its independent effect. Model fit was analysed by 
omnibus tests of model coefficients. Results were indicated as the hazard ratio (HR) 
with 95% confidence interval (95% CI).  P value of less than 0.05 was considered 
significant. 
 
2.2 Human B Regulatory Cells & Troubled Renal Allografts 
2.2.1 Study participants 
Venous blood samples for PBMCs and serum samples were collected from healthy 
volunteers (n=18) and renal transplant recipients (n=88). Written informed consent was 
obtained from all the participants according to the Declaration of Helsinki. Renal 
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transplant recipients were grouped into those with stable graft function (S, n=40) or 
graft dysfunction (GD) based on their serum creatinine and proteinuria assessment as 
described in section 2.1.5. All patients with graft dysfunction had an indication 
transplant renal biopsy and based on the histology patients were divided in those with a 
histological phenotype of chronic antibody mediated rejection (GD-R, n=26) and with 
no evidence of chronic immunological damage (GD-NI, n=22). Chronic immunological 
microcirculatory injury was defined as the presence of glomerulitis, peritubular 
capillaritis and transplant glomerulopathy with or without peritubular C4d deposition in 
the peritubular capillaries in the presence of interstitial fibrosis and tubular atrophy. All 
the biopsies were scored according to the Banff-2011 criteria. All transplant recipients 
irrespective of their graft function were tested for the presence of HLA specific 
antibodies as described in section 2.1.5.1. 
 
2.2.2 Separation of PBMC 
Venous blood was collected in two 10ml K2E (18mg of Potassium EDTA) vacutainer 
tubes. Each blood sample was diluted with an equal volume of RPMI1640 and was 
layered over ficoll in a 50ml conical bottom tube and centrifuged without brake at 2000 
rpm for 20 minutes at room temperature. The opaque layer of mononuclear cells was 
aspirated from the plasma/ficoll interface and washed twice using 1%PBS-BSA.  The 
number of cells was counted on a Neubauer’s cell counting chamber and for the final 
wash the re-suspended cell pellet was centrifuged with brake at 1800 rpm for 10min. 
The final cell pellet was suspended in 1%PBS-BSA to a concentration of 107 cells/ml. 
The cells were stored on ice between the washing steps. 
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2.2.3 Determination of absolute numbers of lymphocytes 
Two trucount tubes with a specific number of absolute count beads were labelled A and 
B. 20l of Multitest CD3/CD8/CD45/CD4 reagent (BD Pharmingen) was added to tube 
A. Similarly 20l of the CD3/CD16/CD56/CD45/CD19 reagent (BD Pharmingen) was 
added to tube B. 50l of undiluted blood was added to each tube. The tubes were 
capped, vortexed gently for 30 seconds and incubated for 15 min in the dark at room 
temperature.  450l of the red cell lysing solution was added to each tube followed by 
incubation for 15 min. Samples were analysed on the flow cytometer. Various 
lymphocyte populations were identified by their staining characteristics. Absolute 
numbers (cells/l) of lymphocyte subsets were determined using BD cell quest 
software by comparing the cellular events to the bead events.  
 
2.2.4 Antibodies, flow cytometry, lymphocyte isolation and cell sorting 
All experiments were performed on fresh cells on the same day of blood sampling. The 
monoclonal antibodies used for cell staining are detailed in Table-3. Once the absolute 
number of lymphocytes was established by the trucount method as described in the 
previous section, further analysis of B subsets was performed on whole blood. PBMCs 
were stained in 200 µL of whole blood at room temperature for 20 minutes using the 
optimal concentration of appropriate antibodies. Red cells were lysed using BD-
FACSlyse. Cells were then washed with ice cold 1% FCS-PBS and fixed in 
formaldehyde-PBS before the analysis of their immunofluorescence either by BD-
FACS Calibur or BD-LSR-Fortessa Flow cytometers.  Flow cytometric data was 
analysed by the Kaluza software after accounting for spectral compensation. 
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Table 3: Monoclonal antibodies for cell staining and their manufacturers 
Monoclonal antibody Clone Manufacturer 
Anti-human CD19-APC H7 SJ25C1 BD Pharmingen 
Anti-human CD20-PerCP-Cy5.5 2H7 Ebioscience 
Anti-human CD24-PE ML5 BD Pharmingen 
Anti-human CD24-BV421 M1/69 Biolegend 
Anti-human CD38-APC HIT2 Ebioscience 
Anti-human CD38-PE Cy7 HB7 Biolegend 
Anti-human CD38-PerCP-Cy5.5 HIT2 BD Pharmingen 
Anti-human CD27-PE MT271 BD Pharmingen 
Anti-human CD27 Alexa 700 0323 Biolegend 
Anti-human IgD-PE IA6-2 BD Pharmingen 
Anti-human CD5-FITC UCHT2 BD Pharmingen 
Anti-human CD1d-PE UCHT2 BD Pharmingen 
Anti-human IgM-FITC G20-127 BD Pharmingen 
Anti-human CD23-APC M-L233 BD Pharmingen 
Anti-human CD10-PE H1Ta BD Pharmingen 
Anti-human CD86-Biotin IT2.2 BD Pharmingen 
Anti-human CD40-FITC 5C3 BD Pharmingen 
Anti-human CD4-APC OKT4 Ebioscience 
Anti-human IL-10-PE JES3-907 BD Pharmingen 
Anti-human TNF-PE MAb11 BD Pharmingen 
Anti-human TNF-Alexa488 MAb11 BD Pharmingen 
Anti-human TNFa-PerCP-Cy5.5 MAb11 Ebioscience 
Anti-human IFNg-Alexa488 B27 BD Pharmingen 
Anti-human IL4-PE 8D4-8 BD Pharmingen 
Anti-human IL17-PE N49-653 BD Pharmingen 
Anti-human TIM1-Alexa488 219211 R & D systems 
Purified anti-human CD3 HIT3a BD Pharmingen 
Anti-human CD25-PE M-A251 BD Pharmingen 
Anti-human CD4-APC OKT4 Ebioscience 
Neutralizing  anti-humanTNFR1 16805 R & D systems 
Neutralizing anti-human TNFR2 22210 R & D systems 
Neutralizing anti-human IL-10 JES3/19F1 R & D systems 
 
 
2.2.4.1 B and T cell enrichment by Magnetic beads and Cell sorting 
Human PBMCs isolated by ficoll-paque density gradient centrifugation as described 
earlier were used for the enrichment of CD19+ B cells or CD4+CD25- T conv cells. 107 
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PBMC were suspended in 2mls of ice cold RPMI1640 supplemented with 10% FBS 
and 1% Penicillin-Streptomycin-L-glutamine (complete RPMI) and centrifuged at 300×g 
for 10 min. The cell pellet was used for the isolation of B or T cells. 
 B lymphocytes were isolated manually from PBMCs using CD-19 coated magnetic 
beads by positive selection (Miltenyi Biotec) as per manufacturer’s instructions. Miltenyi 
MS-columns were used for positive selection, while LD columns for negative 
selection/enrichment.  Briefly the cell pellet was resuspended in 80l of complete RPMI 
along with 20l of CD19+ beads/107 cells and then incubated at 4° for 15 min. After two 
more washes at 300g, the cell suspension in 500l of complete RPMI was applied to a 
magnetic column placed in the magnetic field. The cells were washed twice through the 
column with 500l of complete RPMI. Finally, the column was removed from the 
magnetic field and the labelled cells were flushed in a sterile collecting tube. 
Alternatively untouched B cells were enriched using the B cell isolation kit by negative 
selection (Miltenyi) according to the manufacturer’s instructions. In this method the cell 
pellet was resuspended in 40l of complete RPMI per 107 cells and then 10l of biotin 
antibody cocktail added per 107 cells. After 5 min of incubation at 4° a further 30l of 
RPMI and 20l anti-biotin micro beads were added for a further incubation at 4° of 10 
min. After incubation, the cells were adjusted to 1ml volume with complete RPMI and 
the suspension applied to the magnetic as described before. In this method the 
untouched B cells were collected by washing through the magnetic column in the 
magnetic field. 
 Untouched CD4+ CD25lo and CD4+ CD25hi T Cells were also enriched using MACS 
magnetic bead kits (Miltenyi Biotec).  Here, the cell pellet was suspended in 90l of 
complete RPMI per 107 cells along with 10l of CD4+ T cell biotin antibody cocktail and 
incubated for 5 min at 4°. After a similar step, with anti-biotin micro beads and 
incubation (as described for the B cells), the cells were made up to a volume of 500l 
and applied to a magnetic column in the magnetic field. Untouched CD4+ cells were 
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collected by washing through the column twice with 500l of ice cold complete RPMI. 
Now the CD4 cells were centrifuged at 300g for 10 min.  The cell pellet was again 
resuspended in 90l of RPMI and 10l of CD25 micro beads. After 15 min incubation at 
4° in darkness, the cells were centrifuged once at 300g for 10 min and the cell pellet 
finally resuspended in 500l of complete RPMI. The cell suspension was applied to a 
magnetic column. CD25- CD4+ T cells were washed through the column in the 
magnetic field. CD25+CD4+ T cells were flushed in a separate sterile tube once the 
column was removed from the magnetic field. 
CD19+ cells and CD4 cells were centrifuged at 300g for 10 min and the cell pellet 
resuspended in complete RPMI at appropriate concentrations for cell culture. Pre and 
post enrichment concentrations and appearances of both CD4 subsets and B cells are 
shown in Figure 21. 
 
Figure 21: Enrichment of CD19
+ 
B and CD4
+
 T subsets by magnetic beads 
CD20 PerCP Cy5.5, CD4-APC & CD25-PE monoclonal antibodies are used for this analysis.  
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2.2.5 Cell culture- cytokine detection 
Magnetic bead enriched B lymphocytes were suspended in complete RPMI at a 
concentration of 2X106 cells/ml and stimulated with CpG-ODN2006 (10µg/ml) 
(Invivogen) and CD40L (1µg/ml) (Sigma Aldrich). The cells were cultured in 24 well flat 
bottom cell culture plates (Nunc, Germany) at 37°C and 5% CO2 for 48 hours. Phorbol 
12 myristate 13 acetate (PMA 50ng/ml) (Sigma Aldrich), Ionomycin (1µg/ml) (Sigma 
Aldrich) and Brefeldin A (1µl/ml) (Sigma Aldrich) were added for the last 5 hours of the 
cell culture. Cultured cells were washed twice in ice cold 1% PBS-BSA at 300×g. The 
cells were incubated in 10% human normal serum at 4°C for 15 min and washed once 
in ice cold 1% PBS-BSA before proceeding to surface staining. Appropriate amounts of 
monoclonal CD20-PerCP-Cy5.5, CD24-FITC, CD38-APC, TIM-1-ALexa488 and CD27-
APC antibodies were added to the resuspended cells according to manufacturer’s 
instructions and incubated in darkness at 4°C for another 15 min.  Stained cells were 
fixed and permeabilized using the Cytofix/Cytoperm kit (BD Pharmingen) as per 
manufacturer’s instructions.  Cells were then stained for intracellular cytokines with IL-
10-PE, IFN--PE, IL17-PE, TNF--PerCP-Cy5.5 and TNF--PE for 30min in darkness 
at 4°C. Samples were acquired on BD-FACS Calibur flow cytometer and the data 
analysed by Kaluza software (Beckman Coulter). Alternatively both IL-10 and TNF-
were analysed from the cell culture supernatants of the FACS sorted B lymphocyte 
subsets by bead based multiplex-ELISA (Invitrogen) as described below. 
 
2.2.6 Bead based ELISA 
Untouched B lymphocytes were counted and suspended at 50×106 cells in 250ml of 
1%PBS-BSA. Cells were then stained by CD20-PerCP-Cy5.5, CD24-PE, CD38-APC 
and CD27-FITC for 15 min in darkness at 4°C. The stained cells were sorted by Moflo 
(Beckman Coulter). Transitional B cells were selected as CD20+CD24hiCD38hiCD27- 
(90% purity), memory B cells were selected as CD20+CD24hiCD27+CD38- (>95% 
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purity) and naïve B cells as CD20+CD24+CD38+CD27- (>95% purity). Flow sorted B 
cell subsets were cultured as described in section 2.2.6, but in 96 well round bottom 
tissue culture plates (Nunc) for 48hrs. At the end of 48hrs, the culture plates were 
centrifuged at 500×g for 2 min and the supernatants were collected and stored for 
ELISA. 
Bead based ELISA was performed according to the manufacturer’s instructions 
(Invitrogen). Briefly, 25l of vortexed microbeads were added to the respective wells of 
the ELISA plate provided with the kit. The cells were washed twice with 200l of the 
wash solution with 30sec in between the washes. Then 50l of incubation buffer was 
added to the respective wells. 100l of the diluent for the blank well or the appropriate 
standards were added to the designated wells. 50l of the assay diluent along with 
50l of the samples were added to the wells designated for the patient samples. The 
plate was then covered in tin foil and incubated at room temperature for 2hrs on an 
orbital plate shaker (500rpm). The plate was washed twice with ice cold wash solution 
on a vacuum manifold. 100l of biotinylated antibody was added to the respective wells 
and the plate incubated on the plate shaker again for 1hr. Again, the plate was washed 
twice and 100l of streptavidin-RPE solution was added to each well and the plate 
incubated for 30min on the plate shaker. The plate was finally washed thrice and then 
the beads were resuspended in 150l of the wash buffer. The beads from the 
respective wells were acquired on the Luminex platform and the concentration of the 
cytokines analysed from the standard curve constructed as shown in Figure 22. 
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 Figure 22: Bead based ELISA, standard curves for IL-10 and TNF- 
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2.2.7 B functional assays 
A sterile round bottom cell culture plate was coated overnight at 4°C with 0.5mg/ml of 
monoclonal anti-human CD3 (HIT3A-BD Pharmingen). On the day of the experiment, 
the plate was washed twice with RPMI and then 1×105 magnetic bead enriched 
CD4+CD25lo T Cells in 100ml of complete RPMI were added to the respective wells. 
Either 100ml of complete RPMI or magnetic bead enriched CD4+CD25+ T cells or the 
flow sorted B cell subsets (transitional, memory and naïve B cells) were added (1:1) to 
the representative wells. The culture plate was incubated for 72hrs at 37°C in 5% CO2. 
For the last 6hrs of cell culture 1ml/ml of Brefeldin A along with PMA and ionomycin 
were added. Dead cells were examined by Trypan Blue stain and typically there was 
>85% cell viability as all the experiments were conducted on fresh blood samples 
within a few hours of phlebotomy. The cells were then surface stained with CD4-APC 
and CD20-PerCp-Cy5.5 followed by fixation and permeabilization (BD Perm Fix Kit). 
Cells were further stained for the detection of intracellular cytokines using IFN--
AlexaFluor488, IL-10-PE, TNF--AlexaFluor488 and IL-4-PE. The cells were acquired 
on the BD-FACSCalibur flow cytometer and data analysed by Kaluza software. For the 
purpose of the analysis of CD4 related cytokines, both CD4 and CD19+ B subsets 
were distinguished after cell culture utilising the gating strategy shown in Figure 23. 
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 Figure 23: B functional assays-T and B gating strategy 
Lymphocytes were identified by forward and side scatter properties. CD4 and CD19 cells were gated as shown above 
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2.2.8 Neutralization experiments 
To understand the functional significance of either IL-10 or TNF-, the co-cultures of 
CD4+CD25lo T conv cells and the B subsets were repeated in 3 healthy volunteers 
wherein the T and B subsets were cultured alone as discussed in section 2.2.7 or with 
an addition of 10g/ml of neutralizing IL-10 antibody or TNFR1/R2 antibodies or 
appropriate isotype (IgG2B). Cells were cultured for a total of 72hrs as mentioned 
previously with the addition of PIB for the last 6hrs of cell culture and the cells were 
washed stained and acquired on the BD FACSCalibur flow cytometer for the analysis 
of TNF-+ or IFN- CD4+T cells. 
  
2.2.9 Statistical analysis 
Statistical analysis was performed by SPSS version 17 and Graph pad Prism version 5 
for Windows.  Categorical variables were compared using Fisher’s exact test and 
continuous variables using Mann-Whitney U test for data with skewed distribution and 
independent sample student t-test for normally distributed data. A p-value of <0.05 was 
considered significant.  One way ANOVA with either Tukey or Dunnet post hoc 
correction was used for multiple comparisons. Graft outcomes and survival were 
analysed by the Kaplan Meier method and groups compared by the Log Rank test. A P 
value of <0.05 was considered significant. 
 
2.3 B lymphocyte phenotype & alemtuzumab in renal 
transplantation 
The evolution of B cell phenotype was studied in the context of a randomized controlled 
trial and then, in a small subgroup of 14 patients, the maturation of B cells after 
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peripheral depletion was studied longitudinally at 3, 6 and 12 months after 
transplantation. 
 
2.3.1 Trial design 
Patient blood samples were collected as a part of a single-centre, prospective, open-
label, randomized controlled trial (EudraCT No. 2006-000830-11, International 
Standard Randomised Controlled Trial Number ISRCTN94424606)  
The study was conducted in accordance with the principles of the International 
Conference on Harmonisation Harmonized Tripartite Guidelines for Good Clinical 
Practice and the Declaration of Helsinki. Written informed consent was obtained from 
all patients after receipt of approval from the Research Ethics Committee. All adult 
recipients of renal transplants were considered eligible: donation after brain death 
(DBDs), donation after circulatory death (DCDs), and living donors. Patients considered 
to be at high immunologic risk were excluded (high immunologic risk was defined as 
two HLA-DR mismatch, preoperative positive donor-specific anti-HLA antibodies, or 
previous immunologically mediated graft loss after less than 6 months). Patients with 
pre-existing leukopenia or thrombocytopenia were excluded, and female patients were 
required to have a negative pregnancy test and were advised on appropriate 
contraceptive use. Random numbers were generated using http://www.randomizer.org/ 
in 12 blocks of 10, each block of 10 assigned alternately to the alemtuzumab or 
basiliximab arms. An independent third-party (who had nothing to do with the study) 
then used the random numbers to generate numbered envelopes, into which the 
appropriate treatment arm for that number was sealed. After randomization into the 
study, these envelopes were opened in the predetermined sequential order for each 
patient, thus assigning them to the alemtuzumab or basiliximab arms as per the 
contents of the sealed envelope. Once the envelope was opened, the investigators and 
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patient knew which treatment they were to receive, because this was an open-label 
trial. 
 
2.3.2 Immunosuppression 
Patients were randomized on a 1:1 basis to receive either (a) basiliximab induction (20 
mg intravenously iv on days 0 and 4) and a single dose of 1 g iv methylprednisolone 
intraoperatively followed by MMF at a starting dose of 750 mg orally, twice daily, with 
tacrolimus given orally to achieve trough levels of 9 to 14 ng/mL in months 0 to 3 and of 
4 to 9 ng/mL thereafter or (b) alemtuzumab induction (30 mg I.V intraoperatively) and a 
single dose of 1 g I.V methylprednisolone, followed by tacrolimus orally to the same 
target levels as the basiliximab group, but no MMF. Steroids were subsequently 
avoided entirely unless rejection occurred or another clinical circumstance mandated 
their use. Alterations in mycophenolate dose were left to the discretion of treating 
clinicians, as was any decision to switch to mycophenolate sodium.  
 
2.3.3 Anti-viral and antibiotic prophylaxis  
In the basiliximab group, high-risk patients (D+R-) received 100 days of CMV 
prophylaxis with valganciclovir (dose adjusted according to renal function). In the 
alemtuzumab group, all patients, except low-risk patients (D-R-), received 100 days of 
prophylaxis. Cotrimoxazole was given for 6 months and topical oral antifungal therapy 
was administered for 3 months to all patients.  
 
2.3.4 Clinical end points 
The primary endpoint of the trial was non-inferiority of isotopic GFR at 1 year measured 
by technetium-99m diethylenetriamine penta-acetic acid clearance using the two-blood 
sample method. The recruitment target was set at 120 patients based on a non-
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inferiority limit of 10 mL/min of isotopic GFR, with power level of 0.80 and > of 0.05, 
assuming a dropout rate of 15%. It was predetermined that patients who returned to 
dialysis would be included in the calculations using an assumed GFR of 5 mL/min. 
Secondary endpoints included patient and graft survival, rates of DGF, severity and 
rates of rejection, time to rejection, 24-hr blood pressures at 6 and 12 months, rates of 
cardiovascular, malignant and infective complications, percentage of patients steroid-
free at 12 months, and rates of NODAT. 
 
2.3.5 Patient Samples 
Venous blood samples for serum and PBMCs were collected from consented renal 
transplant recipients participating in the trial. Of the 116 patients randomized for the 
trial, samples were obtained from 96 patients at a mean of 25 +/-2 months after 
transplantation. The outline of the RCT along with the primary outcome measures and 
sampling for DSA and B cell phenotype is summarized in Figure 24. Serum samples 
were analysed for the presence of DSA as described in section 2.1.5.1. PBMCs were 
analysed for B subsets by cell surface staining using CD20-PerCP, CD24-FITC, CD38-
APC and CD27-PE as described previously. 
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Figure 24: SALAMI study-trial design-sample collection 
 
2.3.6 Statistical analysis 
Statistical analysis was performed in Graph Pad Prism version 5.04 and SPSS version 
17 for Windows. Continuous variables were analysed using t tests if normally 
distributed. Mann Whitney tests were used if not normally distributed and were also 
used for nonparametric data. Categorical variables were analysed using chi-square 
testing, unless expected frequencies were less than five in any group when Fisher’s 
exact test was used. Results were analysed on a modified intention to treat basis 
(modified refers to the exclusion of four patients after randomization). 
 
2.3.7 Longitudinal analysis of B subsets 
A random sample of  14 patients, all of whom received alemtuzumab at induction along 
with 1g of intravenous methylprednisolone and who were maintained on tacrolimus 
monotherapy, were consented for this part of the analysis. Venous blood samples were 
collected at 3, 6 and 12 months after transplantation and B  subsets analysed by 
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CD20-PerCP-Cy5.5, CD24-PE, CD38-APC, CD27-FITC and IgD-PE at these time 
points by cell staining as described previously. Given the small patient set, no clinical 
correlates were included in the analysis.   
 
2.4 Ethical approval 
Both clinical and laboratory investigations were performed after approval from the 
regional ethics committees.  York Regional Ethics Committee (Ref No: 8/H1311/41) 
granted the approval for the investigations relating to the identification of the allograft at 
risk and defining Bregs. The Leeds East Regional Ethics Committee (Ref No: 
06/Q1206/64) granted the approval for the RCT. 
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Chapter-3: Identification of allografts 
at risk: utility of proteinuria 
3.1 Introduction 
Renal transplantation offers a significant survival benefit over other forms of treatment 
for end stage renal disease and thereby represents the best form of renal replacement 
therapy available at present (Wolfe, Ashby et al. 1999). However renal transplants do 
not last indefinitely and the late failure of allografts remains a significant problem 
despite improvements in early outcomes (Lamb, Lodhi et al. 2011).. Renal transplant 
recipients have a high early and late mortality and this is a major cause of allograft loss 
(Gill, Rose et al. 2007, Cosio, Hickson et al. 2008).   Although the survival of the renal 
transplant patients is superior to patients with ESRD on dialysis there is still  significant 
room for improvement when compared to matched controls in the general population 
(Foley, Parfrey et al. 1998, Wolfe, Ashby et al. 1999). Unfortunately medical 
management of some of the important causes of allograft loss including, death from 
cardiovascular disease, recurrent renal disease in the allograft and chronic antibody 
mediated rejection (CAMR) has not yielded improved outcomes (Briganti, Russ et al. 
2002, Matas 2006, Cosio, Hickson et al. 2008, Sellares, de Freitas et al. 2012).  
Moreover, the debate that besieges the set diagnostic criteria for CAMR is still sizeable 
(Einecke, Sis et al. 2009, Mengel, Reeve et al. 2009, Reeve, Einecke et al. 2009, 
Mengel, Sis et al. 2012, Sis, Jhangri et al. 2012).   
Several authors have stressed the importance of various clinical variables that can be 
utilized to identify ‘grafts at risk’ at an earlier stage after transplantation. The main 
argument in favour of such a strategy is the principle of ‘early risk modification’ for the 
‘at risk groups’. The commonest variable that gets measured routinely for every renal 
transplant recipient is serum creatinine (Hariharan, McBride et al. 2002). But once 
elevated it signifies advanced allograft damage and often insidious irreversible nephron 
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loss, thereby limiting its clinical utility (Chapman, O'Connell et al. 2005). Studies have 
shown that proteinuria, even at low levels and as early as three months after 
transplantation predicts adverse allograft survival (First, Vaidya et al. 1984, Fernandez-
Fresnedo, Plaza et al. 2004, Halimi, Laouad et al. 2005, Amer, Fidler et al. 2007).  
In a detailed histological analysis of patients with post-transplant proteinuria of 
>2g/day, First et al. have shown that the cause for proteinuria in these patients is quite 
heterogeneous with diagnoses varying from transplant glomerulopathy to renal vein 
thrombosis, but the commonest cause even at this level of relatively high-grade 
proteinuria was transplant glomerulopathy (First, Vaidya et al. 1984). The 
heterogeneous nature of aetiology for post-transplant proteinuria has been confirmed 
by Amer et al. by examining the histology of proteinuria at the first post-transplant year 
(Amer, Fidler et al. 2007). Various risk factors such as hypertension, reduced renal 
function, and increased fasting glucose are known to be associated with proteinuria 
(Fernandez-Fresnedo, Plaza et al. 2004). Moreover hypertension is a modifiable 
determinant of renal function and improvement of renal function and mortality with 
hypertensive agents is recognised (Walker, Neaton et al. 1992, Peterson, Adler et al. 
1995). A report from the Collaborative transplant study demonstrated an association 
between better patient and graft outcomes and improvement in blood pressure control 
(Opelz, Dohler et al. 2005).  
Based on current literature it is tempting to speculate that assessment of proteinuria 
after transplantation provides an important opportunity to intervene in patients at risk of 
premature allograft loss. Moreover it is well established that proteinuria is a marker of 
kidney damage and adverse cardiovascular outcomes in general population (Culleton, 
Larson et al. 2000, Jafar, Stark et al. 2001, Chronic Kidney Disease Prognosis, 
Matsushita et al. 2010, Hemmelgarn, Manns et al. 2010). Furthermore albuminuria has 
been shown to be associated with increased mortality independent of glomerular 
filtration rate (Chronic Kidney Disease Prognosis, Matsushita et al. 2010). There is 
some evidence that proteinuria is a modifiable risk factor and that reduction of 
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proteinuria may be a worthwhile therapeutic intervention in patients with chronic kidney 
disease (Bakris 2008). 
However there remains an important caveat. Patients with proteinuria are also likely to 
have abnormal or progressively deteriorating creatinine which represents irreversible 
nephron loss and intervening in these patients may not necessarily yield fruitful clinical 
results. Although studies have examined the causes for proteinuria histologically, it is 
vital to stratify these patients by their renal function as well, if proteinuria were to be 
identified as potential marker for ‘grafts at risk’, and to plan therapeutic intervention. A 
more detailed understanding of the interactions between proteinuria, blood pressure 
and allograft outcomes would permit risk stratification of renal transplant recipients and 
direct appropriate therapeutic interventions specifically towards these ‘at risk’ groups. It 
should be realized that proteinuria is a dynamic clinical entity that changes with time. 
Even though early low grade proteinuria as early as 3 months after transplantation has 
been shown to be associated with poor graft outcomes, the impact of changes in 
proteinuria especially in relation to blood pressure control remains unknown.  
At St. James’s University Hospital Renal Unit (SJUH), we have established urine 
protein/creatinine ratio (uPCR) as a method of assessment for proteinuria and, every 
patient who attends the outpatient department is routinely tested for proteinuria at 
every clinic visit (Dyson, Will et al. 1992).  The unit therefore has been able to establish 
a comprehensive database of patients with proteinuria. In this chapter, the analysis of 
the impact of changes in proteinuria when assessed longitudinally on overall graft loss 
will be presented. In addition, from a subset of patients transplanted between 1988 and 
2003, all of whom are maintained on a similar immunosuppression regime consisting of 
ciclosporin, azathioprine and prednisolone, results that examine the impact of 
proteinuria very early after transplantation on multiple clinical outcomes will be 
analysed. Finally, with a cross sectional study, histological features of all renal 
transplant recipients who had persistent proteinuria of more than 500mg/day 
(uPCR>50) or deteriorating creatinine will be correlated to graft loss.  
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3.2 Results 
3.2.1 Longitudinal analysis of low-grade proteinuria-impact on graft outcomes  
In this section, results describing the clinical significance of low-grade proteinuria and 
its evolution after renal transplantation will be presented. As described in the methods 
section, patients are divided into groups with and without proteinuria and the groups 
are analysed over the first three years after transplantation for their impact on 10 year 
overall graft survival. 
3.2.1.1 Study population 
A total of 805 patients who have undergone renal transplantation at SJUH (mean 
follow-up of 113 months, SD=14.2) with a functioning graft at 1 year had their urine 
protein excretion (uPCR) recorded. The demographic characteristics of the study 
population divided into groups with and without proteinuria are described in Table-4. 
Patients are dominantly young Caucasians with a male preponderance. The majority of 
the grafts originated from deceased donors and there are no pre-emptive transplants. 
Patients in the low-grade proteinuria group had modestly higher systolic and diastolic 
blood pressures; higher donor age; more antihypertensive medications in use and a 
lower proportion of live transplants. It is of interest to note that there was no difference 
in the proportion of grafts performed across various immunosuppression eras, the 
distribution of the primary renal diagnosis or the serum creatinine achieved at 1 year 
between the two groups. No patients were on sirolimus. 
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Table 4: Demographics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Standard deviation is shown for continuous variables whilst percentage for categorical 
variables in the parenthesis. Continuous variables are compared by student t-test and 
categorical variables by Chi-square test. 
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3.2.1.2 Low-grade proteinuria 1-3 years after transplantation & graft survival 
82.7% of patients in this study had low-grade proteinuria (mean uPCR 353 ± 171) at 1 
year after transplantation. By the second year, there was a net reduction in this 
percentage to 49.7% (mean uPCR 292 ± 152) and further to 42.1% (mean uPCR 318 ± 
171) by the third post-transplant year. As expected these changes were multidirectional 
with patients moving from the low-grade proteinuria group (P) to the proteinuria-absent 
group (A) and vice versa. Thus whilst 56.3% of patients in Group-P had persistent 
proteinuria, 43.7% improved to Group-A by 2 years. Likewise, 17.6% of the patients in 
group A went on to develop low-grade proteinuria (P) by the second year. In a similar 
fashion between years 2 and 3, I have noticed similar dynamics with 68.2% of patients 
in Group-P having persistent proteinuria and 14.9% of the patients in Group-A 
developing low-grade proteinuria (P). DBD donor type, serum creatinine and non-
glomerular aetiology for ESRD were shown to be associated with the development of 
low-grade proteinuria at 1 year in a multivariate logistic regression analysis (Table 5). 
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Table 5: risk factors for low-grade proteinuria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RR relative risk, 95% CI 95% confidence interval for RR, DBD Donation after brain death, DCD 
donation after circulatory death 
 
Next, impact of low-grade proteinuria, assessed at the three annual time points, on 
long-term graft survival was analysed. The Kaplan Meier survival curves in Figure 25A 
show that patients in the low-grade proteinuria group (P) had significantly worse graft 
survival when assessed at any of the three different time points (1 year 87.1% vs. 
77.6%, P=0.01; 2 years 86.9% vs. 74%, P<0.001; 3 years 86.2% vs. 72.3%, P<0.001) . 
The graphic from Figure 25B shows that low-grade proteinuria associates with adverse 
graft survival irrespective of blood pressure, presence of diabetes or eGFR.  However, 
Variable RR 95% CI P-value 
Recipient age (>60yrs vs. <60yrs) 0.97 0.4-2.3 Ns 
Donor age 1.01 0.99-1.03 0.1 
Recipient gender (male vs. female) 0.8 0.45-1.2 Ns 
Graft type    
Live Ref Ref Ref 
DBD 2.1 1.1-4.1 0.02 
DCD 1.02 0.4-2.8 Ns 
Graft number 1.26 0.7-2.4 Ns 
HLA mismatches    
0-2 Ref Ref Ref 
3-4 0.9 0.6-1.4 Ns 
5-6 0.4 0.1-1.5 Ns 
Cause of ESRD: Non-glomerular  vs. 
glomerular disease 
2.5 1.5-4.3 <0.001 
Era of transplantation    
1988-1998 Ref Ref Ref 
1998-2004 1.01 0.57-1.8 Ns 
2004-2008 1.7 0.85-3.4 Ns 
Early rejection 1.3 0.6-2.7 Ns 
Systolic blood pressure 1.01 0.99-1.03 Ns 
Diastolic blood pressure 1.01 0.97-1.05 Ns 
Diabetes mellitus 1.6 0.9-3.0 0.1 
Serum creatinine 1.01 1.0-1.02 0.04 
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the results did not achieve statistical significance in patients with systolic BP≤ 140 mm 
Hg and eGFR>60. It is notable that low-grade proteinuria was selectively associated 
with worse graft survival in younger transplant recipients (age<60yrs) and that a 
significant effect is noted in all the three eras of our immunosuppression protocols 
(1988-98, 1998-04, 2004-08). Proteinuria was also significantly associated with worse 
graft survival in patients with both proteinuric glomerular disease and non-glomerular 
disease as the cause of their ESRD. When renal function was analysed, patients with 
low-grade proteinuria at 3 years had significantly low mean eGFR at 5 years when 
compared to their non-proteinuric counterparts (53.9 ± 18.7ml/min vs. 45.5 ± 
23.4ml/min, P<0.001, independent samples t-test) 
As noted earlier, proteinuria is dynamic and changes with time. Therefore the impact of 
modification of proteinuria over time on graft survival was next analysed. Figure 25C 
shows that between years 1 to 2 (A/A 91.1% vs. P/A 86.1% vs. A/P 79.2% vs. P/P 
73%, P<0.001) and 2 to 3 (A/A 87.9% vs. P/A 81.8% vs. A/P 80% vs. P/P 70.1%, 
P<0.001) patients who had persistent proteinuria (Group-P/P) had the worst graft 
survival while those with no proteinuria throughout the first three years (Group-A/A) had 
the best graft survival. It is important to note that patients who showed resolution of 
proteinuria (Group-P/A) demonstrated significant improvements in overall graft survival. 
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     Figure 25: Low-grade proteinuria 
and overall graft survival 
A. Kaplan Meier survival curves 
demonstrate that overall graft survival for 
the three annual time points is significantly 
superior in patients with no proteinuria. B. 
This is a graphic representing the hazard 
ratio for the overall graft loss in patients 
with low-grade proteinuria stratified into 
various subgroups based on relevant 
clinical parameters as shown in the figure. 
The hazard ratios are obtained by the 
Univariate Cox proportional hazards 
model. C. Patients are divided into groups 
based on the progression of proteinuria 
between years 1-2 and 2-3 and graft 
survival assessed by the Kaplan Meier 
method. These graphs show that patients 
who have persistent proteinuria (P-P) 
through years 1-2 and 2-3 have the worst 
graft survival and that there is an 
improvement in survival for patients where 
proteinuria resolved (P-A).  
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The independent significance of proteinuria was next assessed by the multivariate Cox 
proportional hazard model. Potential confounders including recipient and donor age, 
cause of ESRD, diabetes mellitus, eGFR, early rejection after transplantation, era of 
transplantation and systolic blood pressure were included in the model. Table-6 
summarizes the independent effect of modification of proteinuria during the time 
periods, 1 to 2 and 2 to 3. From the table it is apparent that there was a step wise 
increase in the risk of overall graft failure with the highest risk of graft failure in the 
Group-P/P. Again it is important to note that even after adjusting for potential 
confounders, resolution of low-grade proteinuria (Group-P/A) was associated with 
improved outcomes. 
Table 6: Multivariate analysis 
 
Analysis was by Cox proportional hazards model. Variables including systolic blood pressure, 
eGFR, early rejection, recipient and donor age, era of transplantation, diabetes mellitus and 
cause of ESRD were adjusted for in the multivariate analysis. 
 
3.2.1.3 The impact of proteinuria and systolic hypertension on graft survival 
The assessment of proteinuria remains incomplete without consideration of blood 
pressure. So, the association between systolic hypertension and graft survival was 
examined. The Kaplan Meier survival curves in Figure 26A show that; at the three 
Variable Hazard ratio 95% CI P-value 
Proteinuria longitudinal 
Years 1-2 
   
A/A Ref Ref Ref 
P/A 1.2 0.6-2.5 Ns 
A/P 1.4 0.4-5.1 Ns 
P/P 2.1 1.1-4.1 0.03 
Proteinuria longitudinal 
Years 2-3 
   
A/A Ref Ref Ref 
P/A 1.3 0.7-2.3 Ns 
A/P 1.5 0.8-3.1 Ns 
P/P 2.0 1.3-3.2 0.002 
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annual time-points, patients with a mean systolic blood pressure (SBP) ≥ 140 mmHg 
(year-1 83.2% vs. 75.9%, P=0.03; year-2 84.8% vs. 73.7%, P=0.003; year-3 85.7% vs. 
70.3%, P<0.001) had significantly worse graft survival when compared to those with 
SBP<140 mmHg. It is well documented that tighter blood pressure control is associated 
with improvement in proteinuria. Next, the impact of this interaction on long-term 
outcomes was tested. As shown in Figure 26B, patients were divided into four groups 
based on both blood pressure and the presence of low-grade proteinuria. In year 1, 2 
and 3 patients with a systolic blood pressure ≥140mm Hg and proteinuria (H/P) had the 
worst graft survival when compared to all the other groups (year-1 N/A 85.7% vs. H/A 
87.5% vs. N/P 82.6% vs. H/P 74.3%, P=0.03; year-2 N/A 87.3% vs. H/A 83.5% vs. N/P 
82.2% vs. H/P 66.9%, P<0.001; year-3 N/A 87.9% vs. H/A 81% vs. N/P 80.3% vs. H/P 
60.2%, P<0.001). It is important to note that at the same time points, patients with a 
systolic blood pressure ≥ 140mmHg in the absence of proteinuria (H/A) had remarkably 
better graft survival when compared to their hypertensive counterparts with proteinuria. 
Figure 27 shows that those patients who were persistently hypertensive (H/H) between 
year-1 and year-3 (H/H 86.2% vs. H/N 86.1% vs. N/H 79.7% vs.  H/H 66.4%, P<0.001) 
had the worst graft survival and this finding corroborates with the findings of Opelz et al 
in the Collaborative Transplant Study (Opelz, Dohler et al. 2005).  I have then 
performed a sub-group analysis in patients with SBP above and below 140 mm Hg 
between years 1 and 3. Figure 27 shows that proteinuric patients in the group with 
SBP>140mm Hg had a significantly worse graft survival (82.6% vs. 53.6 %, P<0.001). 
The trend was not as marked in the proteinuric patients who were normotensive 
(87.6% vs. 79.7%, P=0.1).  
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Figure 26: Systolic hypertension and overall graft survival 
A. Kaplan Meier survival curves comparing overall graft survival for the three annual time points 
in various systolic blood pressure groups.  B. Patients were divided into groups based on their 
systolic blood pressure and the presence of proteinuria, these Kaplan Meier estimates analyse 
overall graft survival across the various SBP-proteinuria groups. 
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Figure 27: Longitudinal analysis of systolic blood pressure, proteinuria and graft survival 
A. Patients were divided into groups based on their systolic blood pressure (>/< 140 mm Hg) at 
years 1 and 3. The Kaplan Meier survival curves show that patients with SBP>140 mm Hg at 
both the annual check points had the worst graft survival and interestingly, patients whose blood 
pressure improved at year-3 (H/N) had remarkably better graft survival. B. In a subgroup 
analysis of patients who were either persistently hypertensive or normotensive, the presence of 
low-grade proteinuria has been shown to be significantly associated with worse graft survival in 
the hypertensive subgroup in this set of Kaplan Meier survival curves. 
 
In summary, persistent low-grade proteinuria was associated with adverse graft 
survival after renal transplantation, which improved as proteinuria resolved, facilitating 
the stratification of hypertensive renal transplant recipients.  
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3.2.1.4 Causes of graft loss 
Finally, the causes of graft loss in the study population were analysed. Overall, 20.7% 
(N=167) of grafts were lost during the study period. In this group of patients, the 
dominant cause of the graft loss was death with a functioning graft (67.1%, 
n=112/167). Cardiovascular events (including myocardial infarction, cerebrovascular 
accident and sudden cardiac death) followed by infection and malignancy were the 
three most common causes of death. The most common cause of functional graft loss 
was rejection. This information was obtained from registry returns and represented a 
broad category including refractory acute rejection, chronic transplant glomerulopathy 
and a few slowly failing grafts that were not routinely biopsied. No data was available 
for the histology of graft losses. 
 
3.2.2 Clinical significance of early low-grade proteinuria 
Now, results that describe the impact of early proteinuria on multiple graft outcomes 
shall be analysed in a subset of 477 patients, all of whom were maintained on 
ciclosporin, azathioprine and prednisolone. As described in the methods section, 
patients in this series were divided into four groups based on the degree of proteinuria, 
measured by uPCR (Group-1, uPCR<150; Group-2, uPCR 150-500; Group-3, uPCR, 
500-1000 and Group-4, uPCR>1000) and they were followed up for a mean of 10 
years (+/- SD). Clinical outcomes including patient survival, death censored graft 
survival and cardiovascular event free graft survival were analysed in the groups of 
patients with and without proteinuria. Cardiovascular event was defined as a composite 
of fatal or non-fatal myocardial infarction, sudden cardiac death, congestive cardiac 
failure, cardiac arrhythmia, stroke, transient ischaemic attack and peripheral limb 
revascularization or amputation. 
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3.2.2.1 Patient characteristics-proteinuria groups 
A total of 477 patients undergoing renal transplantation at SJUH between 1988 and 
2003 were included in the analysis with a mean follow-up of 122 months (SD=34.8). All 
477 patients had proteinuria quantitatively assessed at each clinic visit during the 3rd 
month after transplantation (minimum of three readings per patient), and the median of 
these readings was used to divide the patients into groups stratified by increasing 
protein excretion. The demographic characteristics of the study population divided into 
groups are illustrated in Table 7. The patients were relatively young compared with our 
contemporary practice (mean age 43±13 years) and predominantly white (89%) with a 
male preponderance (64%). The majority of grafts originated from deceased donors 
(89%) and the most common cause of death in these donors was cerebrovascular 
disease (44%). The rates of delayed graft function (24.5%) and acute rejection (24.3%) 
were fairly typical for all-comers during this era. 
Further analysis of the demographics across the different groups demonstrated that 
recipient age (group 1: 39±13, group 2: 42±15, group 3: 46±13, group 4: 46±16 years), 
the prevalence of diabetes mellitus (group 1: 3.5%, group 2: 9.4%, group 3: 19%, group 
4: 20%), and systolic blood pressure at 3 months  (group 1: 137±18, group 2: 140±22, 
group 3: 142±17, group 4: 146±18 mm Hg) correlated with increasing proteinuria. 
Interestingly, glomerular disease as a primary diagnosis was more common in the 
lower protein excretion groups, although not significantly so. 
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Table 7: Demographics (groups divided by the degree of proteinuria) 
 
Demographic Group-1 Group-2 Group-3 Group-4 p-value 
Total number 183 203 27 50  
Recipient age in years± SD 44±13.5 47±15.3 37±12.8 44±14.4 0.007 
% male gender 57% 62% 67% 56% 0.7 
% Caucasian 86% 79% 89% 72% 0.08 
Graft number± SD 1.1±0.28 1.05±0.22 1.15±0.36 1.3±0.61 <0.001 
Total HLA-mismatches± SD 1.5±1.1 1.9±1.3 1.9±1.0 2.2±1.3 <0.001 
% CMV R-/D+ 26% 24% 37% 22% 0.5 
Donor type- live donor 21% 19% 4% 22% <0.001 
DBD- donor 72% 59% 92% 54% <0.001 
DCD donor 7% 22% 4% 24% <0.001 
Donor age 46±13.6 46±14.1 38±17.7 49±15.7 0.01 
% diabetic      
Cold ischemia time in hrs± SD 14.9±8.2 14.9±7.6 17.5±4.6 14.7±8.2 0.4 
% Delayed graft function 27% 30% 5% 48% 0.03 
Mean follow-up± SD 48±0 39.5±8 48±0 38.3±7.5 <0.001 
Groups are compared by 
univariate one way ANOVA 
with Dunnet’s post hoc 
correction for multiple 
comparisons. 
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3.2.2.2 Risk factors for Clinical outcomes - Significance of early proteinuria 
The relationship between proteinuria at 3 months and various primary endpoints 
including death-censored graft loss, death with a functioning graft, and vascular events 
during the graft’s life were explored using univariate Cox regression analysis as 
illustrated in Table 8. Recipient age, ethnicity, graft number, acute rejection in the first 
post-transplant year, uPCR groups at 3 months, and serum creatinine at 3 months 
affected death-censored graft loss. Recipient age, uPCR at 3 months, primary renal 
diagnosis, type of donation, graft number, and diabetes mellitus affected patient 
survival, whereas recipient age, uPCR at 3 months, creatinine at 3 months, primary 
renal diagnosis, donor age, and diabetes mellitus predicted the occurrence of the 
vascular end point in the univariate analysis. 
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Table 8: Rick factors for various clinical outcomes (3 months post-transplant) 
 
Factor Death censored graft 
loss (95% CI) 
P-value Death with a functioning 
graft (95% CI) 
P-value Cardiovascular event  
(95% CI) 
P-value 
Recipient age
a
 0.98 (0.96-0.99) 0.009 1.09 (1.07-1.11) <0.001 1.04 (1.03-1.05) <0.001 
Ethnicity-South 
Asian vs. Caucasian  
2.5 (1.2-5.2) 0.02 0.5 (0.1-1.9) 0.3 0.97 (0.4-2.4) 0.9 
Cause of ESRD       
Glomerular disease Ref  Ref  Ref  
Infection/obstructio
n 
1.1 (0.5-2.4) 0.8 2.0 (1.1-3.9) 0.03 2.5 (1.3-4.8) 0.004 
Others 0.98 (0.6-1.6) 0.9 1.6 (0.97-2.6) 0.07 1.7 (1.04-2.8) 0.04 
Donor age
a
 1.004 (0.99-1.02) 0.6 1.008 (0.99-1.02) 0.2 1.02 (1.002-1.03) 0.02 
Cadaveric donor vs. 
live 
0.9 (0.4-1.9) 0.8 10.6 (1.5-7.6) 0.02 2.3 (0.9-5.7) 0.07 
Graft number 1.8 (1.2-2.6) 0.004 0.45 (0.2-0.99) 0.05 1.1 (0.6-1.7) 0.8 
Early acute rejection 2.6 (1.7-4.1) <0.001 0.7 (0.4-1.2) 0.2 1.4 (0.9-2.1) 0.2 
uPCR at 3 months       
Group-1 Ref  Ref  Ref  
Group-2 7.8 (2.0-32.2) 0.005 1.7 (0.9-3.2) 0.09 1.5 (0.8-2.8) 0.2 
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Group-3 12.0 (2.8-51) 0.001 2.5 (1.3-5.0) 0.008 2.6 (1.3-5.0) 0.005 
Group-4 19.0 (4.3-83.4) <0.001 4.5 (2.2-9.4) <0.001 3.2 (1.6-6.7) 0.001 
Creatinine at 3 
months
b
 
1.006 (1.003-1.008) <0.001 1.003 (1.0-1.006) 0.09 1.004 (1.001-1.01) 0.003 
Diabetes mellitus 1.1 (0.6-2.2) 0.8 1.7 (1.02-2.8) 0.04 1.9 (1.1-3.0) 0.01 
 
 
 
a
 Hazard ratio calculated for every year. 
b
 Hazard ratio calculated for every mol/L rise in creatinine. 
95% CI, 95% confidence interval; CVA, cerebrovascular accident; ESRD, end-stage renal disease; HLA, human leukocyte antigen; Ref, reference group; 
CMV, cytomegalovirus; DGF, delayed graft function; PCR, protein creatinine ratio; BP, blood pressure (mm Hg) 
Factors including recipient gender, donor cause of death, HLA mismatches, era of transplantation, DGF, CMV disease, systolic and diastolic blood pressure were 
not significant in the univariate analysis 
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 Table-9 summarizes the independent effect of proteinuria on the three primary 
outcome measures (death-censored graft loss, death with a functioning graft, and 
occurrence of vascular events during the graft’s life). From the analysis, it can be seen 
that the independent effect of low-grade proteinuria (uPCR 0.15– 0.5) on death-
censored graft loss was significant. However, the impact of early proteinuria on death 
with a functioning graft and composite vascular endpoint was modest when compared 
with its effect on death-censored graft loss. Patients in group 1 clearly had a good 
outlook but it should be noted that they only represented 17.8% (85 of 477) of the total 
population. The largest group is group 2 representing 51.4% (245 of 477) of patients. 
Table 9: Independent effect of early proteinuria on clinical outcomes 
uPCR group Hazard ratio 95% CI P-value 
Death censored graft lossa    
Group-1 Ref   
Group-2 7.1 1.7-29.3 0.007 
Group-3 10.5 2.4-45.7 0.002 
Group-4 16.0 3.5-72 <0.001 
    
Death with a functioning graft    
Group-1 Ref   
Group-2 0.95 0.5-1.8 0.9 
Group-3 1.2 0.6-2.5 0.6 
Group-4 2.6 1.2-5.4 0.01 
    
Cardiovascular event    
Group-1 Ref   
Group-2 1.1 0.6-2.1 0.7 
Group-3 1.3 0.7-2.7 0.4 
Group-4 2.2 1.04-4.9 0.04 
 
a
 Death-censored graft survival: adjusted for the effect of recipient age, ethnicity, graft number, 
acute rejection, and serum creatinine at 3 mo. 
b
 Death with a functioning graft: Adjusted for the effect of recipient age, primary renal diagnosis, 
type of donation, graft number and diabetes mellitus 
c
 Cumulative vascular events within the life of the graft: Adjusted for the effect of recipient age, 
serum creatinine at 3 months, primary renal diagnosis, donor age and diabetes mellitus. 
95% CI, 95% confidence interval; Ref, reference group; uPCR, protein creatinine ratio 
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Analysis of the causes of graft loss across various proteinuria groups showed that a 
total of 187 grafts were lost during the follow-up period, and again death with a 
functioning graft was the dominant cause of graft loss in all groups (109 of 187, 58.3%) 
but particularly group 1 in which 12 of the 14 grafts were lost due to death. After death 
with a functioning graft, most grafts were lost due to rejection (50 of 187, 26.7%). As 
mentioned before, this information was obtained from registry returns and represents a 
broad category that includes refractory acute rejection, chronic allograft nephropathy, 
and a few slowly failing grafts that were not biopsied. Recurrent disease was unusual, 
representing only eight lost grafts in total. Although represented in higher absolute 
numbers in group 4 (3 of 35, 8%), there were no significant differences among the 
groups and we would not have expected proteinuria after only 3 months to correlate 
with eventual graft loss due to recurrent disease. 
In summary, with these clinical data, it could be concluded that low-grade proteinuria 
was associated with adverse clinical outcomes. The effect was visible as early as 3 
months after transplantation and when assessed longitudinally resolution of proteinuria 
was associated with improved outcomes, thereby suggesting that measurement of 
proteinuria by uPCR was a potential biomarker for graft loss.  
 
 3.2.3 Histological assessment of troubled allografts 
Now, data describing the histological characteristics of patients presenting with either 
proteinuria or deteriorating creatinine or a combination of the both will be presented 
and finally the ability of clinical or histological phenotype to predict graft outcomes will 
be examined. 
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3.2.3.1 Study population 
A total of 135 patients who underwent consecutive late indication renal transplant 
biopsy for a clinical presentation of either ‘creeping creatinine’ or isolated persistent 
proteinuria were included in this analysis. Of these, 32 patients presented with creeping 
creatinine (CC) only and 44 patients with isolated proteinuria (IP). A total of 59 patients 
were biopsied for a combination of proteinuria and ‘creeping creatinine’ (CP). Figure 
28A summarizes the regression of the 1/creatinine plot against time across ten different 
time points spread over 2 years for the three clinical groups. Similarly, Figure 28B 
shows mean proteinuria measured at the three consecutive time points for the three 
groups.  
 
 
Table 10 compares the demographic characteristics of the three study groups. The key 
differences between the groups included a significantly older age for the recipients in 
the CP group and longer graft vintage for both the proteinuria groups (IP and CP) when 
compared to the CC group. As expected there was a significantly lower serum 
creatinine at the time of biopsy in the IP group when compared to the other groups.  
There was also a trend towards a dominant Caucasian representation in the CP group. 
Finally it is interesting to note that the proportion of patients with glomerulonephritis as 
the cause for ESRD was slightly lower in the proteinuria groups, although these results 
did not achieve statistical significance. This finding corroborates with the previous 
observations in Table 5 and Table 7 suggesting that non-glomerular aetiology for ESRD 
is more common in patients with proteinuria. Patients were followed for a maximum of 
3 years after the biopsy (mean follow-up 31.4 months +/- SD).    
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 Figure 28: The three clinical groups and the broad histological classification 
(A)The three regression plots demonstrate the changes in renal function measured by serum 
creatinine over time. CC Group-R
2
=0.91, P<0.0001; IP Group-R
2
=0.13, P=0.3; CP Group-
R
2
=0.78, P=0.0003. The slopes of the three groups were significantly different. F=21.5, DFn=2, 
DFd=1332, P<0.0001. (B)The mean of the three consecutive proteinuria estimates is shown for 
the three groups (CC, IP, and CP). The error bars represent SEM.  Based on their histology, all 
the three groups of patients were divided into 5 broad classes-recurrent glomerulonephritis, 
microcirculation damage (defined by the presence of ‘g’, ‘ptc’ or ‘cg’ lesion with or without C4d 
deposition), IFTA-no specific cause identified, T cell mediated rejection and others (BK virus 
nephropathy, amyloidosis, hypertensive arteriosclerosis and ascending infection). (C) The 
stacked bar charts demonstrate the distribution of the five histological classes in the three 
clinical groups. There were no statistically significant differences in the distribution of any 
specific histological class between the clinical groups (P=Ns, Chi square test). (D)Even when 
the analysis was repeated by stratifying the groups based on the degree of proteinuria (< or > 
1g/day), the distribution of histological classes remained comparable. 
 
 
    uPCR<1000   uPCR>1000 
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Table 10: Clinical characteristics of patient groups (CC, IP, CP) 
 
Continuous variables were compared across the groups by one way ANOVA with Tukey post 
hoc correction for multiple comparisons. Categorical variables were compared by Chi squared 
test. For continuous variables SD is shown in the parenthesis. 
Characteristics CC IP CP P-value 
Number (N) 32 44 59  
Recipient age in years 41 (17) 47 (17) 49 (15) 0.04 
Gender-male% 47% 66% 58% Ns 
Ethnicity-Caucasian% 66% 73% 81% Ns 
Primary renal diagnosis    Ns 
Diabetes and hypertension 10% 23% 8%  
Glomerulonephritis 52% 33% 41%  
APKD and congenital 19% 27% 21%  
Others 29% 17% 30%  
Graft type    Ns 
Live% 30% 17% 25%  
DBD% 63% 69% 63%  
DCD% 7% 14% 12%  
HLA-MM 2.2 (1.2) 2.7 (1.2) 2.3 (1.2) Ns 
Donor age 43 (17) 40 (20) 48 (21) Ns 
Donor gender-male% 50% 56% 62% Ns 
DSA 22% 21% 27% Ns 
Time since transplant 64 (44) 124 (85) 95 (66) 0.001 
Serum creatinine at biopsy 252 (126) 154 (30) 262 (122) 0.001 
Immunosuppression     
Induction-
methylprednisolone alone 
35% 43% 37% Ns 
Induction –Basiliximab 53% 50% 58% Ns 
Induction-Alemtuzumab 12% 7% 5% Ns 
Ciclosporin 19% 34% 32% Ns 
Tacrolimus 75% 50% 53% Ns 
Mycophenolate 63% 48% 61% Ns 
Azathioprine 23% 29% 20% Ns 
Prednisolone 50% 50% 58% Ns 
Sirolimus 3% 4% 7% Ns 
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3.2.3.2 Allograft histology and clinical presentation 
The distribution of various histological classes stratified by clinical presentation at the 
time of the indication biopsy is first analysed. Figure 28C shows that the distribution of 
histological classes including glomerulonephritis, interstitial fibrosis tubular atrophy-no 
specific cause identified, microcirculation damage (defined by the presence of either 
glomerulitius, peritubular capillaritis, transplant glomerulopathy with or without 
deposition of C4d in the peritubular capillaries), late T cell mediated rejection and other 
diagnoses was quite heterogeneous with similar distribution of both glomerulonephritis 
and microcirculatory damage across all the clinical groups. When the histological 
classes were re-analysed based on the degree of proteinuria (>1g or <1g), again no 
significant differences were noted in the distribution of the histological classes 
irrespective of the degree of proteinuria (Figure 28D). 
Next, a detailed analysis of all the Banff lesions was performed in 106 patients after 
excluding 29 patients with either GN (n=18) or other miscellaneous diagnosis (BK viral 
nephritis, n=6; amyloidosis, n=2; ascending infection, n=1; hypertensive vasculopathy, 
n=2). In Figure 29, the top panel of graphs represent the distribution of Banff scores 
whilst the bottom panel analyses the mean Banff scores across the groups of patients 
stratified by clinical presentation. Figure 29A shows that there was a trend towards a 
higher proportion of patients in the CC group to have both more tubulitis (t) and 
interstitial inflammation (i) and it was notable that the CC group had the highest ‘t’ and 
‘i’ scores, although only ‘t’ scores reached statistical significance. There were no 
significant differences noted in the distribution and the mean levels of either intimal 
arteritis (‘v’) or the total inflammation (‘ti’). The distribution and mean levels of 
microcirculatory inflammation (‘g’, ‘ptc’) were similar across the groups, whilst there 
was a trend towards higher mean levels of the transplant glomerulopathy score and 
mesangial expansion in patients with proteinuria (Figure 29B-C). All the clinical groups 
had prominent features of scarring as depicted by the distribution and the mean values 
of ‘ci’ and ‘ct’, scores (Figure 29D). Again there was a non-significant trend towards 
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slightly higher mean scores for these in patients with both proteinuria and creeping 
creatinine (CP). It has recently been demonstrated that a ‘g+ptc’ score of more than 2 
is indicative of significant microcirculatory inflammation and is associated with worse 
graft survival in patients with de novo donor specific antibodies (de Kort, Willicombe et 
al. 2013). When I analysed the distribution of the biopsies with ‘g+ptc’ scores of 0, 1 to 
2 or 3; no significant differences are noticed between the clinical groups (Figure 29E). 
Finally analysis of the deposition of C4d in the peritubular capillaries has shown a 
slightly but statistically significantly stronger C4d scores in patients with CC (Figure 
29F).  In summary, there was overall heterogeneity in the distribution of the histological 
diagnoses irrespective of the clinical presentation. Whilst there was a propensity 
towards a slightly higher degree of tubulo-interstitial inflammation in patients with CC, 
patients with proteinuria had more chronic changes. 
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Figure 29: Banff lesions and the three clinical groups 
The top panel in this figure shows the distribution of the Banff scores (0, 1, >1) and the bottom panel demonstrates the mean Banff score for each lesion. (1A).Analysis of the Banff scores for tubulointerstitial 
inflammation (‘t’ tubulitis, ‘v’ intimal arteritis, ‘I’ interstitial inflammation, ‘ti’ total inflammation). Patients who presented with CC had a significantly higher‘t’ score (* CC vs. PC, P=0.04). Although there was a 
trend towards a higher ‘i’ score in the CC group in comparison to the others, this did not reach statistical significance. (1B). Microcirculation inflammation scores (‘g’ glomerulitis, ‘ptc’ peritubular capillaritis) 
and these scores were comparable across the clinical groups. (1C).Lesions pertaining to microcirculatory deterioration (‘cg’ transplant glomerulopathy, ‘mm’ mesangial matrix expansion). Patients in the CC 
group had the lowest ‘cg’ and ‘mm’ scores, even though only the ‘mm’ score achieved statistical significance (‘mm’ score CC vs. PC, P=0.02). (1D.) All patients had a significant amount of scarring as 
evidenced by these lesions (‘ct’ tubular atrophy, ‘ci’ interstitial fibrosis, ‘cv’ intimal fibrosis, and ‘aah’ arteriolar hyalinosis). Although there was a trend towards higher scores for scarring in patients with 
proteinuria, these results did not reach statistical significance. (1E). Microcirculatory inflammation (g+ptc) scores across the clinical groups. Again it was evident that there were no significant differences 
between the groups. (1F). C4d scores. Patients within the CC group had stronger scores for C4d deposition. All the Banff lesion scores were compared across the clinical groups by ANOVA with Dunnet’s 
post hoc correction for multiple comparisons. The error bars represent SEM. 
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3.2.3.3 Histological class, clinical phenotype and allograft survival 
Having established the histological heterogeneity in these patient groups I have 
proceeded further to test the prognostic significance of either the clinical presentation 
or the histological phenotype. Table-11 shows that none of the clinical variables were 
significantly associated with worse graft survival in a univariate analysis (univariate Cox 
proportional hazards model). In a univariate Kaplan Meier survival analysis, patients 
with both proteinuria and creeping creatinine (CP) had a significantly worse survival 
when compared to both CC (P=0.002) and P (P=0.05) groups (Figure 30). Whilst there 
was a trend towards slightly worse graft survival in the presence of a DSA, this did not 
reach statistical significance (Figure 30). For the assessment of the histological classes, 
I divided the patients into three broad groups - GN, microcirculatory damage (MCD) 
and others. When these three groups were compared for graft survival after the biopsy, 
patients with both GN (P=0.03) and MCD (P=0.045) had significantly worse graft loss 
when compared to the rest of the patients (Figure 30).  Finally I have examined the 
significance of scarring defined by tubular atrophy, interstitial fibrosis, and arterial 
fibrointimal thickening. For this analysis patients were divided into tertiles bases on 
their composite ‘ct’, ‘cv’ and ‘ci’ scores and from Figure 30, again it can be noted that 
patients in the highest tertile had significantly worse graft survival when compared to 
the other tertiles (P<0.001). 
 
 
 
 
 
. 
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 Table 11: Impact of clinical variables on graft loss after an indication biopsy 
 
 
HR, Hazard ratio; 95% CI, 95% Confidence Interval 
Analysis by univariate Cox proportional hazards model 
Variable HR 95% CI P-value 
Recipient age 1.0 0.98-1.02 0.99 
Recipient gender 1.1 0.6-2.01 0.8 
Recipient 
ethnicity (Caucasian 
vs. Soth Asian 
1.2 0.6-2.5 0.6 
Graft number 1.5 0.7-3.3 0.3 
Time since 
transplantation 
1.0 0.99-1.005 0.6 
HLA mismatches 1.09 0.8-1.5 0.5 
Donor age 1.01 0.99-1.03 0.07 
Type of donor    
DBD vs. live 1.1 0.5-2.6 0.8 
 DCD vs. live 1.4 0.5-4.5 0.5 
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Figure 30: Graft survival after the biopsy-the influence of clinical presentation and histology 
Patients were followed for a maximum of 3 years after the biopsy and death censored graft survival was examined, stratified by clinical presentation and histological 
features using Kaplan Meier method. Survival curves were compared using the Log Rank test. When patients were grouped based on their clinical presentation, the 
CP group had significantly worse survival when compared to CC alone (Chi square=3.8, P=0.05) and IP (Chi square=9.6, P=0.002). Positivity of DSA at the time of 
biopsy was not associated with a significant difference in graft survival. Recurrent GN (Chi square=4.8, P=0.03) and MCD (Chi square=3.9, P=0.045) on the 
histological analysis were associated with worse graft survival. When patients were divided into tertiles based on the cumulative ‘ct’, ‘cv’ and ‘ci’ scores; patients in 
the highest tertile had significantly worse graft survival (Chi square=12.98, P<0.001). 
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To study the independent effect of these variables on graft loss, multivariate analysis 
was next performed using Cox’s Proportional hazard model. In this analysis (Table-12), 
the presence of MCD (HR 2.5, 95% CI 1.1-5.6, P=0.03) and the diagnosis of recurrent 
GN (HR 2.9, 95% CI 1.2-6.9, P=0.015) were independently associated with increased 
risk of graft loss. Most importantly, the degree of scarring noted in the biopsy was the 
strongest predictor of graft loss, with patients in the highest tertile of the cumulative ‘ct’, 
‘cv’ and ‘ci’ scores having the worst graft survival (HR 4.5, 95% CI 1.8-10.5, P=0.001).  
 
Table 12: Multivariate analysis of factors predicting graft loss 
 
Analysis was by multivariate Cox Proportional Hazards model. 
95% CI 95% confidence interval 
 
 
 
Variable Hazard ratio 95% CI P-value 
Histological diagnosis    
GN vs. rest 2.9 1.2-6.9 0.015 
MCD vs. rest 2.5 1.1-5.6 0.03 
Scarring    
Middle tertile vs. lowest 1.2 0.5-3.3 Ns 
Highest tertile vs. lowest 4.3 1.8-10.5 0.001 
DSA 1.02 0.5-2.3 Ns 
Clinical presentation    
IP vs. CC 0.8 0.3-2.3 Ns 
PC vs. CC 1.8 0.8-4.2 Ns 
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Figure 31  shows that there was a decline in renal function in the functioning grafts in 
all the three groups as measured by 1/creatinine over the next 2 years (CC group, 
R2=0.23, P=0.1; P group, R2=0.46, P=0.03; PC, R2=0.75, P=0.001). However, despite a 
significant difference in the serum creatinine at the time of the biopsy in the three 
clinical groups, it was interesting to note the rates of decline of renal function after the 
biopsy, as measured by the slope of the 1/creatinine regression plots was not 
significantly different between the groups.  
 
 
 
 
 
 
 
 
 
Figure 31: 1/creatinine plots for representative patients within CC, P and PC groups after 
the biopsy 
Serial serum creatinine levels were assessed after the biopsy in patients from all the three 
clinical groups. Grafts that were lost were excluded from the analysis at the time of graft loss. 
This graphic shows that the overall elevation of the 1/creatinine plots was not surprisingly 
significantly different with evidence of inequality of intercepts (F=67.8, DFd=960, DF=2, 
P<0.0001) given the initial differences in the serum creatinine at the time of the biopsy. However 
the rate of deterioration of renal function as determined by the slope of 1/creatinine plots was 
not significantly different between the groups (F=0.34, DF=2, DFd=958, p=0.7). 
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Finally, a sub-group analysis of graft survival was performed in the 47 patients with the 
histological diagnosis of microcirculatory damage (MCD). The Kaplan Meier survival 
curves in Figure 32 show that neither clinical presentation nor the DSA status at the time 
of the biopsy was associated with worse graft survival in these patients. Although there 
was a trend towards worse graft survival in patients with either ‘g’ (P=0.1) or ‘ptc’ 
(P=0.09) lesions, patients with ‘g+ptc’ score ≥3 (score≥3 vs. score-0, P=0.04) had 
significantly worse graft survival, highlighting the importance of the ‘g+ptc’ score (MI 
lesion score). Despite the lack of prognostic significance for the presence of DSA, 
deposition of C4d in the peritubular capillaries has been shown to be associated with a 
significantly adverse graft survival after the biopsy (P=0.002). As has been noted in the 
main analysis, worse scarring defined by higher cumulative ‘ci’, ‘cv’and ‘ct’ scores was 
associated with worse graft survival (highest tertile vs. lowest tertile, P=0.02). 
Interestingly, when the graft survival was analysed in groups stratified by the presence 
of MI lesion score≥3 and the detection of C4d in the peritubular capillaries, we noticed 
that patients with an MI score≥3 and with detectable C4d on the biopsy had the worst 
graft survival (Figure 33). 
Therefore, histological phenotype defined by the presence of scarring and the lesions 
of microcirculatory damage along with a diagnosis of GN were associated with 
significantly worse graft survival. The prognostic significance of the histological lesions 
persisted even when the analysis was repeated in a small sub-group of patients with 
MCD alone. 
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Figure 32: Subset analysis of graft survival in patients with MCD 
47 patients who had lesions of either ‘g’, ‘ptc’ or ‘cg’ with or without C4d detection were 
analysed for graft survival based on various Banff characteristics using the Kaplan Meier 
method. This figure shows that clinical presentation and DSA positivity at the time of the biopsy 
were not significantly associated with worse graft survival. Key histological features including, 
the MI lesion score≥3 (Chi square=4.2, P=0.04), C4d deposition in the peritubular capillaries 
(Chi square=9.6, P=0.002) and the degree of scarring based on the cumulative ‘ct’, ‘cv’ and ‘ci’ 
scores (highest vs. lowest tertile, Chi square=5.2, P=0.02) were significantly associated with 
worse graft survival. Tubulitis, glomerulopathy, arteriolar hyalinosis, ‘g’ or ‘ptc’ lesions alone did 
not have statistically significant associations with graft survival. 
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Figure 33: Graft survival-risk stratification by MI score and C4d deposition 
Kaplan Meier survival curve demonstrating the graft survival over three years in patients divided 
into three groups based on MI lesion score and C4d deposition ( Group-1: MI lesion<3, C4d 
neg; Group-2: MI lesion score≥3 and C4d neg or MI lesion score<3 and C4d pos; Group-3: MI 
lesion score≥3 and C4d pos). The curves are compared using the Log Rank test. In comparison 
to Group-1, patients who had positivity for C4d and MI lesion score≥3 had significantly worse 
survival (P<0.001). Although there is a trend towards worse survival in Group-2, this did not 
reach statistical significance. 
 
In summary, with the data presented in this chapter, it can be concluded that low-grade 
proteinuria; despite being a good clinical marker for graft outcomes in renal transplant 
recipients is inferior to the histological phenotype of the deteriorating graft on an 
indication biopsy. In fact histological phenotype is probably superior to clinical 
phenotype once chronic graft dysfunction ensues.   
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3.3 Discussion 
One of the major challenges for the renal transplant community at present is the lack of 
improvement in long-term allograft loss despite significant advances in the 
management of early acute rejection and superior early graft survival (Hariharan, 
McBride et al. 2002, Lamb, Lodhi et al. 2011). Early diagnosis of allograft injury 
remains one of the greatest challenges in renal transplantation. Serum creatinine levels 
are measured as a surrogate marker of renal function, but this is a relatively insensitive 
marker of established renal allograft damage, and by the time levels become 
consistently elevated, significant irreversible nephron loss has usually occurred 
(Chapman, O'Connell et al. 2005). Despite this limitation, elevated serum creatinine at 
12 months after transplantation is strongly associated with a poor outcome, although it 
has a poor predictive value because many grafts that eventually fail have a low 
creatinine level at 1 year (Hariharan, McBride et al. 2002, Kaplan, Schold et al. 2003) 
(21, 22). Consequently, the search continues for a marker of early allograft injury. 
Protocol biopsy of renal tissue has been proposed as one such method. Although safe, 
this procedure is invasive and incurs significant cost. Despite some initially 
encouraging reports, especially in the context of management of early subclinical 
rejection, the benefits in normal clinical practice remain unproven (Nickerson, Jeffery et 
al. 1998, Rush, Nickerson et al. 1998) (2, 23). Consequently, there remains a great 
deal of interest in less invasive methods involving analysis of urine, circulating blood 
cells, or serum. 
 
3.3.1. Low-grade proteinuria- A clinical marker for adverse graft outcomes 
Protein excretion in the urine is a cardinal sign of renal damage and higher levels of 
protein excretion predict poor outcome in many renal diseases. Low levels of albumin 
excretion (microalbuminuria) have been shown to be an early marker of renal 
parenchymal damage and a predictor for cardiovascular events in patients with renal 
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disease and those with no overt renal problems (Grimm, Svendsen et al. 1997, Abbate, 
Zoja et al. 2006, Bakris 2008, Chronic Kidney Disease Prognosis, Matsushita et al. 
2010, Turin, James et al. 2013). Urine protein creatinine ratio (uPCR) provides a simple 
way of investigating proteinuria in patients with renal disease and it has been shown to 
be an accurate reflection of 24 hour protein excretion (Shaw, Risdon et al. 1983, 
Dyson, Will et al. 1992). Formal quantification of proteinuria for every patient at every 
clinic visit at SJUH provided me an opportunity to analyse this dynamic variable in a 
longitudinal fashion and study its impact on long-term graft survival. The majority of 
patients at one year had low-grade proteinuria (82.9%), although there was an 
improvement by year 2 (49.7%) and 3 (42.1%). It is however important to note that a 
significant number of these patients (86.6% at 1 year, 95.1% at year-2 and 94.4% at 
year-3) had very low-grade proteinuria (150mg-500mg/24hrs) and at these low levels, 
there is a distinct possibility that proteinuria can regress. In this study, factors including 
non-glomerular disease, serum creatinine and DBD grafts were associated with the 
development of low-grade proteinuria. It was rather surprising to note that patients with 
glomerular disease had a significantly lower risk in this study population. This is 
potentially attributable to the fact that patients with a potential diagnosis of recurrent 
glomerular disease would likely present with a far more significant level of urine protein 
excretion (>1g/day) and all such patients were excluded from the study. Another 
possible explanation could be that there were no pre-emptive transplants within this 
group and it is very unlikely that protein excretion from the native kidney would be 
persistent beyond the first year (Halimi 2013). However it should be noted that even in 
the analysis of early proteinuria, patients with glomerulonephritis are less represented 
in the group with proteinuria. 
Low-grade proteinuria is associated with worse graft survival in subgroups stratified by 
various clinical variables and its regression is associated with better graft survival when 
compared to those with persistent proteinuria. In the non-transplant literature, 
remission of proteinuria has been shown to be associated with better outcomes in 
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patients with various glomerular diseases (Reich, Troyanov et al. 2007). Post-hoc 
analysis from the RENAAL (Reduction in End-points in Non-insulin dependent diabetes 
mellitus with Angiotensin 2 Antagonist Losartan) study provided further evidence for 
cardiovascular risk modification with the reduction of proteinuria and this beneficial 
effect was shown to be independent of blood pressure control (de Zeeuw, Remuzzi et 
al. 2004, de Zeeuw, Remuzzi et al. 2004). The results from the analysis of systolic 
hypertension and graft failure confirm the findings of Opelz et al. (Opelz, Dohler et al. 
2005)  showing that persistently elevated systolic blood pressure is associated with 
adverse clinical outcomes after renal transplantation. In fact the data presented in this 
chapter also demonstrates that patients with systolic hypertension can be risk stratified 
based on the presence of low-grade proteinuria. Low-grade proteinuria not only 
identifies high risk hypertensive patients at years-1, 2 and 3 but is also found to be 
significantly associated with worse overall graft survival in patients who are persistently 
hypertensive between years 1 and 3. 
The uPCR method used at SJUH to determine proteinuria will pick up both albumin and 
non-albumin proteinuria. Halimi et al. have shown that 76% of protein excreted in 
patients with low-grade proteinuria is tubular, a finding confirmed by other groups 
demonstrating that tubular proteinuria is associated with worse graft outcomes (Teppo, 
Honkanen et al. 2004, Halimi, Matthias et al. 2007, Schaub, Mayr et al. 2007). This 
may reflect donor derived damage, ischemia reperfusion injury or previous 
immunologically mediated graft damage.  A report from Fotheringham et al. has shown 
that patients with donor specific antibodies (DSA) have significantly more proteinuria 
and that proteinuria develops before the detection of DSA with a higher risk of graft 
loss in patients with more than 0.2g/day of proteinuria (Fotheringham, Angel et al. 
2011). Even in the absence of significant proteinuria with its associated recurrent or de 
novo glomerular disease, patients with proteinuria as low as 150mg/day are shown to 
have diverse pathological findings including acute rejection, IFTA, ATN and arteriolar 
hyalinosis and suffer adverse long-term graft survival (Amer, Fidler et al. 2007). In this 
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analysis, the dominant cause of allograft loss was death with a functioning graft 
although loss of a functioning graft was seen in 32.9%, most of which was attributed to 
allograft rejection.  
This analysis has certain limitations. It is a single centre retrospective cohort study, 
which limits my ability to test a wide variety of clinical parameters due to sample size. 
The data on the usage of ACE inhibitors and ARBs is not presented as it is incomplete 
with the type of antihypertensive drugs not being recorded electronically for many 
patients routinely. Although the commonest cause of allograft function is noted as 
rejection, patients are not routinely biopsied and the diagnosis is derived from the 
registry returns. 
In summary, low-grade proteinuria is shown to be a modifiable risk factor for overall 
graft loss after renal transplantation; resolution of which has led to improved overall 
outcomes. Proteinuria measured as early as three months after transplantation is 
identified as a useful marker to risk stratify patients. More importantly the presence of 
low-grade proteinuria risk stratifies hypertensive renal transplant recipients and 
provides a valuable marker to identify potential patients for therapeutic intervention. 
 
3.3.2 Histological analysis of troubled allografts 
Several recent studies which analysed the phenotype of ‘late at risk’ allografts have 
asserted that chronic antibody mediated rejection (CAMR) is the commonest cause of 
late graft dysfunction and graft loss (Einecke, Sis et al. 2009, El-Zoghby, Stegall et al. 
2009, Gourishankar, Leduc et al. 2010). I have systematically analysed the late 
‘indication’ biopsies performed at SJUH with a view to identify a clinical phenotype 
associated with a specific histological phenotype and adverse graft outcome.  The data 
presented in this chapter shows that late histological phenotype is quite heterogeneous 
irrespective of clinical presentation and allografts present with significant chronic 
damage even in the isolated proteinuria group with a stable serum. In a multivariate 
analysis, the histological phenotype of microcirculatory damage, the hallmark of CAMR, 
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and recurrent GN has been shown to be independently associated with worse graft 
survival. More importantly, the degree of chronic damage was the strongest predictor of 
graft survival after a late biopsy. This finding was replicated again in a subset of 
patients with MCD, thus highlighting the fact that significant chronic damage has 
already been established by the time a biopsy is performed for cause and thereby 
limiting the utility of these biopsies for therapeutic intervention.  
The principle finding from the data is the degree of heterogeneity seen within the 
histological phenotype of late indication biopsies, irrespective of the clinical 
presentation. It might have been expected to see a significant contribution of recurrent 
GN and transplant glomerulopathy in patients presenting with proteinuria. To my 
surprise, the distribution of the various histological classes was comparable across the 
clinical groups. The distribution was not altered even in patients that presented with 
proteinuria of more than a gram per day.  
In an analysis of the Banff lesions based on clinical presentation, a trend towards more 
tubulointerstitial inflammation in patients presenting with creeping creatinine and more 
chronic changes in patient groups with proteinuria was demonstrated. Although several 
groups have reported the histological phenotype of the ‘troubled allograft’, histological 
phenotype based on clinical presentation has not been reported before (El-Zoghby, 
Stegall et al. 2009, Gourishankar, Leduc et al. 2010).  First et al. in the earliest report of  
the histological characteristics of patients presenting with persistent proteinuria have 
highlighted the diagnostic heterogeneity, with the spectrum ranging from transplant 
glomerulopathy (TG) and recurrent GN to renal vein thrombosis (First, Vaidya et al. 
1984).  Recurrent GN and TG as dominant histological phenotypes in patients with 
proteinuria have also been established by other groups as well (Yakupoglu, 
Baranowska-Daca et al. 2004, Amer, Fidler et al. 2007). Indeed, my findings are in 
agreement with these reports.  In addition it is shown that the histology in patients 
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presenting with proteinuria is not significantly different to those presenting with 
creeping creatinine alone.  
Several groups have highlighted the importance of proteinuria in its ability to risk stratify 
patients and speculated that measuring proteinuria potentially identifies a group of at 
‘risk individuals’ who may theoretically benefit from therapeutic intervention (Halimi, 
Laouad et al. 2005, Amer, Fidler et al. 2007). Given the fact that a significant degree of 
chronic damage (defined by ‘ct’, ‘ci’, ‘cv’ lesions) has already been established even in 
patients that present with isolated proteinuria and that clinical presentation as an 
independent variable is not significantly associated with adverse graft survival in the 
multivariate analysis, it is less likely that any potential therapeutic intervention can offer 
significant long term benefit once clinical changes have occurred. This assumption is 
strengthened by the finding that the extent of chronic damage noticed in the all the 
three patient groups is significant with proteinuria groups (P, PC) having slightly worse 
chronic scarring. In the multivariate analysis, the degree of chronic damage was found 
to be the strongest predictor of graft survival after the biopsy.   These findings also 
suggest that the prognostic utility of measuring DSA is limited, once the clinical 
phenotype has altered with the development of proteinuria and/or decline in serum 
creatinine. However this study does not inform the discussion over the utility of DSAs 
as biomarkers at earlier time points, prior to the detection of overt clinical abnormalities. 
Despite the limited overall utility of the detection of DSA in this population, in a small 
sub-group analysis of patients who had detectable lesions of microcirculatory changes 
(‘g’, ‘ptc’, ‘cg’), C4d deposition was shown to be associated with adverse graft survival. 
More importantly, detection of C4d in patients with MI lesion score ≥3 was shown to 
confer the worst prognostic outcome. C4d deposition has been shown to be an 
indicator of humoral allograft damage within the graft and its diagnostic significance lies 
in its specificity (Feucht, Felber et al. 1991, Regele, Bohmig et al. 2002, Mroz, Durlik et 
al. 2003). It is quite possible that the C4d deposition was a result of non-HLA DSA. 
There are certain well documented limitations for the diagnostic utility of C4d, e.g its 
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limited applicability in patients transplanted across the ABO blood group barrier (Haas, 
Rahman et al. 2006) and its lack of sensitivity in patients presenting with late CAMR 
(Gloor, Sethi et al. 2007, Sis, Campbell et al. 2007). Based on the findings presented in 
this chapter, the prognostic utility of C4d in renal transplant recipients cannot be 
discounted, despite these short comings. 
The main limitation to this analysis emerges from its single centre and cross sectional 
nature. The numbers in each clinical group were small and this was especially evident 
in the sub-group analysis. Furthermore, the impact of modifications in treatment has 
not been accounted for in the analysis of graft survival. 
The disjunction between clinical presentation, histological changes and the resultant 
clinical outcomes in patients who underwent an ‘indication biopsy’ asks for an 
alternative plan of investigation in renal transplant recipients. Although protocol 
biopsies might be considered, owing to their limited diagnostic yield (Mengel, Bogers et 
al. 2005), modifications are necessary. For example, genomic analysis of these 
biopsies could be considered as there is accumulating evidence that genomic 
transcripts offer significant prognostic information (Einecke, Reeve et al. 2010, 
Halloran, Reeve et al. 2013). Higher risk group patients might be identified by the 
detection of DSAs in the serum, before any clinical abnormalities occur, since they 
have been shown to be powerful biomarkers for poor outcomes (Lachmann, Terasaki 
et al. 2009, Wiebe, Gibson et al. 2012). However adoption of this process requires 
consensus over the best form of treatment when the DSAs are detected. Finally, it is 
hypothetically possible that if patients were identified and biopsied at lower levels of 
proteinuria, earlier histological picture with less scarring and chronic changes may 
emerge and this sub-group of patients may potentially benefit from therapeutic 
intervention.   
In summary the data presented here describes the histological heterogeneity in late 
‘indication biopsies’ and the striking lack of correlation between histological and clinical 
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phenotypes. Importantly, the histological rather than clinical phenotype has been 
shown to be of significant prognostic utility.  
In conclusion, the data presented in this chapter shows that proteinuria, although an 
early and reversible predictor for graft outcomes has limited diagnostic and prognostic 
significance once the damage to the graft with the resultant chronic changes ensues. 
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Chapter-4: Human Bregs and 
troubled renal allografts  
4.1 Introduction 
This chapter presents results that characterize immune regulation by B lymphocyte 
subsets in healthy volunteers and renal transplant recipients based on their allograft 
histology. By comparing them to a random sample of patients with stable graft function, 
I will illustrate the potential significance of B cell mediated immune regulation in renal 
transplantation. 
 It is important to understand the role of B lymphocytes as regulators of the immune 
response in the context of renal transplantation since there is emerging evidence for an 
immune signature in operationally tolerant patients based on the peripheral blood B 
lymphocytes (Sagoo, Perucha et al. 2010). Recent studies have uncovered several 
functions of B lymphocytes beyond the production of antibodies including antigen 
presentation, co-stimulation, germinal centre organisation and cytokine secretion 
(Janeway, Ron et al. 1987, Ron and Sprent 1987, Harris, Haynes et al. 2000, 
Shlomchik, Craft et al. 2001, Yanaba, Bouaziz et al. 2008). An immunoregulatory role 
for B cells, first described in murine colitis (Mizoguchi, Mizoguchi et al. 1997), has since 
been supported by studies demonstrating that B cell depletion or deficiency can worsen 
disease, while transfer of B cell subpopulations can  suppress inflammatory responses 
in experimental models (Fillatreau, Sweenie et al. 2002, Mizoguchi, Mizoguchi et al. 
2002, Mauri, Gray et al. 2003, Hussain and Delovitch 2007, Yanaba, Bouaziz et al. 
2008, Ding, Yeung et al. 2011). Such regulatory B cell (Breg) activity is predominantly 
IL-10 dependent. However, as yet there is no specific marker for Bregs. In various 
murine models, B cells expressing phenotypes such as CD5+ (B-1a) (Silverman, 
Srikrishnan et al. 2008), CD1dhiCD5+ (Yanaba, Bouaziz et al. 2008), CD21hiCD23lo 
(marginal zone) (Gray, Miles et al. 2007), CD21hiCD23hiCD24hiCD1dhi (transitional) 
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(Evans, Chavez-Rueda et al. 2007) and TIM-1+ (Ding, Yeung et al. 2011), have been 
shown to express IL-10 and exhibit regulatory activity. It is noteworthy that even in 
these “enriched” subsets, IL-10+ B cells remain a minority and it is less well appreciated 
that these same subsets may contain cells that express other cytokines, some of which 
are conventionally considered pro-inflammatory (Fillatreau, Sweenie et al. 2002, 
Mizoguchi, Mizoguchi et al. 2002, Evans, Chavez-Rueda et al. 2007, Blair, Chavez-
Rueda et al. 2009). 
In humans, CD19+CD24hiCD38hi Transitional B cells (TrB) isolated from peripheral 
blood, inhibit inflammatory cytokine expression by anti-CD3 stimulated CD4+ T cells in 
vitro (Blair, Norena et al. 2010). Such Th1 inhibition was dependent on the release of 
IL-10 and the engagement of CD80 and CD86.  TrB from patients with Systemic Lupus 
Erythematosis (SLE) were defective in IL-10 expression, and were unable to suppress 
Th1 responses in vitro (Blair, Norena et al. 2010). In contrast  another study 
demonstrated regulatory activity in human B cells, defined by IL-10 expression, was 
mostly represented in the CD19+CD24hiCD27+ “memory” subpopulation (Iwata, 
Matsushita et al. 2011). However, in this study, IL-10 expression by B cells in patients 
with autoimmune disorders was increased compared to healthy controls.  This raises 
the possibility that human Breg populations are heterogeneous similar to their T cell 
counterparts. However these findings cast doubt upon the definition of a functional 
property of a cell subset purely based on one cytokine - “the master regulator-IL-10”. 
Although human Bregs were defined on the basis of IL-10 expression alone, the 
significance of potential pro-inflammatory cytokine release by B cells with the same 
phenotype has not been considered. Despite limited data that human Bregs can inhibit 
Th1-type cytokine production by T cells, their effect on Th2-type cytokine expression is 
unclear.  Such insights may aid further characterization of Breg subsets and clarify 
discrepancies in B cell “function” in inflammatory settings such as chronic antibody 
mediated rejection.  
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In this chapter, results that help further characterize B cells in human peripheral blood, 
based upon both pro-inflammatory (TNF-) and anti-inflammatory (IL-10) cytokine 
expression will be discussed. Next  the ability of various B subsets to regulate either 
Th1 or Th2 responses from autologous T cells in vitro will be analysed. B subsets will 
also be studied in renal transplant recipients with either stable graft function or 
dysfunction with histological evidence of CAMR, with a view to understand the role of B 
cell mediated immune regulation in renal transplantation. 
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4.2 Results 
4.2.1 Human B cell subsets 
PBMCs from 15 healthy volunteers were analysed according to surface expression of 
CD19, CD24, CD38 and CD27 as shown in Figure 34. Three distinct B cell (CD19+) 
subsets were identified including CD19+CD27-CD24hiCD38hi (transitional B; TrB cells), 
CD19+CD24hiCD27+ (CD24hi memory/memory B cells; a minority of memory B cells 
were CD24-) and CD19+CD27-CD24+CD38+ (mature naïve B cells).  
 
 
 Figure 34: Definition of human B cell subsets 
 
 
CD19+CD5hiCD1dhi B cells were initially described in murine literature as B regulatory 
cells by their ability to synthesize and secrete IL-10.  
Next the distribution of these cells within the three B cell subsets was assessed. 
Interestingly, the majority of the CD5hiCD1dhi B cells were contained within the TrB 
population as shown in Figure 35. The next step was to see if the phenotypic 
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differences match cytokine expression by these cells. To address this, these B cell 
subsets were analysed for cytokine expression. 
 
 
 
Figure 35: CD1d
hi
CD5
+
 B cells and the three B subsets.  
Representative dot plots of CD1d
hi
CD5
+
 B cells (CD19 gate; left panel), analysed for their 
expression of CD24, CD38 and CD27 (right panels) and cumulative data (mean ± SEM, n=5 
subjects; *P<0.0001, **P=0.0001, ***P=0.005 by ANOVA).  
 
4.2.2 Stimulation of B lymphocytes for cytokine expression 
B cells were isolated from PBMCs by MACS magnetic bead separation and were 
stimulated for 5hrs with PMA, ionomycin and Brefeldin-A (PIB) or for 48hrs with CPG 
with or without CD40L. PIB was added to these experiments for the last 5hrs of the cell 
culture.  Figure 36 shows that PIB caused the least expression of IL-10 whilst a 
combination of CPG and CD40L caused maximal expression. It is noteworthy that the 
same stimuli that led to maximal expression of IL-10 by B cells also caused an even 
higher expression of TNF-.   Next, other potentially pro-inflammatory cytokines were 
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analysed using the same stimulation protocol. At 48hrs whilst there was strong 
expression of both IL-10 and TNF-, the percentage positivity for both IFN- and IL-17 
was minimal (Figure 37). Based on these initial experiments, it was decided to explore 
the cytokine expression of both IL-10 and TNF- in the three B subsets as described in 
section 4.2.1. 
 
 
Figure 36: Stimulation of B lymphocytes  
Representative of 3 individual experiments. PBMC and CD19+ gates were selected and CD19+ 
cells analysed or various cytokines after stimulation by appropriate stimulus as shown for 48hrs 
 
 
 
 
 
 
 
 Figure 37: Analysis of B cell expression of various cytokines by flow cytometry  
Representative of 3 individual experiments. Purified B cells were stimulated for 48hrs and 
analysed for various cytokines on the B cell gate. 
TNF- IFN- 
132 | P a g e  
 
4.2.3 Cytokine polarization-B cell subsets 
Magnetic bead separated B cells were stimulated with CPG and CD40L as described 
before. The three B cell subsets including the transitional, memory and naïve cells 
were analysed for the expression of both IL-10 and TNF-. Intracellular staining for IL-
10 demonstrated that a significantly higher proportion of both memory and TrB cells 
express IL-10 compared to naïve B cells (Figure 38A-B). These same B cell subsets 
expressed TNF- at a surprisingly high frequency, approximating or even surpassing 
that of IL-10 expression. TrB cells contained the fewest TNF-+ B cells (Figure 38C-D). 
IL-10/TNF- ratio was used as a measure of cytokine polarization. Such a ratio takes 
into account the overall cytokine balance either in a pro or anti-inflammatory direction, 
combining the results of both IL-10 and TNF- expression by any cell population.   
Taken together, TrB cells had the highest IL-10/TNF- ratio whilst naïve B cells had the 
lowest ratio (Figure 38E). This indicates that the CD24hiCD38hi TrB population exhibited 
increased cytokine polarization towards IL-10 relative to other B cell subpopulations. 
When the B cells were analysed for the expression of both IL-10 and TNF- at multiple 
time points, the nature of cytokine polarization within these B subsets remained stable 
when analysed at 12, 24 and 48hrs (Figure 38H). 
So far the results demonstrated that as a subset, TrB cells had the most anti-
inflammatory cytokine profile upon in vitro stimulation. However, individual cells can 
potentially secrete and synthesize more than one cytokine. To address this, individual 
B cells within each subpopulation were examined to see if they could express more 
than simply IL-10, using dual-intracellular staining after cell stimulation. This analysis 
revealed that a significant fraction of IL-10+ B cells also co-express the pro-
inflammatory cytokine, TNF-Whilst TrBs showed the most enhanced IL-10 
expression alone, memory B cells had dominant dual  IL-10+ and TNF-+ populations. 
Both memory and naïve B cells were enriched for pure TNF-+ cells (Figure 38F-G). 
These experiments distinguished both memory and transitional cells with similar levels 
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of positivity for IL-10. The proportion of IL-10 positive cells that were also TNF- 
positive and the total number of TNF- positive cells within the memory cell population 
makes them less polarized towards an anti-inflammatory phenotype in vitro when 
compared to the TrB cells.   
 
 
Figure 38: B cell subsets and cytokine analysis.  
(A)Scatter plots showing IL-10 
+
 cells within the respective B subsets after 48hr stimulation with 
CPG CD40L and PIB. (B) Bar chart representing cumulative results of IL-10 expression in 15 
healthy volunteers expressed as mean ± SEM (* TrB vs. naïve, P=0.0002; memory vs. naïve 
P<0.0001, ANOVA). (C)  Scatter plots showing TNF- 
+
 cells within the respective B subsets. 
(D) Bar chart representing cumulative results of TNF- expression in 15 healthy volunteers 
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expressed as mean ± SEM (**TrB vs. memory, P=0.001; TrB vs. naïve, P=0.006, ANOVA). (E) 
Bar chart representing cumulative mean ± SEM of IL-10/TNF- ratio across the three B subsets 
in 15 healthy volunteers (***TrB vs. memory, P=0.002; ****TrB vs. naïve, P<0.0001, ANOVA). 
(F) Scatter plots showing the analysis by dual staining for both IL-10 and TNF-. (G) Bar charts 
showing cumulative results expressed as mean± SEM in 6 healthy volunteers for IL-10, dual 
and TNF- expression by B subsets (#TrB vs. naïve, P<0.0001; TrB vs. memory, P=0.01; ## 
memory vs. naïve, P<0.0001; memory vs. TrB, P<0.0001; ###TrB vs. naïve, P=0.0002; TrB vs. 
memory, P=0.0004). (H) Graphical representation of IL-10/TNF- ratio at 12, 24 and 48 hrs in 5 
independent healthy volunteers. 
 
As the stimulation of B cells can alter their phenotype, cytokine expression by B cell 
subsets was re-examined with isolation prior to stimulation in vitro. FACS (Flow 
Assisted Cell Sort)-purified B cell subsets were stimulated with CpG and CD40L for 
48h, and IL-10 and TNF-in culture supernatants measured by bead based ELISA. 
The results in Figure 39 parallel those in Figure 38, showing the highest ratio of 
secreted IL-10 to TNF-being produced by the TrB cell subset.  
 
 
 
 
 
 
 
 
Figure 39: IL-10/TNF- ratios obtained from purified B cell subsets   
FACS sorted CD24
hi
CD38
hi
, CD24
hi
CD27
+
 and CD24
+
CD38
+
 B cells were stimulated with CPG 
and CD40L for 48hrs and supernatants were collected without the addition of PIB. The graphs 
represent the ratio of the concentration of IL-10 and TNF- in the supernatants for the 
respective cell subsets (n=11 subjects for each cell type, * TrB vs. memory, P=0.049; ** TrB vs. 
naïve, P=0.0002, ANOVA). 
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In summary, these experiments showed that CD24hi CD38hi TrB cells are most 
polarized towards an anti-inflammatory cytokine profile when analysed as a subset and 
when re-assessed on a per cell basis.  
 
4.2.4 TIM-1
+
 B cells and their significance 
T cell Ig domain and Mucin domain-1 (TIM-1) protein belongs to a family of co-
stimulatory molecules that play an important role in the effector differentiation of CD4 T 
cells (Kuchroo, Dardalhon et al. 2008).  TIM-1 has recently been shown to be 
expressed preferentially on murine B cells and to be an inclusive marker for IL-10+ 
murine B regulatory cells (Ding, Yeung et al. 2011).  
TIM-1 expression on the surface of the B cells had next been examined and  both IL-10 
and TNF-expression on TIM-1+ B cells was assessed after stimulation with CpG and 
CD40L. As seen in Figure 40, TIM-1 expression by human B lymphocytes is minimal 
and although these cells stain for both IL-10 and TNF-when stimulated by CD40L 
and CPG, Further experiments were not possible owing to the very small numbers of 
TIM-1+ cells. TIM-1 expression on the B cell surface did not alter even when cells were 
stained prior to in vitro stimulation. 
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 Figure 40: TIM-1, IL-10 and TNF expression by B cells in healthy volunteers 
TIM1+ B cells were analysed from the B cell gate for both IL-10 and TNF-a in comparison to a 
negative control 
 
 
4.2.5 In vitro assessment of regulatory properties of B cell subsets 
To determine the regulatory capacity of each B cell subset, FACS-purified populations 
(CD19+CD24hiCD38hi, CD19+CD24hiCD27+, CD19+CD24+CD38+) from healthy 
volunteers were examined for their ability to inhibit anti-CD3 stimulated autologous 
conventional (CD4+CD25-) T cell (Tconv) cytokine expression. Tconv co-cultured with 
an equal number of CD4+CD25hi regulatory T cells (Tregs) served as a positive control. 
All of the B, Tconv and Treg cells were initially purified by negative selection using 
Miltenyi magnetic beads prior to cell culture.  Sorting gates and purities of the B cell 
subsets are shown in Figure 41. 
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Figure 41: Representative sort gates and purities for B cell subsets.   
Dot plots showing B cell subsets prior to cell sorting (CD19 gate). Post-sort purity of CD19+ 
cells (lymphocyte gate). Post-sort purities of B cell subsets (CD19 gate) 
 
After 72hrs of cell culture which included a period of stimulation with PIB for the last 
6hrs, cells were washed and analysed by flow cytometry for CD4 T cell expression of 
TNF-, IFN- and IL-4 in the cell culture conditions mentioned above. TrB cells 
significantly suppressed TNF- and IFN- expression by autologous Tconv whilst 
having no effect on IL-4 expression (Figure 42). Selective suppression of pro-
inflammatory cytokine expression by TrB cells was comparable with that mediated by 
Tregs. Neither naïve nor memory B cells were nearly as potent. None of the cell 
populations had a significant effect on IL-4 expression by Tconv. The summary of 
results for B cell mediated regulation of T cell cytokines is shown in Figure 43. 
 
CD19+CD24hiCD27+ 
(memory) 
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The addition of neutralizing anti-IL-10 antibody to TrB co-cultured with autologous 
Tconv cells restored both TNF- (Figure 44A-B) and IFN- expression (Figure 44C-D) 
by CD4 cells to the baseline levels observed when Tconv cells were cultured alone.  
Thus, regulatory activity of TrBs was IL-10 dependent. The influence of TNF-on 
regulatory function of memory or naïve B cells was analysed by adding neutralizing 
antibodies to its receptors, TNFR1 and TNFR2, during co-culture with Tconv (Figure 
44). Neutralizing TNFR1 increased the ability of memory B cells to suppress TNF- 
and IFN- expression to levels comparable to those obtained with TrBs. Neutralization 
of TNFR2 was somewhat less effective than neutralizing TNFR1. Neutralizing TNFR1 
and TNFR2 on naïve B cells also increased suppression, but the effect was much 
smaller than the effect on memory B cells, perhaps due to lower IL-10 expression by 
the naïve subset. In summary, neutralizing IL-10 inhibited the regulatory effects of TrBs 
less regulatory whilst blocking TNF receptors significantly improved the suppressive 
capacity of both memory and naïve B cells. This highlights the significance of both IL-
10 and TNF- in regulation of CD4 T cells by B cell subsets. 
These results match the initial finding of an anti-inflammatory cytokine polarization 
within the TrB cells and indirectly confirm that B cell subset IL-10 and TNF- 
expression (IL-10/TNF- ratio) correlate with suppressive function. To summarize so 
far, TrB cells have been shown to have the strongest in vitro anti-inflammatory 
(regulatory) potential and IL-10/TNF- ratio serves as a good marker to assess the 
ability of a cell subset to actively regulate immune responses in vitro. 
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Figure 42: Assays of B cell regulatory function  
Representative dot plots showing the frequency of TNF-, IFN-, IL-4 expression amongst T conv cells in the respective cell cultures (n=6). Cells were gated on CD4 
and various representative culture conditions demonstrated 
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Figure 43: Cumulative results of the B cell suppression assays. 
 Bar graphs showing the cumulative (n=6) percentage stimulation/inhibition of the frequency of 
TNF-
+
, IFN-
+
, or IL-4
+ 
cells  after culture with Tregs or B cell subsets. Cumulative results 
expressed as mean± SEM. (*TrB vs. memory, p<0.05; ** TrB vs. naive, p=0.03, #TrB vs. 
memory, p=0.02; ## TrB vs. naive, p=0.01). Results compared by ANOVA with Dunnet test for 
multiple comparisons. 
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Figure 44: IL-10/TNF- ratio predicts the capacity of the B subsets to suppress 
autologous Th1 cytokines 
Magnetic bead enriched Tconv cells (CD4
+
CD25
-
) were stimulated for 72hrs with plate bound 
anti-human CD-3 (0.5µg/ml) in the presence of TrB (CD24
hi
CD38
hi
) B cells, CD24
hi
CD27
+
 
memory B cells, CD24
+
CD38
+
 naïve B cells or CD4
+
CD25
hi
 Treg cells with either an isotype 
control or neutralizing antibodies to IL-10, TNFR1, TNFR2 or a combination of TNFR1 and 
TNFR2. PIB was added for the last 6hrs of cell culture. Data derived from 3 healthy volunteers. 
(A, C) Representative scatter plots showing the detection of TNF-and IFN- by intra cellular 
staining when T conv were cultured alone or in the presence of TrB, memory and naïve B cells 
with matched isotype controls or neutralizing antibodies to IL-10, TNFR1 or TNFR2. (B, D) 
Cumulative percentage stimulation/inhibition of the frequency of TNF-
+
 ($ P=0.005, *P=0.02, 
**P=0.1, #P=0.2, ##P=0.8) and IFN-
+
 ($ P=0.03, *P=0.008, **P=0.04, #P=0.2, ##P=0.1) T cells 
(mean ± SEM) after culture with the respective B subsets and neutralizing antibodies. Statistical 
analysis was by paired t-test. 
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4.2.6 Analysis of the subsets of CD24
hi
CD38
hi
 TrB cells 
In experimental animals and human beings, TrB cells have been shown to contain 
distinct sub-populations (T1 and T2) based on the intensity of surface expression of 
CD24 and CD38. To pursue further phenotypic characterization of these cell subsets, 
phenotypic analysis by multi-color flow cytometry was performed in 5 healthy 
volunteers. T-1 cells were defined as CD19+CD24+++CD38+++CD27- whereas T-2 cells 
as CD19+CD24++CD38++CD27-. In comparison, mature naïve B cells were labeled as 
CD19+CD24+CD38+CD27- (Figure 45A). Further analysis of the cell surface phenotype 
of these sub-population revealed that T-1 cells were IgMhi IgD+ CD5hi CD10hi CD20hi 
CD40hi CD86hi CD23+ CD1dhi CD27-; whereas T2 cells expressed CD20int IgD+ IgM+ 
CD1d+ CD5lo CD10lo CD23+ CD40+ CD86lo (Figure 45B).  Interestingly, a combination of 
CD10 and IgM were able to clearly distinguish the T-1 subpopulation from the other two 
subsets of naïve B cells (Figure 45C) 
Cytokine expression and functional differences between these transitional B subsets 
remain unknown. To address this, (CD19+) B lymphocytes were enriched with magnetic 
beads and the enriched cells were stimulated as described in the previous sections.  
Analysis of intracellular cytokine expression for IL-10 and TNF- reveals that a similar 
percentage of T1 and T2 cells express IL-10 (Figure 46 A, B). A much smaller 
percentage of mature naïve B cells are positive for IL-10 in comparison to both T1 and 
T2 subsets. However, T1 cells have a lower proportion of TNF-+ cells leading to a 
higher IL-10/TNF- ratio in comparison to both T2 and mature B cells (Figure 46 C, D).  
Next, the differences between individual TrB cells were explored with regard to 
simultaneous expression of both IL-10 and TNF-, using dual-intracellular staining 
(Figure 47). This analysis revealed that a significant fraction of T1, T2 and mature naïve 
B cells co-expressed both IL-10 and TNF-. Whilst T-1 cells had the highest frequency 
of B cells expressing IL-10 alone, naïve B populations were enriched for cells 
expressing TNF- alone. 
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Figure 45: Phenotypic characterization of transitional B subsets 
(A). Human B cells are classified into transitional T1, T2 and mature naïve based on 
the surface expression of CD19, CD24, CD38 and CD27. (B). When the three 
subsets of cells are analyzed for the expression of other markers, T1 cells are 
characterized as IgM
hi 
IgD
+ 
CD5
hi 
CD10
hi 
CD20
hi 
CD40
hi 
CD86
hi 
CD23
++ 
CD1d
hi 
CD27
- 
; 
T2 cells as CD20
int 
IgD
+ 
IgM
+ 
CD1d
+ 
CD5
lo 
CD10
lo 
CD23
+ 
CD40
+ 
CD86
lo 
; and mature 
cells as CD20
+ 
IgM
+ 
IgD
+ 
CD5
- 
CD1d
lo 
CD10
- 
CD23
+ 
CD40
+ 
CD86
lo
.  (C). A 
combination of CD10 and IgM are able to clearly distinguish T-1 subpopulation from 
the other two subsets of naïve B cells. Figures are representative of 5 independent 
experiments in healthy volunteers. 
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 Figure 46: Functional characterization of transitional B subsets 
Magnetic bead enriched CD19+ B cells are stimulated with CpG and CD40L for 48hrs with the addition of PIB in the last 5 hrs of culture. (A). Scatterplots representing the IL-10 and 
TNF expression after intracellular staining within T1, T2 and mature subsets in a representative healthy volunteer. (B). Cumulative results of the percentage of IL-10 + cells within 
each subset (n=15, *P<0.0001 mature subset compared to either T1 or T2). (D). Cumulative results of the percentage of TNF + cells within each subset (n=15, **P=0.09, T1 vs. T2; 
***P<0.0001, T1 vs. Mature & P=0.02, T2 vs. mature). (E). Cumulative results of the IL-10/ TNF ratio within each subset (n=15, # T1 vs. T2, P<0.0001; ## T1 vs. mature, P<0.0001; 
T2 vs. mature, P=0.0001). The bars in each graphic represent mean whilst the error bars represent SEM. Statistical analysis was by one way ANOVA with Tukey post hoc correction 
for multiple comparisons. 
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Figure 47: Dual intracellular staining for cytokines - transitional B subsets 
Magnetic bead enriched CD19+ B cells are stimulated with CpG and CD40L for 48hrs with the 
addition of PIB in the last 5 hrs of culture. Both IL-10 and TNF are analysed by dual cytokine 
staining (representative of 5 individual experiments). Scatter plots from T1, T2 and naïve 
subsets with either isotype control or the respective cytokines are demonstrated. The bar chart 
summarizes the cumulative results (mean ± SEM). *T1 vs. mature naïve, P<0.0001; ** T1 vs. 
mature naïve, P<0.0001; T1 vs. T2, P=0.04. Analysis was by ANOVA with Dunnet’s correction. 
T1 and T2, respective TrB subsets; M, mature naïve B subset 
 
4.2.7 Analysis of B cells in renal transplant recipients 
Having established the regulatory properties of TrB cells in normal subjects, I next 
investigated whether quantitative differences exist in renal transplant patients with 
stable function versus chronic antibody mediated rejection (CAMR). B cells from 
healthy volunteers (HV; n=15), were compared to 88 renal allograft recipients.  Patients 
were divided into those with; stable function (S; n=40); graft dysfunction with no 
histological evidence of CAMR (GD-NR; n=22); and graft dysfunction with a histological 
phenotype of CAMR (GD-R; n=26) based on serial serum creatinine measurements, 
assessment of urine samples for proteinuria, anti-HLA antibody screening and graft 
IL10+ and TNF-+ 
T1 
T2 
M 
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histology. Clinical parameters of these subjects are detailed in Table 13. Significant 
differences between the groups included a longer time since transplant for GD-NR and 
GD-R groups and a higher usage of maintenance prednisolone for immunosuppression 
in the GD-R group. Histological classification with Banff categories of the GD-R group 
is detailed in Figure 48. The GD-R group was characterized by the phenotype of chronic 
antibody mediated rejection (CAMR) with evidence of either glomerulitiis or peritubular 
capillaritis or transplant glomerulopathy with or without the deposition of C4d in the 
peritubular capillaries.  80% of these patients had a donor specific antibody detected in 
their serum at the time of the biopsy.  Interestingly, 25% of these patients also had a 
component of T cell mediated rejection detected in their biopsies (tubulitis or interstitial 
inflammation). All of the grafts in this group had a significant degree of scarring as 
demonstrated by high ‘cv’, ‘ct’ and ‘ci’ scores. 
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 Figure 48: Summary of Banff scores of the biopsies for GD-R group.  
These findings show that the biopsies had a significant degree of chronic damage as suggested by ct, cv and ci scores. g-glomerulitius; ptc-peritubular capillaritis; 
cg-chronic transplant glomerulopathy; C4d-C4d deposition in the peritubular capillaries; mm-mesangial expansion; t-tubulitis; v-endothelitis; i-interstitial inflammation; 
ti-total inflammation; ct-tubular atrophy; cv- fibrointimal thickening; ci-interstitial fibrosis; aah-arteriolar hyalinosis. (0-absent, 1-mild & >1-moderate to severe). 
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Table 13: Patient Characteristics (healthy volunteers, stable group and GDNR/GDR) 
 
Clinical parameter HV S GD-NR GD-R P-value 
Number (n) 18 41 22 25  
Age in yrs. (95% CI) 45 (41-49) 49 (44-53) 51 (45-58) 49 (43-55) Ns 
Gender-male% 61% 66% 64% 64% Ns 
Ethnicity-Caucasian% 68% 91% 92% 95% 0.03
~
 
Primary Renal Diagnosis     Ns 
Glomerulonephritis n/a 15% 45% 28% 0.01*** 
Hypertension/diabetes n/a 15% 9% 4%  
Inherited n/a 15% 14% 16%  
Others
#
 n/a 55% 32% 52%  
Transplantation details      
Graft number n/a 1.06(1-1.15) 1.26 (1.04-1.48) 1.1 (0.95-1.26) Ns 
Type of allograft donor     Ns 
DCD%
##
 n/a 12% 14% 12%  
DBD%
##
 n/a 68% 68% 64%  
Live%
##
 n/a 20% 18% 24%  
Donor cause of death     Ns 
Trauma% n/a 15% 29% 20%  
Vascular% n/a 77% 47% 53%  
Other% n/a 8% 24% 27%  
HLA mismatches n/a 2.6 (2.1-3.1) 1.6 (1.0-2.3) 2.9 (2.5-3.5) 0.02**** 
Donor age in yrs (95% CI) n/a 39 (33-45) 47 (38-55) 42 (35-49) Ns 
Allograft function      
Age of the graft in months (IQR)
###
 n/a 56 (43-78) 78 (61-128) 83 (51-153) 0.04* 
Best eGFR achieved (95%CI) n/a 74( 69-79) 59 (48-69) 66 (56-76) 0.01*** 
e-GFR in ml/min (95% CI) n/a 65 (61-70) 31 (25-36) 29( 22-36) <0.0001** 
Proteinuria g/L (95% CI) n/a 0.17 (0.13-0.20) 0.84 (0.51-1.18) 1.47 (0.67-2.26) 0.009** 
Maintenance Immunosuppression      
% on CNI
####
 n/a 97% 92% 83% Ns 
% on MMF
@
/Azathioprine n/a 71% 76% 78% Ns 
% on Prednisolone n/a 7% 18% 60% 0.01
~~
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HV- Healthy Volunteers; S-Stable allograft function; GD-NR-Graft dysfunction-no rejection, GD-R-Graft dysfunction-rejection 
 ~significant differences between HV and the rest; ~~ significant differences between GD-R and the rest 
*significant difference between group-S and GD-R; **significant difference between S and GD-NR; S and GD-R; ***significant difference between S and GD-
NR; ****significant difference between GD-NR and other groups (S vs. GD-NR, p=0.02; GD-NR vs. GD-R, P=0.007). #others include obstruction, chronic 
pyelonephritis, unknown causes; ##DCD-Donation after Circulatory Death donor, DBD-Donation after Brain Death donor, Live-live donor; ###. As graft age 
(vintage) is extremely skewed, median and inter quartile ranges have been presented and data analysed by non-parametric test; ####CNI-Calcineurin 
inhibitors- ciclosporin or tacrolimus. @MMF-Mycophenolate mofetil/ Mycophenolate sodium; All categorical variables were compared using Chi-square test. 
All continuous variables are analysed using ANOVA with Tukey post-hoc test for multiple comparisons if normally distributed and Kruskal-Wallis test for 
variables with skewed distribution. Adjusted P values for multiple comparisons after the post-hoc tests are presented, P<0.05 is significant. 
  
 
DSA- HLA Class-1 % positive n/a 9% 2.5% 48% <0.001
~~
 
DSA-HLA Class-2 % positive n/a 0% 2.5% 36% <0.001
~~
 
Late cellular rejection% n/a 0% 23% 25%  
Allograft Pathology n/a n/a    
GN n/a n/a 27%   
Others n/a n/a 32%   
IFTA (scarring) n/a n/a 23%   
Viral Infection   9%   
CNI toxicity n/a n/a 9%   
Chronic antibody mediated 
changes 
     
Glomerulitis (g) n/a n/a 0 44%  
Transplant glomerulopathy (cg) n/a n/a 0 64%  
Peritubular capillaritis (ptc) n/a n/a 0 36%  
Peritubular capillary C4d 
deposition 
n/a n/a 0 48%  
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 4.2.7.1 Analysis of B lymphocyte subsets-Patient groups 
All three patient sub-groups along with healthy volunteers were assessed for their B 
lymphocyte phenotype (Figure 49). Absolute lymphocyte numbers obtained by trucount 
bead analysis on flow cytometry showed that there was a trend towards the patient 
groups being more lymphopenic, though only the GD-R group was significantly 
different from the healthy volunteers (Figure 50A). Further trucount bead analysis of the 
B cells revealed that both GD-NR and GD-R groups had significantly lower B cells 
either when analysed as a percentage of the lymphocytes or as an absolute number 
per microliter of whole blood (Figure 50B-C). It is noteworthy that the two graft 
dysfunction groups were not significantly different with regards to their B cell numbers 
as a whole. There was a trend in the healthy volunteers towards a lower B 
naïve/memory ratio suggesting a relatively higher B memory cell number. This was 
evident again when healthy volunteers were found to have higher numbers of 
CD24hiCD27+ memory B cells (Figure 50D-F). Although slightly lower than healthy 
volunteers, stable patients had no significant change in the quantity of TrB cells 
(P=0.4). GD-NR group showed a trend towards lower percentage of, and a significantly 
lower absolute number of, TrB cells compared to HV and S patients. Compared to GD-
NR patients, those with CAMR (GD-R) displayed a further decrease in the percentage 
of TrB cells and their absolute TrB number was not different from GD-NR group (Figure 
50 G-H). This was reflective of the B cell lymphopenia in the GD-NR group. Thus, 
transplant patients with the phenotype of CAMR showed evidence of quantitative 
decreases in B cells with regulatory potential compared to those with stable graft 
function and to a certain extent, the GD-NR group as well.
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Figure 49: B lymphocyte phenotype in the 
patient groups 
Representative scatter plots demonstrating 
CD24
hi
CD38
hi
 TrB cells, CD24
hi
CD27
+
 
memory B cells and IgD
+
 CD27
-
 naïve B cells 
in healthy volunteers (HV), stable patients 
(Stable), graft dysfunction- non-immunological 
group (GD-NR) and graft dysfunction-CAMR 
group (GD-R) 
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Figure 50: Analysis of B lymphocyte subsets 
in the patient groups 
Comparison of absolute number of (A). lymphocytes per 
l of whole blood (*P=0.003). (B). % of CD19
+ 
B cells (* 
HV vs. GD-NR, P=0.007; S vs. GD-NR, P<0.0001; **HV 
vs. GD-R, P=0.08; S vs. GD-R, P=0.004). (C). absolute 
number of B cells across the groups (*HV vs. GD-NR, 
P<0.0001; S vs. GD-NR, P=0.002; **HV vs. GD-R, 
P<0.0001; S vs. GD-R, P=0.003). (D). B naïve/memory 
ratio (E). % CD24
hi
CD27
+
 B cells (*HV vs. S, P=0.05) 
(F). Absolute number of 24
hi
CD27
+
 B cells (* HV vs. S, 
P=0.0002; HV vs. GD-NR, P<0.0001; HV vs. GD-R, 
P=0.0001.  (G). % TrB cells (* HV vs. GD-NR, P=0.01; 
GD-NR vs. GD-R, P=0.05; **HV vs. GD-R, P<0.0001; S 
vs. GD-R, P<0.0001). (H). absolute number of TrB cells 
(* HV vs. GD-NR, P=0.0001; S vs. GD-NR, P=0.001; 
**HV vs. GD-R, P<0.0001; S vs. GD-R, P<0.0001). 
Statistical analysis by one way ANOVA and post hoc 
correction by Tukey’s test for multiple comparisons. The 
bars in the graphs represent mean whilst the error bars 
represent SEM. HV, healthy volunteers; S, stable; GD-
NR, graft dysfunction-no rejection; GD-R, graft 
dysfunction-CAMR 
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4.2.7.2 Analysis of TrB subsets - patient groups 
Within the transitional B cell population, the balance of T1 and T2 TrB cells was 
examined in healthy volunteers (HV; n=14) and renal allograft recipients (n=88). The 
trends for both T1 and T2 subsets followed that of the entire TrB population with the 
percentage of T1 and T2 subsets from S patients being slightly lower to those from HV; 
GD-NR patients with a trend towards lower proportion of T1 and T2 subsets compared 
to HV and S patients and GD-CAMR with the lowest percentage of T1 and T2 cells 
when compared to S patients. When the T1 and T2 balance within the TrB population 
is assessed in the patient groups using the ratio of T1/T2, the ratio of T1/T2 in S 
patients is comparable to HV and GD-NR patients have a significantly lesser ratio when 
compared to the group-S. Again, GD-CAMR patients have a significantly lower ratio of 
T1/T2 when compared to all the other patient groups (Figure 51). 
 
 
Figure 51: TrB subsets in patient groups 
Comparison of the proportion of T1 cells in the study groups (# GD-R vs. S, P<0.0001). Whilst 
there is a trend towards a lower percentage of T1 cells in S when compared to HV; GD-NR 
compared to S and GD-NR compared to GD-R, these results did not reach statistical 
significance.  Comparison of the proportion of T2 cells in the study groups (## GD-R vs.S, 
P<0.0001; $GD-NR vs. GD-R, P=0.03). Whilst there is a trend towards lower percentage of T2 
cells in S when compared to HV and GD-NR compared to S, these results did not reach 
statistical significance. (E). Comparison of the ratio of T1/T2 cells in the study groups (### GD-
R vs. S,P<0.0001; ### GD-R vs.GD-NR, P=0.02; $$, GD-NR vs. S, P=0.04).The bars in each 
graph represent mean whilst the error bars represent SEM. Statistical analysis is by one way 
ANOVA with Tukey post hoc correction for multiple comparisons. 
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4.2.7.3 Analysis of cytokine polarization in the B subsets - patient groups 
As there is a significant difference in the number of TrB cells in patients with CAMR,  
their functional aspect was further looked into. The first step was to assess the cytokine 
profiles of the TrB cells in different patient groups as described before. CPG and 
CD40L stimulated B cells were gated for TrB cells and intra-cellular cytokine analysis 
for both IL-10 and TNF- revealed that TrB cells in all groups including healthy 
volunteers were not significantly different with regards to the proportion of IL-10+ cells 
(Figure 52B). Then, the difference in cytokine polarization in the patient groups by IL-
10/TNF- ratio was assessed. Patients with stable graft function were not significantly 
different from healthy volunteers in their cytokine polarization. When compared to 
stable patients there is a trend towards a lower IL-10/TNF- ratio in the GD-NR group. 
Patients in the GD-R group had the lowest IL-10/TNF- ratio when compared to all the 
other groups suggesting a relative dominance of TNF- expression in the TrB cells in 
this group of patients (Figure 52A). Interestingly, when whole B cells were assessed for 
IL-10/TNF- ratio, there was no significant difference between the clinical groups 
(Figure 52C). These results revealed functional alterations within the same cell subset 
(TrB) in different clinico-pathologic settings. As a significant number of GD-R patients 
were on maintenance steroids when compared to the other groups, I have re-analysed 
the IL-10/TNF- ratio within the GD-R group divided into sub-groups based on the use 
of corticosteroids. Figure 52D shows that there was a non-significant trend towards 
lower IL-10/TNF- ratio in patients on maintenance steroids. Therefore, the IL-10/TNF-
 ratio in the GD-R group despite being affected by the use of corticosteroids was still 
significantly different from the remaining groups. 
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Figure 52: TrB cytokine analysis-patient groups 
Bar graphs (mean ± SEM) comparing healthy volunteers and patient groups (HV, healthy 
volunteers; S, stable graft function; GD-NR, Graft dysfunction - no rejection; GD-R, Graft 
dysfunction-rejection) for (A-C). IL-10/TNF- ratio-TrB (¥ S vs. GD-R, P=0.0002, ɸGD-NR vs. 
GD-R, P=0.03), %IL-10 for TrB and IL-10/TNF- ratio whole B cells. (D). IL-10/TNF- ratio for 
TrB cells in patient groups - influence of maintenance corticosteroids. Pred-maintenance 
corticosteroids, no pred-no maintenance corticosteroids.  *S vs. GD-R (no pred), P=0.02; **S vs. 
GD-R (pred), P=0.0002; #GD-NR vs. GD-R (no pred), P=0.1; ##GD-NR vs. GD-R (pred), 
P=0.008 
 
 
4.2.7.4 In vitro assessment of B cell subset-mediated regulation - patient groups 
To determine whether the observed difference in cytokine profile of TrBs between 
patient groups correlated with qualitative differences in regulatory function, the ability of 
TrB to inhibit cytokine expression by anti-CD3 stimulated autologous Tconv cells was 
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examined (Figure 53).  Purified TrB cells from transplant patients with stable allograft 
function and those from healthy volunteers exhibited similar levels of inhibition of IFN- 
and TNF- expression by Tconv cells, while sparing IL-4 expression. In contrast, in 
patients with CAMR (GD-R), TrB significantly suppressed IL-4 expression but exerted a 
minimal effect on TNF- and IFN- expression by autologous Tconv. As a control, 
Tregs from the same patients were assessed. Unlike their B counterparts, Tregs from 
patients with rejection were no different in their activity in comparison to those from 
patients with stable function, or healthy controls. Since the same number of TrB cells 
were added in each assay, the principal difference in TrB cells from GD-R and S 
patients was a decrease in their IL-10/TNF-ratio. These results confirmed the 
advantage of the IL-10/TNF- ratio over IL-10 expression alone in predicting Breg 
activity. 
157 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 53: Analysis of B regulatory function in vitro in S and GD-R groups 
(A). Representative dot plots for 1 out of 5 patients in the GD-R group for TNF-, IFN- and IL-4 expression by Tconv cultured alone or in the presence of TrB cells 
or Tregs. Numbers in each plot indicate frequency of Tconv cells expressing each cytokine under respective culture conditions. (B): Graphical representation (mean 
± SEM) of the cumulative results for the suppressive/stimulatory effect of the TrB cells or Tregs on the Tconv cytokine expression in HV (n=6), stable (n=7) and GD-
R (n=5) groups ($ S vs. GD-R: TNF-P=0.0003; $$ IFN-, P=0.002; $$$ IL-4, P<0.0001) Statistical analysis is by ANOVA using Tukey post hoc correction. 
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This far the regulatory properties of TrB cells were demonstrated: 
1. By the virtue of their overlapping phenotype with the murine prototype of Bregs, i.e. 
CD5hi CD1dhi cells. 
2. By their ability to express cytokines that are polarized to an anti-inflammatory 
phenotype. 
3. By in vitro assays to demonstrate their ability to selectively suppress pro-
inflammatory Th1 responses. 
4. In the clinical setting of renal transplantation, where their cytokine polarization is 
altered to a pro-inflammatory phenotype in the context CAMR. There was also loss of 
in vitro suppression of the pro-inflammatory Th1 cytokine expression by autologous 
Tconv cells but a paradoxical suppression of Th2 response.  
 
4.2.7.5 Clinical significance of TrB IL-10/TNF- ratio & the distribution of T1/ T2  
Finally, the clinical significance of altered cytokine polarization and distribution of T1 
and T2 within the TrB subsets was analysed. When the IL-10/TNF- ratio for patients 
with stable grafts and those with rejection was analysed by building a Receiver 
Operating Characteristic (ROC) curve, the area under the curve was reasonable at 
0.823, P<0.0001. In comparison the AUC for T1/T2 ratio was 0.88, P<0.0001. This 
suggested the ability of both TrB IL-10/TNF- ratio and TrB-T1/T2 to distinguish 
patients with stable grafts from those with CAMR, although, T1/T2 ratio seems to offer 
a slightly greater AUC (Figure 54) 
Next, graft outcomes were analysed over a period of 3 years after the biopsy by the 
Kaplan Meier method. For this analysis, only 44 patients with graft dysfunction were 
included as patients with stable graft function would potentially induce a bias in the 
favour of the TrB IL-10/TNF- ratio. The 44 patients with graft dysfunction were divided 
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into two groups at the mean IL-10/TNF- ratio of this group of 0.75. There are 28 
patients with a ratio<0.75 and 15 patients with a ratio>0.75.  Table 14 details the 
characteristics of both these sub-groups. Patients within the lower IL-10/TNF- ratio 
group were more likely to be on maintenance corticosteroids, had a higher incidence of 
anti-HLA-DSA, and had higher mean g, ptc and cg scores on their biopsy. None of 
these differences were statistically significant, owing to small group numbers. 
 
 
Figure 54: Clinical significance of or T1/T2 ratio or IL-10/TNF-   
ROC curves for T1/T2 ratio (AUC=0.88) or IL-10/TNF- ratio (AUC=0.823) to demonstrate the 
ability of these parameters to distinguish stable grafts from those with CAMR. 
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Table 14: Characteristics of patients - IL-10/TNF- groups 
 
Variable 
Low IL-10/TNF- 
ratio 
High IL-10/TNF- 
Ratio 
P-value 
Number 28 15  
Age 50 (43-56) 52 (47-58) Ns 
Time since transplant 108 (80-136) 92 (64-121) Ns 
HLA-MM    
A 0.92 (0.7) 0.7 (0.7)  
B 0.9 (0.6) 0.8 (0.8)  
DR 0.6 (0.6) 0.3 (0.5)  
Clinical features    
DSA 46.4% 20% Ns 
eGFR at biopsy 27.4 (22.4-32.4) 33 (26.9-39) Ns 
Proteinuria 116 (63-168) 119 (23-215) Ns 
Histology    
Late TCMR 18% 20%  
G 0.75 (1.06) 0.29 (0.48) Ns 
Ptc 0.68 (1.1) 0.14 (0.38)  
C4d deposition PTC    
Cg 1.19 (1.1) 0.57 (0.78)  
Cv 0.8 (0.9) 0.7 (0.8)  
Ci 1.9 (0.8) 1.3 (1.0)  
Ct 1.9 (0.8) 1.5 (0.8)  
 
Mean ± SD or percentages of the group are shown in the table. Statistical analysis was by non-
parametric Mann Whitney U test. 
 
When these patients were assessed for the clinical end-point of graft loss by the 
Kaplan Meier method, there was a trend towards worse graft survival in patients with 
lower IL-10/TNF- ratio. This trend persisted even when the analysis was repeated in 
patients with histological evidence of CAMR (Figure 55A and D). In view of the short 
follow-up period, the utility of TrB IL-10/TNF- ratio was re-analysed using a composite 
end-point of graft loss or a doubling of serum creatinine. The results in  Figure 55B 
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show that patients with graft dysfunction & a low IL-10/TNF- ratio had significantly 
lower survival, free of the composite end-point, when compared to their counterparts 
with a higher ratio. A trend nearly achieving statistical significance was seen in patients 
with CAMR as well (Figure55 E). When the same analysis for the composite end-point 
was repeated for T1/T2 ratio, as seen in Figure 55 C and F, the trends were not as 
significant. 
These results highlight the clinical significance of the functional alteration within a small 
subset of B cells as their regulatory properties were altered in patients with CAMR. 
Although T1/T2 ratio, which is reflective of this functional alteration, at least in part 
provides good separation of stable patients from those with CAMR, TrB-IL-10/TNF- 
ratio provided a much useful predictor for graft outcomes.  
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 High ratio 
                                                                   Low ratio 
  
Figure 55: Clinical significance of IL-10/TNF or T1/T2 (graft outcomes) 
(A, D). Kaplan-Meier survival analysis for high and low IL-10/TNF- (TrB) for graft loss over 3 
years in patients with graft dysfunction (B, E). Kaplan-Meier survival analysis for the high and 
low IL-10/TNF- (TrB) for 100% increase in serum creatinine (doubling of serum creatinine) and 
or graft loss over 3 years in patients with graft dysfunction. (C, F). Kaplan Meier survival 
analysis for the high and low T1/T2 (TrB) for 100% increase in serum creatinine and or graft 
loss over 3 years in patients with graft dysfunction. Groups compared using Log Rank test. 
 
Doubling of creatinine or 
graft loss 
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4.3 Discussion 
Bregs have been shown to play an important role in regulating immune responsiveness 
through IL-10 expression in a variety of autoimmune and transplant animal models 
(Mizoguchi, Mizoguchi et al. 1997, Mizoguchi, Mizoguchi et al. 2000, Fillatreau, 
Sweenie et al. 2002, Mizoguchi, Mizoguchi et al. 2002, Evans, Chavez-Rueda et al. 
2007, Gray, Miles et al. 2007, Hussain and Delovitch 2007, Mann, Maresz et al. 2007, 
Matsushita, Yanaba et al. 2008, Yanaba, Bouaziz et al. 2008, Ding, Yeung et al. 2011). 
Their role in human disease is less clear with studies showing that IL-10 is enriched in 
either TrB (CD24hiCD38hi) or memory B cells (CD24hiCD27+) and IL-10 expression may 
be unchanged, elevated, or reduced in patients with various autoimmune diseases 
(Duddy, Niino et al. 2007, Correale, Farez et al. 2008, Yanaba, Bouaziz et al. 2008, 
Blair, Norena et al. 2010, Iwata, Matsushita et al. 2011).  
The results of the experiments discussed in this chapter suggest that renal transplant 
recipients with histological evidence of rejection have both a reduced number of, and 
functionally defective, CD19+CD24hiCD38hi transitional B cells, in contrast to 
immunosuppressed patients with stable function. By directly comparing human TrB and 
memory B cell subsets, shown by others to be enriched for IL-10+ Bregs (Blair, Norena 
et al. 2010, Iwata, Matsushita et al. 2011), I have shown that the CD24hiCD38hi TrB cell 
subset is most potent in suppressing pro-inflammatory cytokine expression by Tconv in 
vitro. Importantly, this is not due to a higher frequency of IL-10 expressing cells within 
the TrB population, but rather diminished expression of pro-inflammatory cytokines 
compared to memory B cells. In fact B cells within naïve, memory, and TrB subsets are 
not only capable of expressing IL-10, but also TNF-. The results from this chapter 
demonstrate that a high IL-10/TNF- ratio, which suggests cytokine polarization, is a 
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better indicator of B cell regulatory activity than IL-10 expression alone. This 
consideration may explain inconsistencies between earlier studies. 
Correlation of the suppressive activity of TrB cells from patients with different clinical 
outcomes lends support to the validity of the IL-10/TNF-ratio as a marker of B cell 
mediated immunoregulation. Despite exhibiting the same frequency of IL-10 
expression, TrB cells from GD-R patients displayed a lower IL-10/TNF- ratio and had 
reduced ability to inhibit Th1 T cell differentiation than those from transplant recipients 
with stable function (S). Th1 responses are generally considered deleterious, whereas 
Th2 responses promote tolerance in experimental animals (Sho, Yamada et al. 2002). 
In GD-R patients, this was compounded by a decrease in the number of TrB cells. 
While causality cannot be established in this retrospective study, these Breg 
“abnormalities” correlated with graft damage, in particular that mediated by CAMR. The 
IL-10/TNF-ratio in TrB not only identifies patients with CAMR but in those with graft 
dysfunction, there was an association between a  low ratio and adverse graft outcomes 
at 3 years justifying further validation of this simple calculation. 
There are several important potential consequences of this pro- and anti- inflammatory 
heterogeneity in B cell function. Firstly TrB cells are not only more polarized towards an 
anti-inflammatory function as a subset, but individual cells within that subset are more 
likely to express IL-10 alone (without TNF- co-expression) compared to either 
memory or naïve B cells. Thus, while the total number of memory and especially naïve 
B cells expressing IL-10 is not significantly lower than TrB cells, a greater proportion of 
the former, express or co-express inflammatory cytokines and are thus phenotypically 
distinct resulting in less suppression of T cell responses. Moreover, in different clinical 
or pathological states, the degree of polarization can change.  Taken together, this B 
cell duality makes it unlikely that any single cytokine expressing subset will adequately 
define human Bregs. Rather, the findings presented in this chapter indicate that 
cytokine polarization is the best predictor of Breg activity, at least in an in vitro setting. 
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Based on these findings a model for TrB cell mediated immune regulation of T cells 
can be drawn (Figure 56) In the future, other combinations of both pro-inflammatory 
and anti-inflammatory cytokines may further refine human Breg definition.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56: Putative model for TrB mediated immune regulation 
Graphic in the top panel is a hypothetical representation of Breg mediated immune regulation 
in patients with stable function.  In this model, a polarized IL-10/TNF-a ration towards IL-10 
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favours Th2 differentiation and promotes graft stability and as shown in the bottom panel, 
reversal of this polarization results in Th1 skewing and allograft rejection. However this model 
has only been examined in a non-cognate fashion and need a further study to examine 
alloresponse.  
 
A combination of CD40 ligand (CD40L) and Cytosine Guanine-Oligodeoxynucleotide) 
CPG-ODN 2006 was used to stimulate B cells for cytokine detection. CPG-ODN 2006 
is Toll like receptor-9  (TLR-9) agonist and has been shown to up regulate the 
production of  IL-10 by the B cells (Barr, Brown et al. 2007). Agonistic stimulation of TL-
9 has been shown to alter the course of various autoimmune diseases in murine 
models (Quintana, Rotem et al. 2000, Wu, Sawaya et al. 2007). In human beings, 
decreased expression of TLR-9 has been shown to increase predisposition to 
autoimmune conditions like Systemic Lupus Erythematosis (SLE) (Tao, Fujii et al. 
2007). CD40 is a membrane associated protein and belongs to the TNF receptor 
superfamily. Prolonged and strong signals via cross linking of CD40 by CD40L 
(CD154) on the surface of T cells in vivo inhibit antibody production by B cells 
(Miyashita, McIlraith et al. 1997). Several studies have shown that the interaction of 
CD40-CD40L is a key pathway in the induction of Bregs (Mizoguchi, Mizoguchi et al. 
2000, Fillatreau, Sweenie et al. 2002). A recent study by Tedder’s group in Durham NC 
has shown that stimulation of B cells by a combination of CD40L and CPG-ODN 2006 
provides optimal stimulation for the expression of IL-10 by the B cells (Iwata, 
Matsushita et al. 2011). It is worthwhile to note that TLR engagement on different B 
cells is associated with differential expression of multiple cytokines (Gray, Gray et al. 
2007, Lampropoulou, Hoehlig et al. 2008). I have focussed on the expression of TNF- 
(a prototype pro-inflammatory cytokine) along with IL-10 by B cell subsets after 
stimulation with a combination of CPG and CD40L. 
In humans, Bregs have predominantly been studied in the context of autoimmune 
disease. A significant reduction in the number of IL-10+ B cells was reported in patients 
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with multiple sclerosis (MS) (Duddy, Niino et al. 2007, Correale, Farez et al. 2008). In 
patients with relapsing MS, B lymphocyte mediated inflammatory cytokine responses 
were shown to be associated with disease activity, in vitro T cell proliferation and 
cytokine release. These responses were modified with B cell depletion using rituximab 
(Bar-Or, Fawaz et al. 2010). CD24hiCD38hi Bregs in patients with SLE have been 
shown to produce less IL-10 in response to CD40L, but not after stimulation with CpG 
(Blair, Norena et al. 2010).  However, in SLE, TLR stimulation is an important 
component of B cell activation (Green and Marshak-Rothstein 2011). These B cells 
were also unable to suppress the differentiation of pro-inflammatory cytokine producing 
T cells in vitro. In contrast, Iwata et al. have described a significantly higher number of 
IL-10+ B cells following in vitro stimulation with CpG and CD40L in patients with various 
autoimmune disorders, but functional studies were not performed (Iwata, Matsushita et 
al. 2011). The observations in this chapter indicate that the study of IL-10 expression 
alone by Breg populations does not correlate well with clinical outcomes at least in the 
setting of clinical renal transplantation.  
As a refinement to the study of the cytokine expression by the B cell subsets, the 
potential reasons that underlie such a difference within the cytokine profiles of the 
same subset of cells in different clinical conditions (i.e. stable vs. GD-R) are explored.  
Interestingly the transitional B cells which have been identified as potential B regulatory 
cells in human beings (Blair, Norena et al. 2010) are indeed heterogeneous and distinct 
subsets (i.e. T1 and T2) can be identified both by phenotypic markers and by their 
ability to express pro and anti-inflammatory cytokines in vitro. Although both the 
subsets are significantly reduced in patients with CAMR, there is a relative depletion of 
T1 cells in comparison to the T2 subset. The distribution of T1/T2 has been identified 
and validated as a simple biomarker for the prediction of graft deterioration in renal 
transplant recipients. 
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CD10, CD24 and CD38 have been previously shown to be immature markers in human 
bone marrow (Tedder, Clement et al. 1984, Loken, Shah et al. 1987, Meffre, Casellas 
et al. 2000). By using a combination of CD24, CD38, IgM and CD10, this data showed 
that transitional B cells can be divided into subsets with T1 cells expressing CD10hi, 
CD24+++ CD38+++ IgM+ and T2 cells expressing CD10lo CD24++CD38++ and IgMlo. In 
contrast to previous studies in both humans and mice, we noticed that T1 B cells had a 
relatively higher expression of CD40 and CD5 (Loder, Mutschler et al. 1999). However 
the initial B cells to emerge from the human bone marrow following stem cell 
transplantation have been shown to be CD5+ in a different study (Waddick and Uckun 
1993). In murine B cells, a subset that express CD5 are predominantly found in the 
peritoneum and have been shown to secrete and synthesize high levels of IL-10 and 
are labelled as regulatory B cells (Mizoguchi, Mizoguchi et al. 1997, Mizoguchi, 
Mizoguchi et al. 2002). In our study, T1 B cells expressed CD5 and were differentiated 
from other B cells by their response to CD40L and CpG. Indeed it has been previously 
shown that transitional B cells can be divided into subsets that differ in response to T 
cell signalling (Chung, Sater et al. 2002). Using the same principle and by studying the 
effect of TLR mediated stimulation, it was demonstrated that T1 cells differ from T2 
cells by relatively limited expression of TNF-. Whilst T1 and T2 cells can be 
differentiated based on TNF- expression, T2 cells can be differentiated from mature 
naïve B cells by greater expression of IL-10 along with the other phenotypic markers 
thereby establishing that T2 cells are distinct from mature naïve B cells. 
There are recent reports that suggest transitional B cells are characterized by reduced 
survival, proliferation, differentiation and chemotaxis (Carsetti, Rosado et al. 2004, 
Sims, Ettinger et al. 2005, Cuss, Avery et al. 2006). Both in animals and human beings, 
isolated BCR mediated stimulation of transitional B cells induced apoptosis or cell 
death by neglect rather than proliferation (Carsetti, Kohler et al. 1995, Loder, Mutschler 
et al. 1999, Su and Rawlings 2002, Sims, Ettinger et al. 2005). This process is believed 
to represent a key negative selection check point for auto-reactive B cells and thus may 
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play a vital role in the pathogenesis of various autoimmune diseases. However T cell 
signals mediated via CD40-CD40L interactions can overcome BCR mediated apoptosis 
of immature B cells and induce proliferation (Tsubata, Wu et al. 1993, Parry, Hasbold 
et al. 1994). I have also shown that transitional B cells fail to suppress pro-inflammatory 
cytokine expression by autologous T cells in vitro, in patients with a histological 
phenotype of CAMR. The finding that not only are the transitional B cells reduced in 
number in CAMR but also there is an altered distribution of the subsets within the TrB 
cells may potentially explain the differences in the cytokine polarization noted within the 
TrB cells in CAMR. This is important because, T1 cells have the most anti-inflammatory 
polarization and despite their limited number and short life-span it is possible that these 
cells act as regulatory cells. Interestingly these cells are relatively reduced in 
comparison to T2 cells in patients with CAMR. Of course there are several possibilities: 
1. These cells act as a reservoir for a much smaller number of B cells that mature into 
antigen-specific regulatory cells in secondary lymphoid organs 
2. They are not detected in the periphery or are lost in assessing the overall population 
given the broad markers that are used and lack of antigen specificity in these 
experiments 
3. T1:T2 ratio is a good predictor of antigen-driven maturation of B cells. So, if changes 
in B cell phenotype were analysed longitudinally over time alterations could potentially 
be seen in most patients, especially with the onset of immunopathology.  
The findings in this chapter are supported by recent studies showing that renal 
transplant patients who were “operationally tolerant” (no maintenance 
immunosuppression), exhibit higher numbers of TrB cells than their non-tolerant 
counterparts, although the potentially confounding effects of immunosuppression in the 
latter group cannot be excluded (Newell, Asare et al. 2010, Pallier, Hillion et al. 2010, 
Sagoo, Perucha et al. 2010).  
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Patients in the GD-R group exhibited microvascular inflammation and scarring with or 
without complement (C4d) deposition, and had serological evidence of circulating 
donor specific HLA antibody in the majority of patients (80%) - all features of CAMR. 
However, 25% of these patients had a component of acute cellular rejection 
superimposed. Whether Breg abnormalities precede development of antibody-
mediated rejection (suggesting causality) or are also involved in acute cellular rejection, 
must await prospective longitudinal study.  However, the findings highlighted in this 
chapter raise the possibility that in addition to affecting T cell effector function, Bregs 
may also play a role in CAMR. Notably, CAMR with features of microcirculatory 
inflammation with or without C4d deposition within the peritubular capillaries is 
proposed as the major cause of chronic renal allograft loss (Kieran, Wang et al. 2009, 
Gaston, Cecka et al. 2010, Brouard, Renaudin et al. 2011, Gaston 2011).  
Another limitation of these studies is that patients who had an acute cellular component 
to their rejection on biopsies were often initiated on treatment with corticosteroids 
before blood samples could be obtained. Thus, more patients with rejection were on 
maintenance corticosteroids. However GD-R patients who were not receiving 
corticosteroids still had a significantly lower number of TrB cells and these cells had a 
lower IL-10/TNF- ratio when compared to both healthy volunteers and patients with 
stable graft function.  Finally, it should be noted that the GD-NR group was 
heterogeneous and at least some patients may have had “immune-mediated” 
pathology which may explain why TrB cells and the IL-10/TNF- ratio were reduced 
from S patients (stable graft function) and healthy volunteers, while remaining 
significantly higher than the GD-R group.  
The studies described in this chapter provide novel insights into the description of B 
cell mediated immunoregulation in humans. Since a significant number of these cells 
express pro-inflammatory cytokines upon in vitro stimulation, it is not unreasonable to 
conclude that any definition of Breg phenotype should take this finding into account. 
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Using such a strategy, I have shown that CD24hiCD38hi B cells outperformed other B 
subsets in their regulatory potential defined by cytokine polarization, and this correlated 
with clinical status and was associated with medium term outcomes in renal transplant 
recipients. Finally, a simple measurement of TrB T1/T2 ratio on blood phenotyping may 
provide a valuable biomarker for predicting graft outcomes in renal transplant 
recipients. 
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Chapter-5: B lymphocyte phenotype 
& alemtuzumab in renal 
transplantation 
5.1 Introduction 
In the previous chapter CD24hiCD38hi transitional B cells, by virtue of cytokine 
polarization were shown to demonstrate immuno-regulatory properties and that these 
cells were shown to be reduced in number with an altered phenotype when tested in 
vitro in renal transplant recipients with chronic antibody mediated rejection (CAMR). 
Now, results that will test the utility of an immune signature based on the peripheral B 
lymphocyte phenotype in renal transplant recipients will be presented. The study 
setting was a randomized controlled trial, comparing alemtuzumab and basiliximab 
induction in a steroid free immunosuppression regime, wherein patients were 
maintained on either tacrolimus or tacrolimus with mycophenolate mofetil for 
maintenance immunosuppression. Alemtuzumab is a mouse monoclonal IgG1- 
antibody against CD52 and causes profound depletion of lymphocytes through 
complement mediated cell lysis (Hale, Bright et al. 1983). This agent has been shown 
to cause profound T lymphocyte depletion and is used as an induction agent in solid 
organ transplantation (Weaver and Kirk 2007, Newell, Cendales et al. 2008). 
Basiliximab is a chimeric mouse human monoclonal antibody to the  chain of IL-2 
receptor and has been shown to significantly reduce the rate of acute rejection 
episodes when used as induction  immunosuppression in renal transplant recipients 
(Nashan, Moore et al. 1997).  
The experience in renal transplantation with alemtuzumab has generally been positive 
with good medium term success in published studies (Knechtle, Fernandez et al. 2004, 
Clatworthy, Friend et al. 2009, Cai and Terasaki 2010, Chan, Taube et al. 2011, 
Hanaway, Woodle et al. 2011). Further interest in alemtuzumab induction was 
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generated by the demonstration that the induction of tolerance in animal models can be 
facilitated by profound T cell depletion (Wells, Li et al. 1999).  Thus, clinical studies 
were carried out to examine its role in novel immunosuppression regimes consisting of 
minimal or calcineurin inhibitor free maintenance treatment (Knechtle, Pirsch et al. 
2003, Kirk, Mannon et al. 2005).  These trials yielded unacceptably high rates of acute 
rejection; however other studies in which alemtuzumab induction was followed by long-
term tacrolimus or ciclosporin monotherapy as maintenance therapy yielded acceptable 
results with excellent graft function (Vathsala, Ona et al. 2005, Margreiter, Klempnauer 
et al. 2008, Tan, Donaldson et al. 2009).   
The first clinical studies in renal transplantation demonstrated that alemtuzumab 
caused profound and prolonged depletion of T lymphocytes (Watson, Bradley et al. 
2005). CD4+ T cells take the longest time to repopulate and the reconstitution may not 
be complete more than one year after treatment.  It has also been shown in human and 
animal models of both autoimmune and alloimmune disease that the reconstituted 
CD4+ T cell pool consists of cells with a predominant memory phenotype (CD45RO+) 
(Brett, Baxter et al. 1996, Trzonkowski, Zilvetti et al. 2008).   Such CD4+ memory  cells 
have also been identified in the biopsies of patients undergoing T cell mediated 
rejection of renal allografts after induction with alemtuzumab (Gallon, Gagliardini et al. 
2006).   Furthermore, a relative increase in the population of CD4+ CD25+ FoxP3+ T 
regulatory cells has been demonstrated in recipients of renal transplants following 
alemtuzumab induction (Bloom, Chang et al. 2008). It has also been shown that CD8+ 
T cells re-establish themselves more rapidly than CD4+ cells and that some of these 
cells possess a regulatory phenotype (Trzonkowski, Zilvetti et al. 2008).  
Human B cells also express CD52 and they are profoundly depleted following 
alemtuzumab induction.  The reconstitution of B cell subsets has not previously been 
studied in human renal transplantation.  In the autoimmune field it has been 
demonstrated that B cells reconstitute within three months of treatment with a 
predominance of the mature naïve phenotype (CD19+CD27-) and that this is 
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associated with a sustained increase in levels of B-cell activating factor (BAFF) 
(Thompson, Jones et al. 2010).  The recent association of certain B cell phenotypes 
with operational tolerance in renal allografts and the demonstration of immune 
regulation by certain human B cell subsets, encouraged me to study the reconstitution 
of B cells following alemtuzumab induction and compare this with standard basiliximab 
induction at our institute in Leeds, in the context of a clinical trial (Lund and Randall 
2010, Mauri and Blair 2010, Newell, Asare et al. 2010, Pallier, Hillion et al. 2010, 
Sagoo, Perucha et al. 2010).   
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5.2 Results: 
A total of 120 patients were recruited for this study as shown in Figure 57. Following 
randomisation one patient withdrew and two patients did not proceed to 
transplantation.  One patient was lost to follow up. Of those remaining, 58 were 
randomised to each treatment arm. Of the enrolled 120 patients, 96 were tested for 
peripheral blood lymphocyte phenotype and for the detection of HLA specific 
antibodies. 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 57: Flow chart showing patient recruitment into the clinical trial 
 
5.2.1 Clinical outcomes 
Table 15 shows key comparative parameters for the two groups. No differences were 
apparent between the groups in mean age, gender ratio, causes of renal disease 
(including percentage of diabetics pre-transplant), transplant types, mean HLA 
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mismatches, CMV statuses, cold and warm ischaemic times, or percentage of 
extended criteria donors.  
Table 15: Characteristics of the study population 
 
Demographic 
Alemtuzumab 
group 
Basiliximab 
group 
P Value* 
Total participants 58 58  
No with Phenotyping 51 45  
No with HLA specific antibody testing 51 45  
Age (mean±SD) in years 46.1 ± 14.2 48.2 ± 14.1 Ns 
Recipient gender (male : female) 16:42 10:48  
Ethnicity    
Caucasian 52 49  
Asian 2 5  
Afro-Caribbean 3 4  
Other 1 0  
Causes of ESRD (number)    
Polycystic kidney disease 10 12 Ns 
Reflux nephropathy/Chronic pyelonephritis 7 5 Ns 
Diabetic nephropathy 7 4 Ns 
Hypertension/Renovascular disease 6 7 Ns 
Glomerulonephritis 14 16 Ns 
Others 8 11  
Unknown 6 5 Ns 
Transplant types (number)    
DBD donor 32 29  
NHBD donor 15 16  
Living donor 11 13  
Extended criteria donors 9 9  
Mean HLA mismatches (mean)    
HLA-A 0.9 1.0  
HLA-B 0.9 1.0  
HLA-DR 0.6 0.7  
Donor age 41.0 ± 16.7 46.4 ± 14.7  
Donor gender (male : female) 22:36 31:27  
Donor causes of death (number)    
Stroke 23 33  
Hypoxic brain injury 4 4  
Trauma 7 1  
Other 24 20  
Cold ischaemia time (mean±SD) 773.2 ± 329.8 747.9 ± 362.3  
Total warm ischaemia time (mean±SD) 37.6 ± 11.5 39.9 ± 18.8  
Donor pre-transplant creatinine (mean±SD) 89.1 ± 43.5 93.0 ± 45.9  
 
*Continuous variables are compared by independent samples student t test whilst 
categorical variables are compared by chi-square test 
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5.2.1.1 Assessment of Renal function 
The primary outcome measure was the isotopic GFR at 1 year after transplantation. 
Mean uncorrected isotopic GFR at one year was 57 ± 26 ml/min in the alemtuzumab 
group and 53 ± 21 ml/min in the basiliximab group (p=0.42). These figures include 
patients returned to dialysis by one year, each with an assumed GFR of 5 ml/min. 
Neither excluding such patients, nor correcting isotopic GFRs for recipient body surface 
area (nor both) demonstrated any difference between the groups. One year mean 
creatinine was 147.1 ± 93.7 µmol/L (alemtuzumab group) and 151.4 ± 46.6 µmol/L 
(basiliximab group; p=0.769).  Latest mean MDRD eGFRs for the two groups are 57 ± 
20 ml/min (alemtuzumab) and 51 ± 19 ml/min (basiliximab; p=0.106); median time to 
latest eGFR was 41 months (range 12.4-62.2 months, at January 2012). Patient 
survival was 96.6% in both groups. Four deaths occurred in total – one cardiovascular 
death in each group, one death from sepsis in the basiliximab group, and one death 
from malignancy (an EBV driven B cell lymphoma) in the alemtuzumab group. Three 
grafts were lost in each group – graft survival 94.8% (basiliximab group) 94.9% 
(alemtuzumab group, where n=59 for graft survival, since the lost to follow up patient 
had a functioning graft at one year, but that was the only information obtainable). Two 
cases of primary non-function occurred in the basiliximab group. Intractable rejection 
leading to graft loss was seen in both groups – two cases in the alemtuzumab group 
(one associated with deliberate non-compliance) and one in the basiliximab group. A 
case of progressive interstitial fibrosis and tubular atrophy leading to graft loss was also 
seen in the alemtuzumab group. 
5.2.1.2 Rejection episodes 
By 12 months, 6 patients had biopsy proven acute rejection in the alemtuzumab group, 
compared to 14 in the basiliximab group (p=0.049). A 7th patient in the alemtuzumab 
was clinically treated for rejection without biopsy proof and responded as would be 
expected in a case of rejection. Including this patient in the analysis yields a P value of 
0.082. Median time to rejection was longer in the alemtuzumab group: 116 days (range 
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18-314days) vs. 8 days (range 4-166), p=0.015. Death censored rejection free survival 
is shown in Figure 58 (log rank test p=0.063). More severe rejection episodes of Banff 
grade II and above occurred at similar frequencies in the alemtuzumab group (4 /6) and 
the basiliximab group (5 /14).  Only 3 rejection episodes failed to return to within 10% 
of baseline creatinine on treatment, 2 (28.5%) in the alemtuzumab group, 1 (7.1%) in 
the basiliximab group.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 58: Death censored rejection free graft survival in alemtuzumab and basiliximab 
groups (curves compared by Log Rank test) 
 
5.2.1.3 Immunosuppression 
There was no difference in mean tacrolimus levels between the two groups at 3, 6 or 
12 months (p=0.238, 0.461 and 0.315 respectively) (Figure 59). Percentages of patients 
remaining steroid free at 12 months were 81% and 74% for the alemtuzumab and 
basiliximab groups respectively. Commencing steroids was at the discretion of the 
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treating clinicians. Reasons for steroid use at one year were as follows- alemtuzumab 
group: 4 patients switched to sirolimus (and prednisolone), 1 patient developed 
tacrolimus neurotoxicity and 1 patient was treated for PTLD. A further 6 patients were 
on prednisolone following rejection episodes. 81% of the alemtuzumab group were on 
tacrolimus monotherapy at 12 months. In the basiliximab group: one patient developed 
calcineurin-inhibitor-pain-syndrome (CIPS) and was changed to a steroid containing 
regimen, one had MMF withdrawn for leucopoenia with steroids substituted, and one 
had neurotoxicity with tacrolimus resulting in a regimen change to one incorporating 
steroids. A further 13 patients were on prednisolone following rejection episodes – one 
of these was being concurrently treated for recurrent membranous nephropathy with a 
steroid containing protocol. The mean mycophenolate mofetil dose in the basiliximab 
group at one year was 1.2 ± 0.3g / 24h (median 1.5g / 24h).  
 
 
 
 
 
 
 
 
 
 
 
Figure 59: Tacrolimus levels in alemtuzumab and basiliximab groups (mean ± SD).  
Means compared by independent sample t test. 
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5.2.1.4 Other clinical outcomes and adverse events 
Rates of diagnosed NODAT at 12 months for the alemtuzumab and basiliximab groups 
were 8.9% and 12.5% respectively (with n=56 at 12 months in each group). No 
statistically significant differences in NODAT rates were apparent at any of the time 
points (4 weeks, 6 months and 12 months). Both groups had excellent blood pressure 
control demonstrated by the 24hr ambulatory blood pressure measurements. Urine 
protein creatinine ratios measured at 3, 6 and 12 months after transplantation were 
similar in both the groups.  
Similar numbers of hospitalisations for cardiovascular events occurred in each group – 
8 (of which 4 were myocardial infarctions) and 6 (of which 4 were myocardial 
infarctions) in the alemtuzumab and basiliximab groups respectively. De novo 
neoplasia was seen in 3 patients (5.1%) in the alemtuzumab group – 2 post-transplant 
lymphoproliferative disorders (PTLD): one leading to death, one now in complete 
remission with good graft function. One thyroid carcinoma (successfully treated) was 
also seen. Two neoplasias were seen in the basiliximab group (3.4%) – one PTLD, and 
one renal cell carcinoma – both successfully treated. Hospitalisations for infective 
episodes occurred more frequently in the alemtuzumab group (36 vs. 30), but in a 
similar number of patients (22 vs. 17 in the basiliximab group). Further details are given 
in Table 16. CMV syndrome was seen in 3 patients in the basiliximab group, all in 
intermediate risk patients (D+/R+ or D-/R+) who did not receive prophylaxis with 
valganciclovir. Only 1 patient (D+/R-) in the alemtuzumab group developed CMV 
syndrome after the 100 day prophylaxis period. There was no invasive CMV disease. 
Two cases of BK virus nephropathy occurred, both in the basiliximab group. 
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Table 16: Details of the hospitalization episodes over the first post-transplantation year 
in alemtuzumab and basiliximab groups 
 
Type of infective 
episode 
Alemtuzumab Basiliximab *P-value 
 No of patients 
No of 
episodes 
No of patients 
No of 
episodes 
 
Urinary tract 
infection 
17 6 5 3 Ns 
Gastroenteritis 4 4 7 4 Ns 
Sepsis-unknown 
cause 
5 5 7 5 
Ns 
Chest infection 2 2 4 4 Ns 
Cellulitis 1 1 2 2 Ns 
peritonitis 2 2 0 0 Ns 
other 5 4 5 3 Ns 
 
*Groups compared by Chi-square test. Frequency is shown as absolute numbers 
 
In summary, the results so far have shown that alemtuzumab induction allows for 
minimization of maintenance immunosuppression with avoidance of mycophenolate 
and prednisolone in a significant majority of the patients and results in comparable 
clinical outcomes to patients who are maintained on tacrolimus and mycophenolate 
after basiliximab induction. In the next few sections, an analysis of the peripheral blood 
B lymphocyte phenotype in both the groups will be presented. 
 
5.2.2 Analysis of reconstituted peripheral lymphocyte phenotype 
5.2.2.1 Absolute lymphocyte number in Alemtuzumab and Basiliximab groups 
Figure 60 shows the differences in the mean number of lymphocytes in the peripheral 
blood of patients in both  groups at various time points after transplantation. 
Lymphocyte depletion was profound in the alemtuzumab group and repopulation 
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occurred gradually over the first year. By 9 months after transplantation, there was no 
longer any statistically significant difference between lymphocytes in the two groups. 
 
 
Figure 60: Mean number of lymphocytes compared between the two groups. 
Time points are marked on the x-axis and the y- axis shows the scale for the number of 
lymphocytes (× 10
9 
/l of whole blood). Even though there is a marked decrease in the 
lymphocyte number early after transplantation, no statistically significant differences exist at the 
time of sampling (p=0.3, independent samples t-test) 
 
5.2.2.2 Lymphocyte phenotype in Alemtuzumab and Basiliximab groups 
Figure 61 summarizes the analysis of lymphocyte subsets using the trucount beads.  
This analysis of the absolute numbers of lymphocyte subpopulations in the peripheral 
blood was carried out using trucount beads at a mean of 25 months post 
transplantation. Figure 62 summarizes the differences in the proportion and absolute 
numbers of lymphocytes between the two groups and the two control groups that 
include dialysis patients (n=10) and healthy volunteers (n=10).  
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 Figure 61: Identification of lymphocyte subsets by flow cytometry. 
Lymphocytes are identified by the lack of granularity and positivity for CD45. This gated 
population is further classified as helper-T cells (CD45+CD3+CD4+), Cytotoxic T-cells 
(CD45+CD3+CD8+), B cells (CD45+CD19+) and NK cells (CD45+CD16+CD56+). 
 
The proportion and the absolute number of CD3+ T lymphocytes were less in the 
alemtuzumab group when compared to both healthy volunteers and dialysis patients. In 
large part, this was due to the significantly depleted CD4+ lymphocyte population in this 
group. There was also an increase in the proportion of both CD19+ B cells and NK cells 
in the alemtuzumab group when compared to both control groups. The absolute 
numbers were only increased in comparison to dialysis patients due to relative 
lymphopenia of this population compared to healthy controls. When the same set of 
controls were compared to the basiliximab group, no significant differences were 
demonstrated in the proportions of any of the lymphocyte subsets but the absolute 
number of CD3+ T cells, CD4+ T cells, CD19+ B cells and NK cells were significantly 
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lower than in healthy controls. This is once again a reflection of the relative 
lymphopenia of these patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 62: Comparison of lymphocyte subsets in healthy volunteers, dialysis 
patients and alemtuzumab/basiliximab groups. 
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This graph shows that both alemtuzumab and basiliximab groups were lymphopenic when 
compared to healthy controls. The alemtuzumab group had significantly lower CD3
+
T cells and 
CD4
+
T cells whilst CD8
+
T cells were comparable to those of healthy controls and dialysis 
patients. The proportion of B cells and NK cells were significantly higher in the alemtuzumab 
group when compared to both controls. The absolute numbers of these cell types were 
comparable to healthy controls even though they were significantly higher than the dialysis 
patients. The proportions of the various lymphocyte subsets in the basiliximab group were 
comparable to those of other controls. However the absolute number of CD3
+ 
T cells, CD4
+ 
T 
cells, B cells and NK cells were significantly lower when compared to healthy controls. 
 
Further analysis within the CD4+ T and B cell compartments is summarized in Figure 63 
and Figure 64. Within the CD4+ T cell compartment of patients treated with 
alemtuzumab, the ratio of naïve (CD45RA+ CD45RO-) to memory cells  (CD45RA- 
CD45RO+) was not significantly different to either healthy controls or dialysis patients 
even though a trend towards a higher ratio could be seen. In contrast the basiliximab 
group had a significantly higher ratio of naïve to memory CD4+ cells in comparison to 
both healthy controls and dialysis patients (Figure 64a) 
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Figure 63: Representative dot plots of the various T and B subsets in healthy volunteers, 
dialysis patients, alemtuzumab and basiliximab groups  
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Figure 64: Comparison of CD4+T and B cell subsets in the control groups and 
alemtuzumab/basiliximab groups 
Patients in the basiliximab group had a signifiantly higher naïve to memory CD4+ T cell ratio, 
whilst a similar trend was seen in the alemtuzumab group as well, the results were not 
statistically significant (a). Alemtuzumab group had the highest naïve to memory B ratio when 
compared to both control groups and even the basiliximab group had a high naïve to memory B 
cell ratio when compared to healthy controls but the results were not significantly different to 
those of the dialysis controls (b). The proportion of transitional B cells were significantly higher 
in the alemtuzumab group when compared to both the controls groups but the absolute 
numbers were only high in comparison to the dialysis patients. In contrast, the absolute number 
of  transitional B cells were significantly lower in the basiliximab group when compared to 
healthy controls (c). Whilst the proportion and absolute numbers of the B regs were significantly 
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lower in the basiliximab group when compared to healthy controls they were comparable in the 
alemtuzumab group (d). 
 
Within the reconstituted B cell compartment, the alemtuzumab group had a significantly 
higher number of CD19+CD27-IgD+ naive cells when compared to both healthy controls 
and dialysis patients. This group also had a lower number of  memory B cells (both 
CD19+CD27+IgD+ non-class switched and CD19+CD27+IgD- class switched) when 
compared to healthy controls but these numbers were similar to those seen in dialysis 
patients. This was reflected in a significantly higher naïve to memory B cell ratio in the 
alemtuzumab group when compared to both control groups (Figure 64b). Furthermore 
the alemtuzumab group had a significantly higher proportion of transitional B cells 
when compared to both control groups with absolute numbers that were restored to 
levels found in healthy controls (Figure 64c). The proportion and absolute number of 
CD5+CD1dhi B cells in this group were comparable to healthy controls but higher than 
dialysis patients (Figure 64D).   
There was a relative increase in the numbers of naïve B cells in the basiliximab group 
when compared to both the controls although this difference was not as marked as that 
in the alemtuzumab group (Figure 64b). However, in contrast to the alemtuzumab 
group, the basiliximab group had significantly lower absolute numbers of both 
transitional B cells (Figure 64c) and CD5+CD1dhi B cells (Figure 64d). 
 
5.2.2.3 Correlation of B cell subsets with graft function 
Lymphocyte phenotype was correlated with graft function assessed by eGFR at the 
time of the analysis and by ∆eGFR, an indicator of the stability of graft function 
between 6 and 25 months after transplantation. Table 17 summarizes the correlation of 
absolute numbers of lymphocyte subsets with both eGFR and ∆eGFR. There was a 
significant correlation between graft function and the absolute numbers of B cells, 
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naïve B cells, transitional B cells and regulatory B cell cells in the alemtuzumab group. 
A similar correlation was demonstrated between these subsets and stability of graft 
function. These correlations remained statistically significant in a multivariate analysis 
after adjusting for significant confounding clinical variables including recipient age, 
donor age and donor retrieval creatinine (Table 18). 
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Table 17: Correlation of Lymphocyte phenotype to graft function 
 
 
 
 
 
 
 
 
 
 
eGFR was calculated at the time of sampling (a mean of 25 months after transplantation). ∆ eGFR was the difference between the eGFR at 6 months and at the 
time of sampling. 
 
 
 
Alemtuzumab group 
 
Basiliximab group 
Lymphocyte Phenotype Spearman 
R 
(eGFR) 
p- 
value 
Spearman 
R 
(∆ eGFR) 
p- 
value 
Spearman 
R 
(eGFR) 
p- 
value 
Spearman 
R 
(∆ eGFR) 
p- 
value 
CD4
+
 T ells  1.5 0.3 -0.14 0.3 0.4 0.007 0.2 0.2 
CD8
+
 T cells 0.1 0.5 -0.2 0.3 0.2 0.2 0.1 0.3 
CD4
-
CD8
-
 T cells 0.2 0.2 0.14 0.3 0.06 0.7 -0.02 0.9 
Naïve CD4
+
  T cells 0.2 0.1 0.03 0.9 0.6 <0.001 0.3 0.1 
Memory CD4
+
  T cells 0.02 0.9 -0.1 0.5 0.1 0.4 -0.02 0.9 
NK cells 0.1 0.4 0.1 0.3 0.17 0.2 -0.06 0.7 
B cells 0.3 0.03 0.3 0.04 0.36 0.02 0.16 0.3 
Naïve B cells 0.3 0.03 0.4 0.003 0.4 0.01 0.25 0.1 
Class un-switched Memory B cells 0.35 0.01 0.15 0.3 0.3 0.04 0.07 0.7 
Class switched Memory B cells -0.12 0.4 -0.2 0.2 0.1 0.4 -0.1 0.3 
Transitional B cells 0.3 0.02 0.5 0.001 0.3 0.03 0.1 0.3 
Cd5+CD1dhi B cells 0.34 0.01 0.4 0.003 0.4 0.008 0.3 0.03 
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 Table 18: B cell phenotype- correlation to eGFR and ∆ eGFR- multivariate analysis 
 
*Adjusted for recipient age, donor age and donor retrieval creatinine in partial correlation 
analysis. 
 
 
 
In the basiliximab group there were significant correlations between absolute numbers 
of CD4+ T cells, and in particular CD4+ CD45RA+ cells, and eGFR but not ∆eGFR. 
Naïve and transitional B cells also correlated with eGFR but not ∆eGFR. Regulatory B 
cells correlated with both eGFR and ∆eGFR.  Both the alemtuzumab and basiliximab 
groups were divided into tertiles (stratified by absolute numbers of transitional B cells, 
regulatory B cells and naïve B cells) for further functional analysis. Figure 65 
demonstrates that the patients with the highest numbers of these B cell subsets were 
almost entirely restricted to the alemtuzumab group, although there was some overlap 
with the basiliximab group in lower tertiles. There was a stepwise increase in the eGFR 
and ∆eGFR across the three tertiles of all three B cell subsets within the alemtuzumab 
group. Patients in the lowest tertile of all three B subsets had the worst eGFR and the 
greatest deterioration in eGFR whilst the converse was true of patients in the highest 
tertile. Patients with the highest tertiles of transitional and regulatory B cells had no 
DSA and only one patient in the highest tertile for naive B cells had a DSA (Figure 66). 
B cell type 
R 
(unadjusted) 
R 
(adjusted-partial correlation)* 
eGFR   
Naïve B cells 0.3 (p=0.03) 0.4 (p=0.01) 
Transitional B cells 0.3 (p=0.02) 0.43 (p=0.003) 
Cd5+CD1dhi B cells 0.34 (p=0.01) 0.35 (p=0.02) 
   
∆ eGFR   
Naïve B cells 0.4 (p=0.01) 0.4 (p=0.004) 
Transitional B cells 0.3 (p=0.03) 0.44 (p=0.002) 
Cd5+CD1dhi B cells 0.4 (p=0.008) 0.3 (p=0.02) 
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Such a clear relationship could not be demonstrated across the tertiles of the 
basiliximab group (Figure 67). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 65: Comparison of absolute numbers of transitional and CD5+CD1dhi B 
cells in basiliximab and alemtuzumab groups 
A comparison of the absolute numbers of naive, transitional and regulatory B cells across the 
three tertiles in both the basiliximab and alemtuzumab groups is made with those of healthy 
volunteers and dialysis patients. Patients in the highest tertile alemtuzumab group had the 
highest number of naive (P<0.001), transitional (P<0.001) and regulatory B cells (p<0.01) 
respectively.
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Figure 66: Comparison of eGFR, 
∆eGFR and HLA specific antibodies 
across the three B subset tertiles 
(Alemtuzumab). 
For all  three B cell subtypes, the lowest 
tertile had the lowest eGFR and the 
highest tertile the best eGFR (Naive B 
cells, lowest vs. highest tertile P=0.07; 
Transitional B cells, lowest vs. highest 
tertile, P=0.05; CD5hiCD1d+ B cells, 
lowest vs. highest tertile, P=0.01) Similar 
trends were also seen with ∆GFR as well 
(Naive B cells, lowest vs. highest tertile 
P=0.03; Transitional B cells lowest vs. 
highest tertile, P=0.005; CD5hiCD1d+ B 
cells, lowest vs. highest tertile, P=0.002) . 
No patients within the highest tertiles of 
the transitional and regulatory B cells had 
DSA whilst only one with the highest 
tertile of the naive B cells had DSA. 
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Figure 67: Comparison of eGFR, ∆eGFR 
and HLA specific antibodies across the 
three B subset tertiles (Basiliximab)                                                                                                                     
For all  three B cell subtypes, the lowest tertile 
had the lowest eGFR and the highest tertile 
the best eGFR (Naive B cells: lowest vs. 
highest tertile, P=0.02; Transitional B cells: 
lowest vs. highest tertile, P=0.05; 
CD5hiCD1d+ B cells lowest vs. highest tertile, 
P =0.03). Despite trends, ∆GFR was not 
significantly different across the tertiles (Naive 
B cells: lowest vs. highest tertile, P =Ns; 
Transitional B cells: lowest vs. highest tertile, 
P =Ns; CD5hiCD1d+ B cells lowest vs. 
highest tertile, P =0.052). DSA/NDSA 
development post -transplant did not follow a 
specific trend. 
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116 patients 
43/58 
Basiliximab 
positive 
30.2% (n=13) 
NDSA 
18.6% (n=8) 
DSA 
11.6% (n=5) 
negative 
69.8% (n=30) 
51/58 
Alemtuzumab 
negative 
68.6% (n=35) 
positive 
31.4% (n=16) 
NDSA 
15.7% (n=8) 
DSA 
15.7% (n=8) 
5.2.2.4: HLA specific antibodies 
Similar number of patients in each group had HLA specific antibodies with no 
difference in the number of patients with donor specific or non-donor specific antibodies 
(Figure 68). 
 
 
 
 
 
 
 
Figure 68: HLA specific antibodies in both the groups 
 
Patients with DSA in the alemtuzumab group had a significantly lower number of naïve, 
transitional and regulatory B cells when compared to those without antibody (Figure 69). 
 
Figure 69: Comparison of the absolute numbers of B lymphocyte subsets in patients with 
and without HLA-specific antibodies. 
 In comparison to those without HLA-specific antibody, patients with DSA had significantly lower 
numbers of transitional B cells {No HLA antibodies 33.8/l (95% CI 25.8 to 41.8/l) vs. DSA 
14.1/l (95% CI 6.9 to 21.3/l), p=0.01}; regulatory B cells that express CD5 and CD1d {No HLA 
antibodies 41.6/l (95% CI 29.4 to 53.8/l) vs. DSA 17.8/l (95% CI 9.5 to 26.1/l), p=0.03} and 
a lower naive to memory B cell ratio {No HLA antibodies 6.8 (95% CI 5.1 to 8.5) vs. DSA 2.7 
(95% CI 0.9 to 4.4), p=0.005}. 
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Such a relationship could not be demonstrated within the basiliximab group (Figure 70) 
 
 
Figure 70: Comparison of the absolute numbers of B lymphocyte subsets in patients with 
and without HLA specific antibodies in the basiliximab group.  
No significant differences existed between the patients with DSA, NDSA and those with no HLA 
antibody. 
 
 
5.2.3 Validation of T-1/T-2 ratio as a clinical marker 
Results discussed in the previous chapter show that transitional B cells are 
heterogeneous containing distinct phenotypic and functional subsets (T-1, T-2). They 
also conclude that the ratio of T-1 and T-2 provides a simple and valuable biomarker to 
predict graft outcomes. Now the TrB cells are re-analysed in both alemtuzumab and 
basiliximab groups which has shown distinct clinical correlations to the B phenotype 
based on the distribution of T-1/T-2. This provided an opportunity to validate the utility 
of T-1/T-2 in an independent random sample of patients all of whom received same 
immunosuppression. ΔeGFR was measured from 6 months post-transplantation to 3 
years after blood sampling. When these patients were divided into three tertiles based 
on their T-1/T-2 ratio; highest percentage of patients who were in the lowest tertile of 
the T-1/T-2 ratio had a donor specific antibody detected at the time of the analysis. 
Similar to the results seen in the test set, patients in the lowest tertile had a significantly 
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lower (negative) ΔeGFR compared to the highest tertile thus confirming the clinical 
applicability of T-1/T-2 ratio (Figure 71). 
 
 Figure 71: Clinical significance of T1/T2 ratio  
The top panel of pie charts show that a significantly higher proportion of patients in the lowest 
tertile are positive for a DSA when compared to those in the highest tertile in both Alemtuzumab 
and Basiliximab groups. Similarly the bar charts show that Δ eGFR is significantly lower 
(negative) within the lowest tertile when compared to the highest tertile (## P=0.01). The 
proportions of patients with DSA are compared across the tertiles by Chi square test and the Δ 
eGFR compared by independent t-test. The bars in the bar charts represent the mean whilst the 
error bars represent SEM. 
5.2.4 Longitudinal assessment of B subsets after alemtuzumab induction 
 So far, the data presented shows that alemtuzumab causes depletion of both T and B 
cells and now analyzed the reconstitution of the T1, T2 and mature naive B cells after 
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lymphocyte depletion with alemtuzumab induction in renal transplant recipients (n=14). 
All 14 patients received intra-operative induction therapy with 1g of intravenous 
methylprednisolone along with 30mg alemtuzumab and were maintained on tacrolimus 
monotherapy. Serial analysis of the B subsets at 3, 6 and 12 months after 
transplantation in this group revealed that the proportion of mature naïve B cells 
(CD24+CD38+) increased over time while that of the immature T1 and T2 cells 
decreased accordingly (Figure 72). At 1 year after transplantation the majority of B cells 
comprise the mature phenotype followed by T2 cells and then T1 cells in the lowest 
number. In all these patients at time-0, the number of lymphocytes in the peripheral 
blood was zero or close to zero making it impossible to assess B subsets at that time 
point. Given the very small numbers in this subset of patients, clinical correlation was 
not possible. 
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Figure 72: Longitudinal analysis of T1, T2 and mature naïve B cells after lymphodepletion 
with alemtuzumab 
Renal transplant recipients who received induction with alemtuzumab along with a single dose 
of methylprednisolone were followed up for 1 year and B subsets analysed longitudinally. (A). 
Representative scatter plots showing the T1, T2 and mature B cells at 3 months, 6 months and 
1year after transplantation. (B). Graph demonstrating T1, T2 and mature B cells at different time 
points after transplantation. Each bar in the graph represents mean and the error bars represent 
SEM. At time 0 the mean number of peripheral lymphocytes was zero thereby giving a value of 
‘0’ at the starting point. 
 
5.2.5 Summary  
In summary, the clinical data presented here shows that alemtuzumab offers 
comparable short term graft and patient outcomes to basiliximab induction and it is 
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encouraging to see that the rate of early acute rejection is marginally superior in the 
alemtuzumab group. There are notable differences in the reconstitution of T and B cell 
compartments at nearly 2 years after transplantation. In an independent small group of 
patients the development of the B phenotype within the first post-transplant year was 
also examined. It is noteworthy that the B cell repopulation is dominated by an 
immature and a naïve phenotype which contrasts that of the T cell phenotype. More 
importantly, those patients who had a higher number of these immature cells 
experienced better graft outcomes with a superior eGFR and no DSA. 
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5.3 Discussion 
In the setting of a RCT of two steroid avoidance regimes, a conspicuous and significant 
difference in the phenotype of the reconstituted lymphocyte pool following 
alemtuzumab induction was demonstrated. Although there was slightly less rejection in 
the alemtuzumab group, clinical outcomes were otherwise similar. Both groups were 
exposed to similar tacrolimus levels but the basiliximab group was also exposed to 
MMF and there is limited data to suggest that this drug may affect both B and T 
lymphocyte subpopulations (Weigel, Griesmacher et al. 2002, Salinas-Carmona, Perez 
et al. 2009). Information regarding the effects of MMF on lymphocyte populations 
following profound depletion is lacking, though recent experiments in primates do not 
suggest that MMF has a profound effect on subsets other than CD4+ T cells (van der 
Windt, Smetanka et al. 2010).  
 
5.3.1 Clinical outcome measures 
This clinical trial with its non-superiority design shows that the clinical outcomes are 
similar in both groups of patients. It is encouraging to note that a high percentage of 
patients in both the groups (81% alemtuzumab group, 74% basiliximab group) 
remained steroid free at one year. The study patients remain on tacrolimus 
monotherapy, an approach first described by the group in Pittsburgh (Shapiro, Basu et 
al. 2005, Thomas, Woodside et al. 2007). A relatively simple immunosuppression 
regime based on a single maintenance agent has potential advantages. It is 
economical and enables most patients to take fewer tablets. This strategy may lead to 
better adherence to treatment. 
Although the time to rejection episode for patients who received alemtuzumab in this 
study is longer when compared to that of basiliximab, there remains a trend towards 
reduced rejection rate in the alemtuzumab group. This finding is in agreement with that 
reported by Woodle’s group in Cincinnati (Hanaway, Woodle et al. 2011). They 
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propose that the lower rejection group in their study is attributed to the absence of DCD 
donor transplants. However, DCD transplants are included in this study.  Groups led by 
Calne in Cambridge and Singapore have described a higher rate of late acute rejection 
between 6 and 12 months (Vathsala, Ona et al. 2005, Margreiter, Klempnauer et al. 
2008) and this can possibly be due to the inclusion of high immunological risk 
transplants and the use of ciclosporin monotherapy, as opposed to tacrolimus. It is also 
important to note that the rate of severe grade rejection (histological Banff grade 2 or 
above) in both  groups is similar.        
5.3.2 Alemtuzumab induction and the lymphocyte phenotype 
In this study, patients in both the alemtuzumab and basiliximab groups had total 
lymphocyte counts similar to those seen in dialysis patients but were lymphopenic 
when compared to healthy volunteers. It is possible that lymphopenia in both groups is 
caused by a combination of two factors. Firstly these patients probably came to 
transplantation with reduced numbers of lymphocytes since they were suffering with 
end stage renal disease. Superimposed on this background are the effects of 
immunosuppressive agents including the induction agents, basiliximab or 
alemtuzumab. 
The relative proportion of CD3+ T cells, even 25 months after transplantation, was 
significantly lower in the alemtuzumab group when compared to both control groups. 
This was largely due to a reduction in the CD4+T cell pool. The basiliximab group had a 
significantly higher naïve to memory CD4+T cell ratio when compared to both control 
groups. In contrast such a distinction was not demonstrated in the alemtuzumab group, 
a finding which accords with previous studies (Pearl, Parris et al. 2005, Trzonkowski, 
Zilvetti et al. 2006, Trzonkowski, Zilvetti et al. 2008, Scarsi, Bossini et al. 2010).  
The phenotype of reconstituted B cells after alemtuzumab induction has not previously 
been studied in renal transplant recipients. In patients with multiple sclerosis treated 
with alemtuzumab, rapid recovery of B cells has been described with development of 
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supra-normal levels (65% above baseline) by 12 months following treatment 
(Thompson, Jones et al. 2010).  This observation was associated with increased 
numbers of transitional B cells in the early phase of recovery, prolonged suppression of 
memory B cells, and a brisk and augmented BAFF response. Two years following 
alemtuzumab induction, a distinct phenotype within the regenerated B cell 
compartment was demonstrated for patients with good clinical outcomes which was 
less pronounced following basiliximab induction. A B cell repertoire with prominent 
naïve, transitional and regulatory components is consistent with the recent description 
of elevated BAFF levels in patients induced with alemtuzumab (Bloom, Chang et al. 
2009). In the alemtuzumab group there was a significant increase in the naïve B cell 
population reflected by a high naïve/memory B cell ratio compared to both sets of 
controls. This is similar to recent observations in patients with multiple sclerosis and 
suggests a block in differentiation to the memory phenotype (Thompson, Jones et al. 
2010). A similar though less significant result was demonstrated in the basiliximab 
group. Limited data after alemtuzumab induction for islet cell transplantation in humans 
has also demonstrated a loss of memory B cells although further subset analysis was 
not available (Toso, Edgar et al. 2009).  The fact that T cells were markedly depleted in 
the alemtuzumab group could possibly explain the prolonged suppression of the 
memory B cells since naive B cells require T cell help for maturation (Steele, Laufer et 
al. 1996).  
Following alemtuzumab, the proportion of transitional B cells (CD19+CD24hi CD38hi) 
was high when compared to both control groups, with absolute numbers restored to 
levels seen in healthy volunteers despite the absolute lymphopenia. In contrast the 
basiliximab group had both a lower proportion and absolute number of transitional B 
cells when compared to healthy volunteers. Transitional B cells represent an immature 
phenotype, intermediate between bone marrow precursors and mature naive B cells. 
Studies of B cell depletion therapies with Rituximab (anti-CD20) in autoimmune 
diseases have identified transitional cells as immature cells that feature prominently in 
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homeostatic repopulation following lymphocyte depletion (Sutter, Kwan-Morley et al. 
2008, Palanichamy, Barnard et al. 2009).  A recently proposed subset of the 
transitional cells, termed T3 cells, were shown to develop from mature naïve B cells 
upon chronic exposure to antigen (Merrell, Benschop et al. 2006). In the clinical setting 
transitional B cells have been proposed as regulatory cells in patients with systemic 
lupus erythematosus (Blair, Norena et al. 2010, Mauri and Blair 2010, Mauri and Blair 
2010).   
Another B cell subgroup associated with regulatory function (CD19+CD5+CD1dhi) was 
also distinct in patients who received alemtuzumab induction. Whilst patients who 
received alemtuzumab had a comparable number of CD19+CD5+CD1dhi B cells to 
healthy volunteers, the basiliximab group had a significantly lower proportion and 
absolute number of these cells.  This subset has been shown to produce IL-10 and is 
associated with antigen-specific regulatory properties in murine experimental models 
(Mizoguchi, Mizoguchi et al. 2002). Interestingly, cells with such a phenotype were 
recently shown to be associated with operational tolerance in human kidney transplant 
recipients (Pallier, Hillion et al. 2010). 
The observations in these patients are noteworthy but may simply reflect a 
phenomenon contingent upon the underlying immunosuppressive regime, especially 
since there were similar clinical outcomes in the two treatment arms.  However, two 
associations increase the impact of these observations.   Firstly, B cell subset numbers 
were shown to correlate with graft function, most closely in the group of patients treated 
with alemtuzumab.  Secondly, similar lymphocyte phenotypes have recently been 
demonstrated in recipients of kidney transplants with operational clinical tolerance 
(Newell, Asare et al. 2010, Pallier, Hillion et al. 2010, Sagoo, Perucha et al. 2010). 
Moreover, when the patients in the alemtuzumab arm were divided into tertiles 
according to absolute numbers of B cell subsets (either naïve, transitional or regulatory 
B cells) there was a significant correlation with graft function, improved stability of 
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function and reduced humoral allo-sensitisation.  This finding suggests that it may be 
possible to use peripheral B cell phenotype analysis by flow cytometry to monitor or 
even predict immunological graft function.  
There are however limitations in this analysis and caution should be exercised when 
interpreting the findings. All of the observations were made at a fixed time point 
approximately two years following transplantation and it is now necessary to 
prospectively study this phenomenon to document the time course, evolution and 
stability of these phenotypic changes. Even though the role of the immature B cells in 
the regulation of immune response and the change of function noticed in the same 
cells in patients with CAMR was discussed in the previous chapter, it is still important to 
study the functional significance of these cells in the regulation of the alloresponse. It is  
crucial to note that graft outcomes are affected by other important non-immunological 
mechanisms and this analysis has not taken these into account. 
Such a striking relationship was not seen following basiliximab induction and it could be 
speculated that this phenomenon is more prominent in the regenerating B cell 
compartment following profound lymphocyte depletion. Certainly in animal models 
there is evidence that following lymphocyte depletion a B cell compartment 
regenerating in the presence of alloantigen is dominated by transitional B cells which 
can mitigate a tolerant state and prevent alloantibody production (Parsons, Vivek et al. 
2011). 
Recent studies in patients who have stable renal allograft function in the absence of 
on-going immunosuppressive medications (“operational tolerance”) have demonstrated 
an association with distinct B cell phenotypes. One group demonstrated a relationship 
between operationally tolerant patients and the presence of naïve and transitional B 
cells in peripheral blood (Newell, Asare et al. 2010). Other similar results suggest the 
intriguing possibility that certain peripheral B cell phenotypes may be predictive of good 
outcomes and even a potentially tolerant state (Pallier, Hillion et al. 2010, Sagoo, 
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Perucha et al. 2010). It is possible that antigens presented by naive B cells possibly 
promote tolerance by favouring the development of regulatory rather than the effector 
memory T cells (Fuchs and Matzinger 1992, Reichardt, Dornbach et al. 2007).  
Certainly transitional B cells have been shown to produce IL-10 and have regulatory 
functions in human autoimmune disease (Blair, Norena et al. 2010).  
Patients in the basiliximab group had comparable graft function to those in the 
alemtuzumab group in the short term and the relationship between lymphocyte 
subtypes and graft function was less clear-cut. However it is possible that the 
mechanism of immune regulation is different following non-depletional induction 
therapy. The lower B cell numbers in the basiliximab group might be explained in part 
by the anti-proliferative effects of MMF on the B cell compartment but also possibly 
there is less lymphoid space for B cells to expand into since basiliximab is a non-
depleting antibody.  
 
5.3.3 Summary 
In summary it is demonstrated that, in the context of a randomised controlled trial, two 
years after renal transplantation, alemtuzumab rather than basiliximab induction was 
associated with a highly significant and novel peripheral lymphocyte phenotype, 
although clinical outcomes were broadly similar.  This phenotype was notable for the 
prominence of naïve and regulatory B cell subtypes. Patients with a significantly higher 
number of these regulatory cells had better and more stable graft functions. 
Intriguingly, these are similar cell types to those that are prominent in the peripheral 
blood of operationally tolerant renal allograft recipients. Prospective studies monitoring 
peripheral blood lymphocyte phenotype with long term clinical follow up are now 
required in patients undergoing alemtuzumab induction, to explore how this may aid 
clinical management. 
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Chapter-6: Discussion   
 
In the preface to this thesis, I have briefly discussed a plan to address certain pertinent 
questions to the field of renal transplantation. Here, I will reflect upon those questions 
and examine whether any further insight has been gained as a result of the clinical and 
experimental research conducted over the last four years. 
6.1 Can clinical phenotype be linked to histological picture & graft 
outcomes? 
This is clearly a complex question as the answer depends heavily on the clinical 
context.  Early low-grade proteinuria either measured at 3 months post-transplantation 
or at 1 year has been shown to be associated with worse graft outcomes and poor 
overall survival. The results presented in chapter-3, support previously reported data. 
However, proteinuria is a dynamic variable that changes with time. For example, 
resolution of proteinuria in a subset of non-transplant patients in the RENAAL study of 
diabetic nephropathy demonstrated superior clinical outcomes. However, proteinuria 
was assessed over a short period of only 6 months. There is a dearth of data looking at 
the impact of modification of proteinuria over longer periods of time. This issue has 
been addressed here by the longitudinal assessment of proteinuria. I have analysed 
patients with proteinuria less than 1g/day during three years of assessment. One major 
finding from this analysis is that resolution of low-grade proteinuria is associated with 
improved overall graft outcomes. Moreover, proteinuria helps to risk stratify 
hypertensive renal transplant recipients. Given these findings, low-grade proteinuria 
seems to be a promising clinical marker. However, this should be validated in a larger 
prospective multi-centre study. This is to avoid the same pitfall encountered when 
using creatinine as a predictive marker. We should remember that although high 
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creatinine is strongly associated with worse long-term graft outcomes, the predictive 
value is not much different from the toss of a coin. The next question that these 
findings pose is the potential benefit of anti-proteinuric therapy for hypertensive 
patients with low-grade proteinuria.  This should be explored in a trial setting. 
As proteinuria has been shown in our experience to be associated with worse graft 
survival, patients with three consecutive proteinuria assessments of more than 
0.5g/day were offered an indication transplant biopsy. Surprisingly, there was no 
clinical correlation between the histological phenotype and clinical presentation of 
either isolated change in creatinine, proteinuria or both. Even more important is the 
finding that clinical presentation does not independently predict graft loss in this highly 
selective group of patients defined by graft dysfunction. From these findings, we can 
postulate that proteinuria whilst showing a strong clinical association in a population 
based analysis, is of limited significance once graft dysfunction ensues. Therefore one 
can argue that the actual prognostic utility of proteinuria in patients with graft 
dysfunction is rather limited. This could be explained by two possibilities 
1. Clinical intervention once graft dysfunction ensues may not be very effective 
2. Possibly the interventions are not effective, irrespective of the presentation. 
3. It is too late since original observations were at three months 
One potential solution can be offered to address the issue of early diagnosis. This 
could be addressed by early biopsies at 3 months. One major issue regarding a 
planned early biopsy again will be the timing. To address this, patients can be 
screened routinely for the presence of DSA at a regular basis through the life of that 
graft and those with DSA could undergo a biopsy irrespective of clinical function. 
Alongside conventional histology, molecular diagnostics may prove useful as a 
predictive tool (Einecke, Reeve et al. 2010). 
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6.2 Can Bregs be identified by both pro and anti-inflammatory 
cytokines? 
Bregs have traditionally been identified by their ‘signature’ cytokine IL-10 (Mauri and 
Bosma 2012). Various groups have suggested that either memory or immature B cells 
are capable of secreting and synthesising IL-10 leading to them being classified as 
Bregs. However these are in vitro experiments and B cells can be made to express IL-
10 depending on the culture conditions. Lund and colleagues have argued that B cell 
subpopulations in mice are capable of expressing multiple cytokines. In humans, 
similar evidence emanated from Bar-Or‘s group, working on multiple sclerosis. They 
have shown that B cells are capable of expressing both pro and anti-inflammatory 
cytokines and they used the whole B cell IL-10/lymphotoxin ratio to distinguish healthy 
volunteers from patients with remitting multiple sclerosis. However, they did not identify 
a subset of B cells capable of expressing IL-10 or lymphotoxin. My experiments in 
healthy volunteers with in vitro B cell stimulation using CPG and CD40L aimed to 
address this issue. Both TLR9 (CPG agonist) and CD40-CD40L interactions have been 
identified as crucial for the generation and function of Bregs in animal studies. In these 
experiments, I have been able to demonstrate that 
1. B cells are able to express both IL-10 and TNF- 
2. This duality of expression remained valid even when analysed on a per-cell 
basis 
3. The differential expression of these two cytokines distinguished immature 
transitional B, naïve and memory B cells 
4. Transitional B cells, by the virtue of relative cytokine polarization towards IL-10, 
possess the most anti-inflammatory profile 
5. This anti-inflammatory profile correlates well with in vitro suppressive capacity  
Based on these results, immature transitional B cells can be identified as a significant 
population with regulatory potential based on both pro and anti-inflammatory cytokine 
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expression. These results raise more questions than answers. One significant query 
that needs addressing in the future will be to decipher the role of other cytokines 
expressed by these cells. Although one can argue about the plasticity of these 
populations, the other major limitation is the lack of an inclusive marker.   For example, 
TrBs which have been shown to demonstrate regulatory properties only constitute 10% 
of B population and on an average only 10-15% of these cells are pure expressers of 
IL-10. A potential more inclusive marker can probably be identified by in vitro gene 
expression studies with a hope to identify a transcription factor akin to the Tregs. 
 
6.3 Is the role of Bregs diverse in renal transplantation? 
My interest in B cells and in particular, Bregs in the context of renal transplantation 
stemmed from the studies of operational tolerance. First, in a cross sectional study I 
have shown that transitional B cells are reduced in number with an abnormal pro-
inflammatory cytokine profile in patients with a histological phenotype of CAMR. 
Histological rather than clinical identification of patient groups has been preferred in 
light of my findings discussed in chapter-3 suggesting histological phenotype has a 
stronger association with clinical outcomes. Importantly, this alteration in cytokine 
polarization resulted in the loss of in vitro suppressive capacity and correlated with graft 
outcomes in these patients with a late indication biopsy. Secondly, I have shown that 
alemtuzumab induced lymphodepletion results in a repopulated phenotype which is ‘B 
dominant’. This is not a universal finding and patients who had a dominance of B cells; 
in particular cells with the phenotype of Bregs had superior and more stable graft 
function. This validated the utility of the phenotype of Bregs as a potential clinical 
marker. Finally, the issue of the diverse roles of B cells in renal transplantation. More 
than half of the patients with CAMR have an identifiable DSA in their serum. This is a 
reflection of the antibody producing role of the B cells. In contrast, patients with stable 
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function have a significantly higher number of B cell subsets that express an anti-
inflammatory cytokine profile. Interestingly the same B cell subset, in the context of 
CAMR demonstrates a pro-inflammatory profile and this correlated with graft function. 
Therefore diversity is a feature of the B populations even when assessed for particular 
subsets and in fact for each individual cell.  
There are certain limitations to this body of work. 
1. This is a cross sectional analysis and does not address the longitudinal 
variability of the phenotype and function of these cells over time. 
2. All these assays were performed by non-cognate stimulation. The significance 
of the cytokines and their suppressive capacity has not been assessed in an 
allo-specific manner. 
3. These findings need to be replicated prospectively in larger groups of patients 
to assess their clinical applicability. 
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